EP1062222A1 - Serine peptidase modulators - Google Patents
Serine peptidase modulatorsInfo
- Publication number
- EP1062222A1 EP1062222A1 EP99911781A EP99911781A EP1062222A1 EP 1062222 A1 EP1062222 A1 EP 1062222A1 EP 99911781 A EP99911781 A EP 99911781A EP 99911781 A EP99911781 A EP 99911781A EP 1062222 A1 EP1062222 A1 EP 1062222A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compounds
- prolyl
- phosphonate
- pyrrolidine
- cooh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091005804 Peptidases Proteins 0.000 title claims abstract description 56
- 102000035195 Peptidases Human genes 0.000 title claims abstract description 52
- 235000019833 protease Nutrition 0.000 title claims abstract description 31
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 150
- 230000000694 effects Effects 0.000 claims abstract description 47
- 239000004365 Protease Substances 0.000 claims abstract description 24
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 102100033320 Lysosomal Pro-X carboxypeptidase Human genes 0.000 claims abstract description 8
- 108010057284 lysosomal Pro-X carboxypeptidase Proteins 0.000 claims abstract description 8
- 101710087084 Dipeptidyl peptidase 2 Proteins 0.000 claims abstract description 6
- -1 biphenyl diester Chemical class 0.000 claims description 133
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 47
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 45
- 229910052739 hydrogen Chemical group 0.000 claims description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 37
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 28
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 27
- 229960001153 serine Drugs 0.000 claims description 26
- 235000004400 serine Nutrition 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000004305 biphenyl Substances 0.000 claims description 17
- 229960002429 proline Drugs 0.000 claims description 16
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 15
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 14
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 14
- 229960003767 alanine Drugs 0.000 claims description 14
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 13
- 235000004279 alanine Nutrition 0.000 claims description 13
- 229940024606 amino acid Drugs 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 12
- 235000019419 proteases Nutrition 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 102000012479 Serine Proteases Human genes 0.000 claims description 11
- 108010022999 Serine Proteases Proteins 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 235000010290 biphenyl Nutrition 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 208000007536 Thrombosis Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 9
- 238000002054 transplantation Methods 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 claims description 8
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 8
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 7
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 7
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 229960005190 phenylalanine Drugs 0.000 claims description 7
- 229960004441 tyrosine Drugs 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 6
- 206010053759 Growth retardation Diseases 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 231100000001 growth retardation Toxicity 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 230000036407 pain Effects 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 5
- 201000006306 Cor pulmonale Diseases 0.000 claims description 5
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 208000032843 Hemorrhage Diseases 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 208000019022 Mood disease Diseases 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 208000028070 Vascular pulmonary disease Diseases 0.000 claims description 5
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 230000001066 destructive effect Effects 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 229940072221 immunoglobulins Drugs 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- 230000009826 neoplastic cell growth Effects 0.000 claims description 5
- 230000000626 neurodegenerative effect Effects 0.000 claims description 5
- 230000000955 neuroendocrine Effects 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 5
- IADUEWIQBXOCDZ-UHFFFAOYSA-N (2S)-azetidine-2-carboxylic acid Natural products OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 claims description 4
- XPRCPVGCTGELMN-QMMMGPOBSA-N (2s)-2-amino-3-(4-carbamimidoylphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C(N)=N)C=C1 XPRCPVGCTGELMN-QMMMGPOBSA-N 0.000 claims description 4
- MNZLMQYCEWHPPS-REOHCLBHSA-N (2s)-2-azaniumyl-5,5,5-trifluoro-4-(trifluoromethyl)pentanoate Chemical compound OC(=O)[C@@H](N)CC(C(F)(F)F)C(F)(F)F MNZLMQYCEWHPPS-REOHCLBHSA-N 0.000 claims description 4
- JHHOFXBPLJDHOR-AXDSSHIGSA-N (2s)-4-phenylpyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)CC1C1=CC=CC=C1 JHHOFXBPLJDHOR-AXDSSHIGSA-N 0.000 claims description 4
- XFZIPCXDWCWTCH-VKHMYHEASA-N (4s)-1,3-oxazolidin-3-ium-4-carboxylate Chemical compound OC(=O)[C@@H]1COCN1 XFZIPCXDWCWTCH-VKHMYHEASA-N 0.000 claims description 4
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 claims description 4
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 4
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 claims description 4
- VMAOKVWDXNFNQQ-UHFFFAOYSA-N 2-amino-2-(4-carbamimidoylphenyl)acetic acid Chemical compound OC(=O)C(N)C1=CC=C(C(N)=N)C=C1 VMAOKVWDXNFNQQ-UHFFFAOYSA-N 0.000 claims description 4
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical group CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 claims description 4
- XFGVJLGVINCWDP-UHFFFAOYSA-N 5,5,5-trifluoroleucine Chemical compound FC(F)(F)C(C)CC(N)C(O)=O XFGVJLGVINCWDP-UHFFFAOYSA-N 0.000 claims description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 4
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 4
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 4
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 claims description 4
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 claims description 4
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 claims description 4
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 4
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 4
- KAFHLONDOVSENM-HNNXBMFYSA-N O-Benzyl-L-tyrosine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OCC1=CC=CC=C1 KAFHLONDOVSENM-HNNXBMFYSA-N 0.000 claims description 4
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 4
- GHBAYRBVXCRIHT-VIFPVBQESA-N S-benzyl-L-cysteine zwitterion Chemical compound OC(=O)[C@@H](N)CSCC1=CC=CC=C1 GHBAYRBVXCRIHT-VIFPVBQESA-N 0.000 claims description 4
- ULXKXLZEOGLCRJ-BYPYZUCNSA-N S-ethyl-L-cysteine zwitterion Chemical compound CCSC[C@H](N)C(O)=O ULXKXLZEOGLCRJ-BYPYZUCNSA-N 0.000 claims description 4
- IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 claims description 4
- 108010077895 Sarcosine Proteins 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 229960002173 citrulline Drugs 0.000 claims description 4
- 235000013477 citrulline Nutrition 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- 229960002433 cysteine Drugs 0.000 claims description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 229960002885 histidine Drugs 0.000 claims description 4
- 235000014304 histidine Nutrition 0.000 claims description 4
- 229960002591 hydroxyproline Drugs 0.000 claims description 4
- QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 208000013104 leukocyte disease Diseases 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 4
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 229940043230 sarcosine Drugs 0.000 claims description 4
- 229960002898 threonine Drugs 0.000 claims description 4
- 235000008521 threonine Nutrition 0.000 claims description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 3
- 125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000001744 histochemical effect Effects 0.000 claims description 3
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 3
- 229960001639 penicillamine Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 238000010186 staining Methods 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 claims description 2
- 125000005239 aroylamino group Chemical group 0.000 claims description 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000093 cytochemical effect Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- AFGCRUGTZPDWSF-BYPYZUCNSA-N (2s)-2-azaniumyl-3-ethoxypropanoate Chemical compound CCOC[C@H](N)C(O)=O AFGCRUGTZPDWSF-BYPYZUCNSA-N 0.000 claims 2
- MWWYWNADBKPIKY-JPPWUZRISA-N [1-[(2s)-pyrrolidine-2-carbonyl]pyrrolidin-2-yl]phosphonic acid;hydrochloride Chemical compound Cl.OP(O)(=O)C1CCCN1C(=O)[C@H]1NCCC1 MWWYWNADBKPIKY-JPPWUZRISA-N 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 229940124277 aminobutyric acid Drugs 0.000 claims 2
- 229940078547 methylserine Drugs 0.000 claims 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 abstract description 20
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 abstract description 20
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 abstract description 11
- 108010072257 fibroblast activation protein alpha Proteins 0.000 abstract description 10
- 230000004936 stimulating effect Effects 0.000 abstract description 8
- 108090000212 dipeptidyl peptidase II Proteins 0.000 abstract description 7
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract description 6
- 108010028275 Leukocyte Elastase Proteins 0.000 abstract description 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 87
- 238000005160 1H NMR spectroscopy Methods 0.000 description 62
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 43
- 239000003112 inhibitor Substances 0.000 description 38
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 37
- 239000008259 solid foam Substances 0.000 description 36
- 230000005764 inhibitory process Effects 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 22
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 18
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 17
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 108010016626 Dipeptides Proteins 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 7
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 125000006267 biphenyl group Chemical group 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical class C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- RGIKBGGGNMQWRA-QDVCFFRGSA-N C(C1=CC=CC=C1)OC(=O)N1[C@@H](CCC1)C(=O)N1C(CCC1)P(O)(=O)O.C1=C(C=CC=C1)C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC(=O)N1[C@@H](CCC1)C(=O)N1C(CCC1)P(O)(=O)O.C1=C(C=CC=C1)C1=CC=CC=C1 RGIKBGGGNMQWRA-QDVCFFRGSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 5
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000002427 irreversible effect Effects 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 4
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101000931864 Homo sapiens Dipeptidyl peptidase 2 Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- CDXVUROVRIFQMV-UHFFFAOYSA-N oxo(diphenoxy)phosphanium Chemical compound C=1C=CC=CC=1O[P+](=O)OC1=CC=CC=C1 CDXVUROVRIFQMV-UHFFFAOYSA-N 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- NMFZTJOPTRNMGL-UHFFFAOYSA-N 1,1-diethoxybutan-2-amine Chemical compound CCOC(OCC)C(N)CC NMFZTJOPTRNMGL-UHFFFAOYSA-N 0.000 description 3
- GFLPSABXBDCMCN-UHFFFAOYSA-N 4,4-diethoxybutan-1-amine Chemical compound CCOC(OCC)CCCN GFLPSABXBDCMCN-UHFFFAOYSA-N 0.000 description 3
- GDBUZIKSJGRBJP-UHFFFAOYSA-N 4-acetoxy benzoic acid Chemical compound CC(=O)OC1=CC=C(C(O)=O)C=C1 GDBUZIKSJGRBJP-UHFFFAOYSA-N 0.000 description 3
- NIRCAUPPZAUKDX-UHFFFAOYSA-N 5-benzyl-2-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]-6-methylpyridazin-3-one Chemical compound O=C1C=C(CC=2C=CC=CC=2)C(C)=NN1CN(CC1)CCN1C1=CC=CC(Cl)=C1 NIRCAUPPZAUKDX-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- RDFMDVXONNIGBC-UHFFFAOYSA-N (+-)-2-amino-heptanoic acid Natural products CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 2
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- QXSAKPUBHTZHKW-UHFFFAOYSA-N 4-hydroxybenzamide Chemical class NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 229930195730 Aflatoxin Natural products 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- WHXDLJOHWHFXJR-UHFFFAOYSA-N CC(=O)NC1=CC=C(O)C=C1.CC(=O)NC1=CC=C(O)C=C1 Chemical compound CC(=O)NC1=CC=C(O)C=C1.CC(=O)NC1=CC=C(O)C=C1 WHXDLJOHWHFXJR-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108090000617 Cathepsin G Proteins 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 102100033174 Neutrophil elastase Human genes 0.000 description 2
- KNTFCRCCPLEUQZ-VKHMYHEASA-N O-methylserine Chemical compound COC[C@H](N)C(O)=O KNTFCRCCPLEUQZ-VKHMYHEASA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- SXZMAOWOXXPXKR-UHFFFAOYSA-N P(O)(O)=O.NCC Chemical compound P(O)(O)=O.NCC SXZMAOWOXXPXKR-UHFFFAOYSA-N 0.000 description 2
- 108090000113 Plasma Kallikrein Proteins 0.000 description 2
- 102100034869 Plasma kallikrein Human genes 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000005409 aflatoxin Substances 0.000 description 2
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- IMHDGJOMLMDPJN-UHFFFAOYSA-N biphenyl-2,2'-diol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1O IMHDGJOMLMDPJN-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- CLZHKMJXVZEVRP-UHFFFAOYSA-N dihydroxyphosphanyl 2-(2-phenylphenyl)acetate Chemical compound OP(O)OC(=O)CC1=CC=CC=C1C1=CC=CC=C1 CLZHKMJXVZEVRP-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- KRMVXLWZDYZILN-UHFFFAOYSA-N methyl 2-acetamido-3-(4-hydroxyphenyl)propanoate Chemical compound COC(=O)C(NC(C)=O)CC1=CC=C(O)C=C1 KRMVXLWZDYZILN-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- YJASRJZSSUOGKB-UHFFFAOYSA-N n-(4-hydroxyphenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=C(O)C=C1 YJASRJZSSUOGKB-UHFFFAOYSA-N 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- OGBPILLJZSJJRC-UHFFFAOYSA-N phenoxyphosphonoyloxybenzene Chemical class C=1C=CC=CC=1OP(=O)OC1=CC=CC=C1 OGBPILLJZSJJRC-UHFFFAOYSA-N 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- JWABGIWHYAMKIF-UHFFFAOYSA-N pyrrolidin-2-ylphosphonic acid;hydrochloride Chemical class Cl.OP(O)(=O)C1CCCN1 JWABGIWHYAMKIF-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
- TWEDFGQCFNUDCU-VIFPVBQESA-N (2S)-1-(4-hydroxyphenyl)-5-oxopyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1CCC(=O)N1C1=CC=C(O)C=C1 TWEDFGQCFNUDCU-VIFPVBQESA-N 0.000 description 1
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
- JKVUKSZMPYIMLI-AWEZNQCLSA-N (2s)-3-(4-carbamimidoylphenyl)-2-[3-(furan-2-yl)prop-2-enoylamino]propanoic acid Chemical compound C1=CC(C(=N)N)=CC=C1C[C@@H](C(O)=O)NC(=O)C=CC1=CC=CO1 JKVUKSZMPYIMLI-AWEZNQCLSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- BFASOGCHMDYMBM-UHFFFAOYSA-N (4-carbamoylphenyl) acetate Chemical compound CC(=O)OC1=CC=C(C(N)=O)C=C1 BFASOGCHMDYMBM-UHFFFAOYSA-N 0.000 description 1
- GOWMBYUZXIZENX-CAUSLRQDSA-N 1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hexadecylamino)pyrimidin-2-one Chemical compound O=C1N=C(NCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 GOWMBYUZXIZENX-CAUSLRQDSA-N 0.000 description 1
- MDPJOJBNZKKURJ-UHFFFAOYSA-N 1-diphenoxyphosphorylethanamine Chemical compound C=1C=CC=CC=1OP(=O)(C(N)C)OC1=CC=CC=C1 MDPJOJBNZKKURJ-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- AWHHVZGCUOSCLP-UHFFFAOYSA-N 2-[4-carbamimidoyl-n-[3-(furan-2-yl)prop-2-enoyl]anilino]acetic acid Chemical compound C1=CC(C(=N)N)=CC=C1N(CC(O)=O)C(=O)C=CC1=CC=CO1 AWHHVZGCUOSCLP-UHFFFAOYSA-N 0.000 description 1
- VCEHWDBVPZFHAG-UHFFFAOYSA-N 2-[[1-[2-[[2-[[2-[[1-[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid Chemical compound NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(O)=O)CCC1 VCEHWDBVPZFHAG-UHFFFAOYSA-N 0.000 description 1
- WRFWTYGMKIUAKL-UHFFFAOYSA-N 3-methylphenol Chemical compound CC1=CC=CC(O)=C1.CC1=CC=CC(O)=C1 WRFWTYGMKIUAKL-UHFFFAOYSA-N 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- FOHAXXVIYAVXST-UHFFFAOYSA-N 4-hydroxy-n-propylbenzamide Chemical compound CCCNC(=O)C1=CC=C(O)C=C1 FOHAXXVIYAVXST-UHFFFAOYSA-N 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- FSSGZJLNUFGVQX-UHFFFAOYSA-N Br.P(O)(O)=O.C1(=CC=CC=C1)C(C)(N)C1=CC=CC=C1 Chemical compound Br.P(O)(O)=O.C1(=CC=CC=C1)C(C)(N)C1=CC=CC=C1 FSSGZJLNUFGVQX-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- YVWPUOIUNRDQJB-JMFXEUCVSA-N C(C)(C)(C)OC(=O)N1[C@@H](CCC1)C(=O)N1C(CCC1)P(O)(=O)O.C1=C(C=CC=C1)C1=CC=CC=C1 Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](CCC1)C(=O)N1C(CCC1)P(O)(=O)O.C1=C(C=CC=C1)C1=CC=CC=C1 YVWPUOIUNRDQJB-JMFXEUCVSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- YRNZUXBVLNRXPL-NRFANRHFSA-N CS(=O)(=O)NC1=CC=C(C=C1)C1=C(N(C=C1)C([C@H]1NCCC1)=O)C1=CC=C(C=C1)NS(=O)(=O)C Chemical compound CS(=O)(=O)NC1=CC=C(C=C1)C1=C(N(C=C1)C([C@H]1NCCC1)=O)C1=CC=C(C=C1)NS(=O)(=O)C YRNZUXBVLNRXPL-NRFANRHFSA-N 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 102100025975 Cathepsin G Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- USNUOVFJONBOSU-CNAJMHLNSA-N Cl.C(C1=CC=CC=C1)(=O)NCC(=O)NC1=CC=C(C=C1)OP(O)(=O)C1N(CCC1)C([C@H]1NCCC1)=O Chemical compound Cl.C(C1=CC=CC=C1)(=O)NCC(=O)NC1=CC=C(C=C1)OP(O)(=O)C1N(CCC1)C([C@H]1NCCC1)=O USNUOVFJONBOSU-CNAJMHLNSA-N 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 108050000048 Gonadoliberin Proteins 0.000 description 1
- 102000009165 Gonadoliberin Human genes 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 241000581002 Murex Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- OYTBLOLBENUVGR-UHFFFAOYSA-N OP(O)=O.C1=CC=CC=C1C1=CC=CC=C1 Chemical compound OP(O)=O.C1=CC=CC=C1C1=CC=CC=C1 OYTBLOLBENUVGR-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- JLFMHYBOXHFZOT-UHFFFAOYSA-N P(O)(O)=O.C1(=CC=CC=C1)C(C)(NC(=O)OCC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound P(O)(O)=O.C1(=CC=CC=C1)C(C)(NC(=O)OCC1=CC=CC=C1)C1=CC=CC=C1 JLFMHYBOXHFZOT-UHFFFAOYSA-N 0.000 description 1
- OEMQISJBGYQOPW-WCCKRBBISA-N P(O)(O)=O.N1[C@H](C(=O)O)CCC1 Chemical class P(O)(O)=O.N1[C@H](C(=O)O)CCC1 OEMQISJBGYQOPW-WCCKRBBISA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 108700015930 Prolyl Oligopeptidases Proteins 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- FZMCXBAOCDONEF-UHFFFAOYSA-N [4-(propylcarbamoyl)phenyl] acetate Chemical compound CCCNC(=O)C1=CC=C(OC(C)=O)C=C1 FZMCXBAOCDONEF-UHFFFAOYSA-N 0.000 description 1
- LJSAJMXWXGSVNA-UHFFFAOYSA-N a805044 Chemical compound OC1=CC=C(O)C=C1.OC1=CC=C(O)C=C1 LJSAJMXWXGSVNA-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- OVJPAZPOZBFVCH-HNNXBMFYSA-N benzyl (2S)-2-(pyrrole-1-carbonyl)pyrrolidine-1-carboxylate Chemical compound C(C1=CC=CC=C1)OC(=O)N1[C@H](C(=O)N2C=CC=C2)CCC1 OVJPAZPOZBFVCH-HNNXBMFYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- ROFXXIJTKINLBY-LBPRGKRZSA-N benzyl n-[(2s)-1-(4-hydroxyanilino)-1-oxopropan-2-yl]carbamate Chemical compound N([C@@H](C)C(=O)NC=1C=CC(O)=CC=1)C(=O)OCC1=CC=CC=C1 ROFXXIJTKINLBY-LBPRGKRZSA-N 0.000 description 1
- YWOXKKRKNGWXEG-FQEVSTJZSA-N benzyl n-[2-[(2s)-2-[(4-methyl-2-oxochromen-7-yl)carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamate Chemical compound C([C@H]1C(=O)NC2=CC=3OC(=O)C=C(C=3C=C2)C)CCN1C(=O)CNC(=O)OCC1=CC=CC=C1 YWOXKKRKNGWXEG-FQEVSTJZSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- OCLIFMFBYRCDEP-UHFFFAOYSA-N dioxaphosphepane Chemical compound C1CCPOOC1 OCLIFMFBYRCDEP-UHFFFAOYSA-N 0.000 description 1
- QLZHNIAADXEJJP-UHFFFAOYSA-L dioxido-oxo-phenyl-$l^{5}-phosphane Chemical class [O-]P([O-])(=O)C1=CC=CC=C1 QLZHNIAADXEJJP-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- AJXNRLPIDHNZBV-UHFFFAOYSA-N ethyl 2-[(4-hydroxybenzoyl)amino]acetate Chemical compound CCOC(=O)CNC(=O)C1=CC=C(O)C=C1 AJXNRLPIDHNZBV-UHFFFAOYSA-N 0.000 description 1
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 230000009546 growth abnormality Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- QLNWXBAGRTUKKI-UHFFFAOYSA-N metacetamol Chemical compound CC(=O)NC1=CC=CC(O)=C1 QLNWXBAGRTUKKI-UHFFFAOYSA-N 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- SLDPVDHIVYBMLJ-UHFFFAOYSA-N methyl 3-[(4-acetyloxybenzoyl)amino]propanoate Chemical compound COC(=O)CCNC(=O)C1=CC=C(OC(C)=O)C=C1 SLDPVDHIVYBMLJ-UHFFFAOYSA-N 0.000 description 1
- UHOIUZFPTOBBTI-UHFFFAOYSA-N methyl 3-[(4-hydroxybenzoyl)amino]propanoate Chemical compound COC(=O)CCNC(=O)C1=CC=C(O)C=C1 UHOIUZFPTOBBTI-UHFFFAOYSA-N 0.000 description 1
- UZCXPYDBYUEZCV-UHFFFAOYSA-N methyl 3-aminopropanoate Chemical compound COC(=O)CCN UZCXPYDBYUEZCV-UHFFFAOYSA-N 0.000 description 1
- COYFQHHMOWGSJL-UHFFFAOYSA-N methyl 4-bis(4-methoxycarbonylphenoxy)phosphanyloxybenzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OP(OC=1C=CC(=CC=1)C(=O)OC)OC1=CC=C(C(=O)OC)C=C1 COYFQHHMOWGSJL-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- NQRYGPXAYYDKJB-UHFFFAOYSA-N phenyl hydrogen phosphonate Chemical class OP(=O)OC1=CC=CC=C1 NQRYGPXAYYDKJB-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- BTURSMUPRYMLJE-UHFFFAOYSA-N pyrrolidin-2-ylphosphonic acid Chemical compound OP(O)(=O)C1CCCN1 BTURSMUPRYMLJE-UHFFFAOYSA-N 0.000 description 1
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical compound N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- XDJBNNHXEHVVLT-SKCDSABHSA-N tert-butyl (2S)-2-[2-bis(4-methoxycarbonylphenoxy)phosphorylpyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound COC(=O)C1=CC=C(C=C1)OP(OC1=CC=C(C=C1)C(=O)OC)(=O)C1N(CCC1)C([C@H]1N(CCC1)C(=O)OC(C)(C)C)=O XDJBNNHXEHVVLT-SKCDSABHSA-N 0.000 description 1
- LFXFZLHJDSVYGL-AWEZNQCLSA-N tert-butyl (2s)-2-(4,4-diethoxybutylcarbamoyl)pyrrolidine-1-carboxylate Chemical compound CCOC(OCC)CCCNC(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C LFXFZLHJDSVYGL-AWEZNQCLSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- AWMSTUJDWIUHFA-UHFFFAOYSA-N tris(3-acetamidophenyl) phosphite Chemical compound CC(=O)NC1=CC=CC(OP(OC=2C=C(NC(C)=O)C=CC=2)OC=2C=C(NC(C)=O)C=CC=2)=C1 AWMSTUJDWIUHFA-UHFFFAOYSA-N 0.000 description 1
- DKWOCPCDQZHYCM-UHFFFAOYSA-N tris(4-acetamidophenyl) phosphite Chemical compound C1=CC(NC(=O)C)=CC=C1OP(OC=1C=CC(NC(C)=O)=CC=1)OC1=CC=C(NC(C)=O)C=C1 DKWOCPCDQZHYCM-UHFFFAOYSA-N 0.000 description 1
- JMDQYARJPJNJGX-UHFFFAOYSA-N tris[4-(methanesulfonamido)phenyl] phosphite Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OP(OC=1C=CC(NS(C)(=O)=O)=CC=1)OC1=CC=C(NS(C)(=O)=O)C=C1 JMDQYARJPJNJGX-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
Definitions
- the present invention relates to novel modulators (inhibitors and stimulators) of serine peptidases and proteases in general and dipeptidyl peptidase IV, prolyl oligopeptidase (PO) , dipeptidyl peptidase II (DPP II) , fibroblast activation protein ⁇ (FAP ⁇ ) , lysosomal Pro-X carboxypeptidase and elastase in particular.
- the invention further relates to the preparation and use of these compounds for selective modulation (inhibition or stimulation) of serine peptidases and proteases and to pharmaceutical preparations comprising them.
- peptidase and “protease” are used interchangeably.
- Serine peptidases/proteases like granzymes, mast cell tryptase, elastases, trypsin-like enzymes, prolyl oligopeptidase, dipeptidyl peptidase II and dipeptidyl peptidase IV are involved in various processes that take place in the body, such as blood coagulation, inflammation, immune response, and control of peptide hormone metabolism in general.
- serine peptidases are a physiological necessity they may also constitute a potential health hazard in case serine peptidase activity in the body is not controlled.
- Serine peptidases have been described to be involved in various medical indications. Blood coagulation serine proteases are for example responsible for vascular clotting as well as cerebral and coronary infarction. Chymotrypsin-like enzymes and plasmin are involved in tumour invasion, tissue remodeling and clot dissociation. Pancreatitis, emphysema, rheumatoid arthritis, inflammation and adult respiratory distress syndrome may in some instances be caused by the uncontrolled proteolysis by other serine proteases such as elastase. Serine peptidases form a large group with many members that are divided into clans and families.
- DPP IV dipeptidyl peptidase IV
- EC 3.4.14.5 dipeptidyl peptidase IV
- DPP IV EC 3.4.14.5
- DPP IV is a highly specific exopeptidase with a serine type mechanism of protease activity, cleaving off dipeptides from the amino-terminus of peptides with proline or alanine at the penultimate position.
- DPP IV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues, and is also found in body fluids. In the hematopoietic system, DPP IV was identified as the leukocyte antigen CD26.
- Prolyl oligopeptidase (PO, EC 3.4.21.26) was discovered in the human uterus as an oxytoein-degrading enzyme.
- the enzyme shows a high specificity for proline residues and hydrolyses the peptide bond at its carboxyl side, provided the proline is not at the peptide amino- terminus.
- This endopeptidase has like DPPIV, a serine type mechanism and it is characterised by its activity on oligopeptides.
- PO cleaves specifically the Pro-Xaa bond in biological active peptides (substance P, ocytoxin, vasopressin, gonadoliberin, bradykinin, neurotensin) and it is likely to participate in the in vivo regulation of their actions.
- FAP ⁇ Fibroblast activation protein ⁇
- Dipeptidyl peptidase II (DPPII, EC 3.4.14.2) releases N-terminal dipeptides from oligopeptides, provided their N-termini are unsubstituted.
- the preferred PI residues are Ala and Pro.
- An increase in serum DPPII has been observed in cancer patients and extremely high levels of DPPII are present in human carcinoma cells.
- DPPII can be inhibited by the classical (unspecific) inhibitors of serine type peptidases (J.K.McDonald in Barrett, supra. p. 408-411) .
- Elastases are defined by their ability to release soluble peptides from insoluble elastin fibers by a proteolytic process called elastinolysis.
- Elastase belongs to the chymotrypsin family of leucocyte serine- type proteases.
- Human leucocyte elastase (EC 3.4.21.37) preferentially cleaves peptides with a Val in PI but also peptide bonds with Ala, Ser and Cys in PI are hydrolyzed and it is believed to possess an extended substrate- binding site.
- the possible involvement of leucocyte elastase in inflammatory diseases triggered the search for development of specific inhibitors.
- a pathological role in lung emphysema, cystic fibrosis and adult respiratory distress syndrome has been suggested (J. Bieth in Barrett, supra. p. 54-60; D.Farley et al. in Pharmaceutical Enzymes, ed. A. Lauwers and S. Scharpe, Marcel Dekker, Inc., 1997, p. 306-326).
- Lysosomal Pro-X carboxypeptidase (prolylcarboxypeptidase, angiotensinase C, EC 3.4.16.2) cleaves C-terminal amino acids from peptides with the general structure X-Pro-Y, where X is either a blocking group, another protected amino acid, or a peptide, and Y is an aromatic or aliphatic amino acid with a free carboxylie group.
- the enzyme is recovered from the lysosomal fraction of different tissues. Although the enzyme has an acidic pH optimum for small synthetic substrates (pH 5.0), it retains 50% of its maximal activity at physiological pH towards larger peptide substrates.
- the phosphonate may be substituted with one or two phenyl groups which in turn may be mono-, di- or trisubstituted with a halogen, C 1 -C 6 alkyl, C 1 -C 6 perfluoralkyl, C.-C 6 alkoxy, N0 2 , CN, OH, C0 2 H, amino, C 1 -C 6 alkyla ino, C 2 -C 12 dialkylamino, C 1 -C 6 acyl, and C 1 -C 6 alkoxy-CO-, C,-C 6 alkyl-S-.
- the present inventors in the research that led to this invention, developed independently the same compounds. However, they found that regarding toxicity, stability and efficacy these compounds did not perform optimally.
- the object of the present invention to provide inhibitors of serine peptidases/ proteases that have a more optimal combination of inhibitor capacity, stability in plasma, safety, bioavailability, duration of action and straightforward synthesis.
- the invention has for its object to provide compounds that have a stimulating activity on serine peptidases/ proteases.
- modulating compounds More in particular, the invention provides compounds having such a more optimal combination for modulating the activity of DPP IV, PO, 5
- DPP II DPP II, FAP ⁇ , lysosomal Pro-X carboxypeptidase and elastase.
- compounds as claimed in claim 1 are very potent modulators, in particular inhibitors, of serine peptidases/proteases in general and DPP IV, DPP II, PO, FAP ⁇ , lysosomal Pro-X carboxypeptidase and elastase in particular.
- the compounds as listed in claim 12 were found to be potent inhibitors of DPP IV and PO.
- the compounds of the invention are based on peptides. These peptides are constituted by either naturally occurring amino acids or other amino acids. The C-terminal carboxyl function is replaced by a phosphonate group.
- - A is (R2) or H or C,-C 6 alkyl or halogenoalkyl, except perfluoroalkyl, 6 the phenyl group is mono-, di- or trisubstituted with Rl or R2;
- X is a peptide- or amino acid-derived moiety; A and the phenyl group substituted with Rl may optionally form a biphenyl diester; all Rl substituents and R2 substituents are each independently selected from the group consisting of: a) C 1 -C 6 acylamino; b) aroylamino, optionally substituted at the o- and/or p- and/or m- position with alkyl, in particular C ⁇
- C 6 alkyl, and/or a halogen c) C 1 -C 6 alkylsufonylamino ; d) arylsulfonylamino, optionally substituted at the o- and/or p- and/or m- position with alkyl, in particular C 1 -C 6 alkyl, and/or a halogen; e) ⁇ aminoacylamino wherein the ⁇ aminoacyl represents a side chain blocked or unblocked ⁇ -amino acid residue with the L, D or DL configuration at the ⁇ -carbon atom selected from the group consisting of: alanine, methionine, methionine sulfoxide, arginine, homoarginine, phenylalanine, aspartic acid, proline, hydroxyproline, asparagine, serine, cysteine, threonine, histidine, glycine, tyrosine, glutamic acid, pyroglutamic
- X is a moiety of the general formula (AA) -aa-, wherein: p indicates that there may be 0, 1, 2, 3, 4 or
- AA and aa are selected from one of the following: a) ⁇ -amino carboxylic acids with in ⁇ position an optionally substituted C 1 -C 6 alkyl or aryl or aralkylmoiety; b) alanine, methionine, methionine sulfoxide, arginine, homoarginine, phenylalanine, aspartic acid, proline, hydroxyproline, asparagine, serine, cysteine, threonine, histidine, 8 glycine, tyrosine, glutamic acid, pyroglutamic acid, tryptophan, glutamine, valine, norvaline, isoleucine, lysine, leucine, norleucine, thioproline, homoproline, 1,2,3,4-tetrahydro- isoquinoline-3-carboxylic acid (Tic) ,
- X is M-(AA) p -aa- wherein: p, AA and aa are as defined above;
- M is selected from: a) the group consisting of optionally substituted -CONH 2 , -CSNH 2 , -S0 2 NH 2 , phenyl-S0 2 -, phenyl-CH 2 S0 2 -, 2-furyl- acryloyl ; and b) the group of protecting groups consisting of: acetyl, adamantyloxycarbonyl, benzyl- oxycarbonyl, benzoyl, benzyl, t-butoxycarbonyl, t-butyl, 2,4-dinitrophenyl, formyl, fluorenylmethoxycarbonyl, 4-methoxybenzyl, tosyl, trifluoro- acetyl, trityl, phthaloyl, phenylalkylcarbonyl, 2-indanylacetyl, 2-(l,2,3,4-tetrahydronaphty1) acetyl,
- X represents AA-aa-, wherein aa is proline and AA is as defined above.
- X represents AA-aa-, wherein AA and aa are both proline.
- Rl and R2 may further be selected from:
- aa is alanine and preferably at least the AA coupled to aa is proline or phenylalanine.
- Preferred examples of the compounds are Phe-Ala-diphenyl- phosphonate or Pro-Ala-diphenylphosphonate and pharmaceutically acceptable salts thereof.
- the invention can be divided in three groups of compounds.
- the phosphonate group is a diphenyl-phosphonate group
- the first group thus consists of compounds of the general formula II: 10
- the compounds are 2,2' biphenyl diesters of ⁇ -aminoalkyl phosphonic acid having the general formula III:
- the third group (group 3) consists of compounds having the general formula IV: Rl o
- A wherein X and Rl are as defined above, A is H or C 1 -C 6 alkyl or halogenoalkyl, except perfluoroalkyl.
- X is preferably selected from Cbz-Gly-Leu-Phe-, Z-Phe- Pro-Phe, and Suc-Val-Pro-Phe-.
- prolyl oligopeptidase X may be selected from among the following: Cbz-Gly-Gly- Pro-, Cbz-Pro-Pro-, Boc-Val-Pro-Val-, MeO-Suc-Ala-Ala- Ala-Val-, MeO-Suc-Ala-Ala-Pro-Val-.
- X is as follows: Ala-Pro-, Pro-Pro-, Ala-Pip-, Phe-Pro-, lie- Pro-, Arg-Pro-, pF-Phe-Pro-, cyclohexylala-Pro-, Pro- azetidine-, Phe-azetidine-, Lys-Pro-, Lys-azetidine-.
- X is selected from among Suc-Lys(Cbz) -Val-Pro-Val-, Z-Ala- 11
- X may be selected from Cbz-(4-amidinophenylalanine)-, Z- Met-, 3-phenyl propanoyl-Pro-(4-aminophenylalanine)-, Cbz-Thr-(4-amidinophenylglycine)-, and Boc-D-Phe-Pro-(4- amidinophenylalanine)-.
- X may be Z-Phe-Pro-Phe-, Z-Phe-, Suc-Val-Pro-Phe-, MeO-Suc-Ala-Ala-Pro-Phe-, or MeO-Suc- Ala-Ala-Ala-Phe- when the enzyme to be inhibited is chymotrypsine.
- X may be selected from among Cbz-Orn-, Cbz-Lys-Ala-, Cbz- Lys, Cbz-Ho oLys-, Cbz-(4-amidinophenylalanine)-, Cbz-(4- amidinophenylglycine) -, Ph-CH 2 -S0 2 -Gly-Pro- (4-amidino- phenylglycine)-, 3-(2-furyl)acryloyl-(4-amidinophenyl- glycine) , Cbz-Lys-(4-amidinophenylglycine)-, Cbz-Lys-Ala- (4-amidinophenylglycine)-, Cbz-Thr-(4-amidinophenyl- glycine)-, 3-(2-furyl)acryloyl-(4-amidinophenylalanine)
- V8 protease of S . aureus X can be either Acetyl.Glu- or Acetyl.Asp-.
- Rl and R2 are preferably selected from the group consisting of: 3-AcNH, 4-AcNH, 4-MeS0 2 NH, 3-H 2 NCONH, 3-H 2 NCONH, 4-(N-Bz-Gly-NH) , 4-(H-Gly-NH) , 4 (H- (S) -Ala-NH) , 4-((S)-Pyr-NH) , 4-((2S)-Me0 2 CCH(NHAc)CH 2 ) , 4-Me0 2 C, 4- (Et0 2 CCH 2 NHCO) , 4-(Me0 2 C(CH 2 ) 2 NHCO) , 4-CH 3 (CH 2 ) 2 NHCO.
- Particularly preferred compounds of group 1 are the following:
- a compound having an inhibitory activity for DPP IV is for example 2 , 2 ' -Biphenyl l-( (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate hydrochloride (19) or a pharmaceutically acceptable salt.
- Powers' leaving groups are among others 2- methylphenol (o-cresol) , 3-methylphenol (m-cresol) and 4- methylphenol (p-cresol) .
- the compounds belong to the group of cresols, which are desinfectants. These compounds are toxic to humans. Chronic poisoning from oral or percutaneous absorption may produce digestive disturbances, nervous disorders, vertigo, skin eruptions, jaundice, oliguria, uremia.
- Another leaving group in Powers' compounds is 4-hydroxybenzoic acid methylester (methyl paraben, Nipagin M) which is also a preservative in foods beverages and cosmetics and of which allergic reactions are frequently observed.
- 1,4-Benzenediol (hydroquinone) is a photographic developer and reducer and is used as an antioxidant. At very low concentrations there is no systemic toxicity. However, ingestion of more than 1 g results in nausea, vomiting, shortness of breath, cyanosis, convulsions and collapse. It is lethal in a dose above 5
- the leaving groups of the compounds of the invention are for example 4-hydroxyacetanilide (paracetamol, compound He) which is used commonly as a very safe analgesic/antipyretic drug.
- Another leaving group is 4-hydroxyhippuric acid ethyl ester (compound lln) of which no toxicity has been noticed, and hippuric acid is known to be a metabolite occurring in human metabolism and a normal constituent in human urine.
- the compounds of the invention can be used for the therapy of pathological states associated with excessive, impaired or unbalanced activity of said enzymes.
- the invention relates to the compounds for use as a therapeutical agent.
- the invention relates to the compounds for use in the treatment or prophylaxis of inflammation, vascular diseases, organ specific or systemic auto-immune diseases (e.g. Graves' disease or multiple slerosis, inflammatory bowel disease) , joint diseases, muscle diseases, neurological diseases, obesity, diseases associated with benign and malign cell transformation, spreading of malignant cells, conditions of glucose-intolerance, abnormal growth or growth retardation, rejection of foreign cells or tissues after transplantation, abnormalities in blood cell development, abnormal blood clotting, pain, or diseases of the central nervous system.
- organ specific or systemic auto-immune diseases e.g. Graves' disease or multiple slerosis, inflammatory bowel disease
- joint diseases e.g. Graves' disease or multiple slerosis, inflammatory bowel disease
- muscle diseases e.g. Graves' disease or multiple slerosis, inflammatory bowel disease
- neurological diseases e.g
- the involvement of plasma prekallikrein or kallikrein in shock is described by W. Colman in Barrett, A., et al., supra. page 147-153.
- the compounds of the invention can be used for prevention and treatment of thrombosis and conjunction therapy of acute myocardial infarction by specifically inhibiting Factor X (Vlasuk, G.P. in New Therapeutic Agents in Thrombosis and Thrombolysis, Sasahara, A., Loscalzo, J., eds (1997), pages 261-283), thrombin
- Elastase plays a role in autoim unity diseases such as rheumatoid arthritis (Mo ohara, S. et al., Clin. Rheumatol. 16 (1997), 133-140; and Shinguh, Y. et al., Eur. J. Pharmacol. 337 (1997), 63-71; Barrett, supra. Lauwers & Scharpe, supra) .
- PO Chappell, M.C. et al., Braz. J. Med. Biol. Res. 31 (1998), 1205-1212; and Umemura, K. et al., Br. J. Clin. Pharmacol. 43 (1997), 613-618). PO is furthermore involved in muscle dystrophy
- DPP IV is a very versatile enzyme according to its localisation and different substrates and correlated with pain (Shane, R. et al., Brain Res. 815 (1999), 278- 286) and obesity (Pederson, R. et al., Diabetes 47 (1998) 1253; Flint, A. et al., J. Clin. Investigation 101 (1998), 515-520) and tissue repair (Drucker, D. et al., Am. J. Physiol. 276 (1999), G79-91) .
- the present invention also includes derivatives which have been modified in the N-terminal amino acid side chain without abolishing the reactivity with the active site.
- modifications are the incorporation of a radioactive label such as Iodine 125 into tyrosine, extension of the side chain to attach biotin or a fluorophore.
- a radioactive label such as Iodine 125 into tyrosine
- extension of the side chain to attach biotin or a fluorophore to improve the half-life in the circulation the peptide bond between the two amino acids may be replaced by a non-hydrolyzable bond.
- the incorporation of a radioactive label is useful in diagnostic methods using the modulating compounds.
- the compounds are for example labeled for use in diagnostic and research methods such as fluorescence and radio-assays, imaging, in situ histochemical and cytochemical staining etc. as will be further explained hereinbelow.
- the invention relates to the use of the compounds for the preparation of a therapeutical composition for modulating (inhibiting or stimulating) the activity of serine proteases.
- a therapeutical composition for modulating (inhibiting or stimulating) the activity of serine proteases.
- Such therapeutical composition is then specifically intended for treatment and prophylaxis of the conditions listed above. 18
- the invention provides a pharmaceutical preparation comprising one or more compounds of the invention and a suitable excipient, carrier or diluent.
- Such pharmaceutical preparations are intended for the treatment and prophylaxis of the above conditions.
- Acceptable excipients, carriers and diluents are well known and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985) .
- Preservatives, stabilizers, dyes and flavoring agents may be provided in the pharmaceutical compositions.
- sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives.
- antioxidants and suspending agents may be used.
- the compounds of this invention may be formulated and used as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for injectable administration, aerosols, galenic preparations for topical and bucal administration and aerosols for nasal administration.
- absorption enhancing preparations e.g. liposomes
- the amount of the active substance (s) in a dosage unit may vary between 0.001 mg and 1 g.
- the compounds or pharmaceutical compositions of this invention can be used alone or in combination with one another, or in combination with other therapeutic or diagnostic agents.
- Such other therapeutic or diagnostic agent(s) can have a different dosage form or can be present in the same dosage form as the compounds of the invention.
- the dosage for the compounds of the present invention can range broadly depending upon the desired effects and the therapeutic indication.
- the invention also relates to a method for in vitro inhibition or stimulation (modulation) of protease activity by means of a suitable concentration of a 19 compound of the invention.
- a suitable concentration of a 19 compound of the invention is in particular useful when a protease inactivates a peptide prior to measurement thereof in a peptide assay.
- the compounds of the invention can be used to inhibit the degradation of the peptide substrate by the enzyme in such assay.
- the compounds of the invention are also useful in a method for the 'ex vivo' inhibition of protease activity, such as the treatment outside the body of cells and organs for transplantation in order to avoid rejection thereof by the recipient body.
- the compounds of the invention can be used in a method for in vivo inhibiting or stimulating (modulating) protease activity by means of administering to a living organism a suitable amount of a compound of the invention.
- Such modulation can be used for pharmacotherapy of disease states related to one of the following conditions: inflammation, organ specific or systemic auto-immune diseases, non-malignant disorder of leukocytes and/or immunoglobulins, rejection of cells or tissues after transplantation, tissue destructive and bone degenerative diseases, neuroendocrine dysfunction, glucose-intolerance, obesitas, functional gastrointestinal disorder, abnormal growth or growth retardation, thrombosis and hemorrhage, vascular and cardiopulmonary diseases, neurodegenerative and affective disorders, pain, diseases associated with neoplasia.
- the invention also relates to the diagnostic use of the compounds.
- Labeled inhibitors or stimulators can be used essentially in the same type of applications as labeled monoclonal antibodies, e.g. fluorescence and radioassays, cytofluorimetry, fluorescence activated cell sorting etc.
- the principles of such techniques can be found in immunochemistry handbooks, for example: Coligan, J. et al., Current Protocols in Immunology, vol. 1, 2 & 3, Wiley, 1998. 20
- the compounds of the present invention can also be used as affinity ligands for analytical and preparative purposes.
- modulators can be used to directly visualize the cellular distribution of the target protease.
- the label can be fluorescent for fluorescence microscopy, radioactive for autoradiography, or electron dense for electron microscopy.
- the target structures can be whole cells, cells fixed onto slides or sections through solid tissue.
- a useful modification of these techniques is to use an indirect (“sandwich") assay employing the specific high affinity interaction between biotin and avidin (Coligan et al . , supra) .
- modulators labeled with a suitable isotope can be injected.
- tumour can be visualized by radioscintigraphy.
- the principles of imaging are summarized by A. Bamias & A.A.Epenetos (1995) , Monoclonal antibodies, production, engineering and clinical application (M.A. Ritter and M.M. Ladyman, eds.) Cambridge University Press, Cambridge, pp. 222-246) .
- the modulators of the invention are suitable for the diagnostic applications described above, such as imaging and histochemical staining of the respective proteases end peptidases, because they form covalent, long-lived adducts with the proteases and peptidases. Because of their small size they are expected to penetrate tissue more easily than, for example, antibodies. In the case of DPP IV it was found that the modulators only recognize DPP IV which is native and enzymatically active. Formulations of the compounds to be used in diagnostic applications are also part of this invention. 21
- the invention is not limited to the compounds as claimed but also relates to pharmaceutically acceptable salts thereof.
- the compounds of the invention may be pure diastereo-isomers or racemic mixtures.
- Serine protease activity can interfere with enzymatic assays for other substrates by cleaving the substrate used in the test and thereby giving either false positive (when a chromogenic substrate is cleaved) or false negative results (when a peptide substrate is degraded) .
- the inhibitors of this invention can be used to inactivate contaminating serine proteases or peptidases before carrying on with the analysis.
- This application relates to compounds that can either inhibit or stimulate the activity of serine proteases and peptidases. Because the activity of individual compounds of the group of compounds may be opposed (i.e. either inhibiting or stimulating) the general terms "modulating” and “modulation” are intended when reference is made to a group of compounds. 22
- Individual compounds will have either a inhibitory or a stimulatory activity on individual serine peptidases and proteases.
- a prerequisite of the invention is that the compounds that are claimed are active, i.e. have a modulatory (either inhibitory or stimulatory) activity on serine peptidases or serine proteases.
- di(4-acetamidophenyl) l-(S)-prolyl- pyrrolidine-2-(R,S)- phosphonate (He) is considered as a major improvement and will be a highly valuable DPP IV inhibitor for further studies on the biological function of the enzyme and the therapeutic value of its inhibition.
- R Z, Boc or Trr ⁇ ivorv
- Reagents i) PC1 3 ; ii) HC1 ; iii) HOAc, 90 °C, 2 h ; iv) HCl/EtOAc (1 M) ; v) H 2 , Pd/C
- Rl a) H ; b) 4-OMe ; c) 4-OAc (4-OH for 11) ; d) 3-NHAc ; e) 4-NHAc ; f) 4-NHS ⁇ 2 Me ; g) 3-NHCONH 2 ; h) 4- (N-Bz-Gly-NH) ; i) 4- (N-Z-Gly-NH) [4-(H-Gly-NH) for 11] ; j) 4- (N-Z-(S) -Ala-NH) [ 4- (H-(S) -Ala-NH) for 11] ; k) 4-( (S) -Pyr-NH) ; 1) 4-[(2S)-Me0 2 CCH(NHAc)CH 2 ] ; m) 4-COOMe ; n) 4-(CONHCH 2 COOEt) ; o) 4-[CONH(CH 2 ) 2COOMe] ; p) 4-(CONH(CH 2 COOEt
- the 4-methylsulfonyl- aminophenol 8f was prepared from the corresponding sulfonylchloride and 4-aminophenol.
- the 4-acylaminophenols 8h-k were prepared by condensation of the corresponding carboxylic acid with 4-aminophenol using the mixed anhydride method.
- N-acetyl-L-tyrosine methyl ester (81) was prepared as described (Jackson, E. L. O-p-Toluenesulfonyl-L-tyrosine, its N-acetyl and N-benzoyl Derivatives. J. Am. Chem. Soc. 1952, 74, 26
- the glycine derivative 8n was obtained after condensation of glycine ethyl ester with 4-hydroxybenzoic acid using diphenylphosphoryl azide (DPPA) .
- DPPA diphenylphosphoryl azide
- the synthesis of the 4-hydroxybenzoic acid amides 8o and 8p was accomplished by coupling of 4-acetoxybenzoic acid with the corresponding amine using the mixed anhydride method followed by mild alkaline hydrolysis of the phenyl esters 12 and 13 (B ⁇ chi, G. ; Weinreb, S. M. Total Syntheses of Aflatoxins Ml and Gl and an Improved Synthesis of Aflatoxin Bl. J. Am. Chem. Soc. 1971, 93, 746-752).
- the triaryl phosphites 9 were then synthesised from the corresponding substituted phenols 8 and phosphorous trichloride.
- Cyclic N-protected 2 , 2 ' -biphenyl derivatives 17a and 17b were prepared by reacting 2,2 '-biphenylacetyl phosphite (16) with aldehyde 7a or 7b in acetic acid (Scheme 2) . Attempted removal of benzyloxycarbonyl (Z) protection from phosphonate 17a by hydrogenolysis with a Pd/C catalyst in methanol resulted in the opening of the dioxaphosphepan ring to give the mixed methyl aryl ester 18. Deprotection of the Boc-derivative 17b with HCl/EtOAc yielded free 2,2' -biphenyl phosphonate 19.
- 3-Acetamidophenol (8d) 4-aminobutyraldehyde diethyl acetal, PC1 3 , diphenyl- phosphoryl azide (DPPA) and 4-acetoxybenzoic acid were obtained from Sigma-Aldrich Chemie BV, Belgium.
- 4-Acetamidophenol (paracetamol) (8e) was obtained from Sterling Organics Ltd., England. Purity of all new synthesised compounds were checked by TLC, ⁇ - MR, 13 C-NMR or MS. The final products were checked by TLC, 1 H-NMR, 13 C-NMR, FAB-MS and(or) elemental analysis.
- Optical rotation was measured on a Perkin-Elmer 241 polarimeter. Melting points were determined on a Digital Melting Points Apparatus (Electrothermal) and are uncorrected. Z- and Boc-protected amino acids were prepared according to standard procedures (Bodanszky, M. & Bodanszky, A. In The Practice of Peptide Synthesis, 2nd ed. ; Springer-Verlag: Berlin Heidelberg, 1994; pp 11-18 and 28-29) using Z-Cl and (Boc) 2 0, respectively.
- ⁇ -Alanine methyl ester was synthesised by treatment of the amino acid in methanolic HC1 similarly to described procedure (Bodanszky & Bodanszky (1994), supra) .
- the preparation of 4- (Z-(S) -prolyl) aminobutyraldehyde diethyl acetal (6a) was described earlier (Belyaev et al., (1995), supra) . 28
- Tris (3-acetamidophenyl) phosphite (9d) Tris (3-acetamidophenyl) phosphite (9d) .
- Tris (4-acetamidophenyl) phosphite (9e) Tris (4-acetamidophenyl) phosphite (9e) .
- Tris (4-methylsulfonylaminophenyl) phosphite (9 ) Tris (4-methylsulfonylaminophenyl) phosphite (9 ) .
- Tris(4-methoxycarbonylphenyl) phosphite (9m) Tris(4-methoxycarbonylphenyl) phosphite (9m) .
- Tris 4- r 2 - (methoxycarbonyl ) ethylaminocarbonyl ] henyl ) phosphite (9o) .
- diaryl l-(t-butyloxycarbonyl-(S) -prolyl) - pyrrolidine-2-phosphonate (10) or diaryl l-(trityl-(S)- prolyl) pyrrolidine-2-phosphonate (10, 5 mmol) was dissolved in a IM HC1 solution in EtOAc (25 mL) and the solution was stirred for 2 h at room temperature. Dry ether (30 mL) was added and the mixture was left in the fridge overnight. If the product crystallised, the crystals were collected by filtration, otherwise the oil was triturated in dry ether. The material obtained was dried in vacuum over NaOH pellets.
- Diphenyl alanine phosphonates were synthesized following the principle described by Oleksyszyn et al., Synthesis 1979, 985-986. The method was used with acetaldehyde for the preparation of the alanine analogue, diphenyl 1-benzyloxycarbonylaminoethane phosphonate.
- the mixed anhydride method was used to couple diphenyl 1-aminoethane phosphonate to various amino acids : glycine, L-alanine, L-valine, L-isoleucine,
- the mixture was heated at 80-85°C for one hour and the volatile products were removed on a rotary evaporator under reduced pressure with heating on a boiling water bath.
- the oily residue was dissolved in methanol (180 ml) and left overnight for crystallization at -10°C.
- the crystalline ester was collected by filtration, redissolved in a small amount of hot chloroform (30-40 ml) and recrystallization occurred by adding a 4-fold volume of methanol.
- Diphenyl 1 (R.S) -rN-benzyloxycarbonyl-L-phenylalanyl]- aminoethane phosphonate Diphenyl l(R.S)-fN-benzyl- oxycarbonyl-L-prol ⁇ l1 aminoethane phosphonate (T, Q) General procedure for the mixed anhydride coupling with isobutyl chloroformate.
- the Z-protected amino acid (5 mmol) was dissolved in dry tetrahydrofuran (25 ml) and cooled to -150°C in an ice-sodium chloride bath.
- N-Methyl- morpholine (5 mmol, 0.51 g) and isobutyl chloroformate (5 mmol, 0.68 g) were added to this solution and stirring was continued for 10 minutes.
- a solution of Y (5 mmol, 1.79 g) and triethylamine (5 mmol, 0.51 g) in dimethyl- formamide (10 ml) was introduced dropwise to the stirring mixture, keeping the temperature below -100 °C.
- the Z-protected dipeptide phosphonates T and Q (1.5 mmol) were dissolved in dry methanol (20 ml) and acetic acid (0.7 ml). After the addition of palladium on charcoal (10%, 0.25 g) , the air above the solution was displaced with nitrogen and hydrogen was led over the solution for 3 hours. Before removing the solvent under reduced pressure, the flask was flushed with nitrogen for 10 minutes. The residue was dissolved in dry chloroform (15 ml) and 0.5N hydrogen chloride in ethyl acetate was added slowly to the stirring solution. Removal of the solvent under reduced pressure and co-evaporation with 0.5N hydrogen chloride in ethyl acetate (10 ml) afforded a white foam, which was triturated with dry ether. After 46
- 4-alanylamino (llj) have a comparable activity, but are considerably less stable in plasma than the 4-acetylamino (He) substituted diphenyl phosphonate.
- the O-methyl derivative (18) is almost as potent and stable as 5.
- DPP IV was purified from human seminal plasma as described previously (De Meester et al., J. Immunol. Meth. 189, 99-105 (1996)). Enzymatic activity was measured at 37 ⁇ C in a Spectramax 340 (Molecular Devices) microtiterplate reader using Gly-Pro-p-nitroanilide (Sigma) as a chromogenic substrate. The reaction was monitored at 405 nm and the initial rate was determined between 0 and 0.25 absorbance units. The reaction mixture contained 2 mM substrate, approximately 1 mU of DPP IV, 40 mM TRIS-HC1 buffer, pH 8.3, and a suitable amount of inhibitor (ranging between 0 an 10 mM) in a total volume of 0.2 ml. Activity measurements were routinely performed in duplicate.
- the IC 50 value is defined as the concentration of inhibitor required to reduce the DPP IV activity to 50% after a 15 min pre-incubation with the enzyme at 37 °C before addition of the substrate.
- Inhibitor stock solutions 100 mM were prepared in DMSO or phosphate buffer, pH 7.4, depending on the solubility of the compound, and stored at -20°C. Stock solutions were diluted with 50 mM TRIS-HC1 buffer, pH 8.3, as required, immediately before the experiment. Since the compounds described in this paper completely inactivate DPP IV following pseudo-first order kinetics, the IC 50 value is inversely correlated with the second order rate constant 49 of inactivation (Lambeir et al., (1996), supra) .
- IC 50 values were determined after 15 min pre-incubation with DPP IV at 37 *C. The listed values are the average of n independent measurements ⁇ the standard deviation. Functional stability in plasma was estimated by fitting the inverse of the apparent IC 50 values versus time with a single exponential decay. The half-life is listed ⁇ the standard error of fit. 50
- the inactivation rate constant was determined from the time course of inhibition as described before (Lambeir et al., (1996), supra) .
- the functional stability of the inhibitors was estimated by measuring the inhibitory potency (apparent IC 50 ) of a 1 mM dilution of the compounds in citrated human plasma at 3 or 4 time points between 0 and 300 min at 37 °C. Fitting the inverse of the apparent IC 50 values versus time with a single exponential decay gives the half-lives reported in table 1.
- IC 50 values are expressed in ⁇ M
- Prolyl oligopeptidase was purified from human platelets and the enzyme activity was measured using Z-Gly-Pro-AMC (4.4 mM) as the substrate in a K-phosphate buffer 100 mM, pH 7.5 containing 1 mM EDTA, 1 mM dithiothreitol and 1 mM NaN 3 . The incubation was carried out during 20 min at 37°C. The reaction was stopped by the addition of 5 volumes 1.5 M acetic acid. Fluorescence was measured at 370 and 440 nm as excitation and emission wavelengths respectively. The inhibitors were added at concentrations varying between 1 ⁇ M and 1 mM.
- Dipeptidyl peptidase II was semi-purified from rabbit kidney and its activity was determined by the hydrolysis of Lys-Ala-4-Me0-2-NA 1.4 mM (Sigma, L-2270) in 100 mM acetate buffer, pH 5.5 containing 2 mM EDTA. After incubation during 20 minutes at 37 °C, the reaction was stopped by the addition of 10 fold excess sodium-acetate pH 3.6. The fluorescence of the formed 4-MeO-2-NA was measured at 340 and 425 nm as excitation and emission wavelengths respectively. For the determination of the IC 50 values the compounds were tested 52 at a series of concentrations ranging from 1 ⁇ M to 5 mM during incubation.
- Peripheral blood mononuclear cells were isolated from buffy coats (obtained from the blood transfusion center of Antwerp). After dilution (1/4) in phosphate buffer saline (PBS) , cells were layered onto Ficoll-Hypaque density gradient (Pharmacia, Uppsala, Sweden) and centrifuged at room temperature at 550 x g during 20 min. The interfaces were collected and washed 3 times in RPMI-1640. Finally the cells were resuspended at lxlO 6 cells/mL in RPMI-1640 containing 10 % heat-inactivated foetal calf serum, and antibiotics (penicillin/streptomycin) (Gibco) .
- PBS phosphate buffer saline
- the remaining cells were washed 3 times in PBS and the final cell pellet was solubilised in 200 ⁇ L PBS containing 1 % v/v Triton X-100 and 100 KIU/mL aprotinin (Bayer) and centrifuged during 10 min at 20000 x g. Supernatants were used immediately for enzyme assay and protein determination by the Bradford micro-assay. Specific activities (U/g protein) are compared and the % inhibition is given toward control samples without inhibitor.
- FIG. 5 depicts residual plasma DPP IV activity in rats treated subcutaneously on days 0 to 5 with He.
- mice Male New Zealand white rabbits (2.5-3.5 kg), istar rats (250-350 g) and Swiss mice (23-36 g) were allowed to adjust to their environment for at least 7 days. They received standard diet and water ad lib. Test compounds were dissolved in 50 mM phosphate buffer pH 7.4 at concentrations ranging from 10-100 mg/mL and stored in aliquots at -80"C and were thawed ex tempore. Rabbits 55 received a single slow intravenous bolus injection of test compound or vehicle alone in the marginal ear vein. Blood was sampled from the central ear artery. Rats and mice were injected subcutaneously or intraperitoneally.
- Rat blood samples were obtained under anesthesia (Forene) from the vena femoralis by puncture after incision of the skin. The mice were bled by orbita puncture after induction of anesthesia with pentobarbital. After clotting, blood samples were centrifuged (3000 x g, 10 min) and the resulting sera were stored at -80 ⁇ C until assayed for DPP IV activity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to new compounds having modulatory (inhibitory and stimulatory) activity on serine peptidases and proteases in general and dipeptidyl peptidase IV, prolyl oligopeptidase (PO), dipeptidyl peptidase II (DPP II), fibroblast activation protein α (FAPα), lysosomal Pro-X carboxypeptidase and elastase in particular. These new compounds can be used for the treatment of a variety of disease states in which these peptidases are involved.
Description
1
SERINE PEPTIDASE MODULATORS
Field of the invention
The present invention relates to novel modulators (inhibitors and stimulators) of serine peptidases and proteases in general and dipeptidyl peptidase IV, prolyl oligopeptidase (PO) , dipeptidyl peptidase II (DPP II) , fibroblast activation protein α (FAPα) , lysosomal Pro-X carboxypeptidase and elastase in particular. The invention further relates to the preparation and use of these compounds for selective modulation (inhibition or stimulation) of serine peptidases and proteases and to pharmaceutical preparations comprising them. The terms "peptidase" and "protease" are used interchangeably.
Background of the invention
Serine peptidases/proteases, like granzymes, mast cell tryptase, elastases, trypsin-like enzymes, prolyl oligopeptidase, dipeptidyl peptidase II and dipeptidyl peptidase IV are involved in various processes that take place in the body, such as blood coagulation, inflammation, immune response, and control of peptide hormone metabolism in general. Although serine peptidases are a physiological necessity they may also constitute a potential health hazard in case serine peptidase activity in the body is not controlled.
Serine peptidases have been described to be involved in various medical indications. Blood coagulation serine proteases are for example responsible for vascular clotting as well as cerebral and coronary infarction. Chymotrypsin-like enzymes and plasmin are involved in tumour invasion, tissue remodeling and clot dissociation. Pancreatitis, emphysema, rheumatoid arthritis, inflammation and adult respiratory distress syndrome may in some instances be caused by the uncontrolled proteolysis by other serine proteases such as elastase.
Serine peptidases form a large group with many members that are divided into clans and families. One member of the clan SC is dipeptidyl peptidase IV (DPP IV, EC 3.4.14.5), which is a highly specific exopeptidase with a serine type mechanism of protease activity, cleaving off dipeptides from the amino-terminus of peptides with proline or alanine at the penultimate position. In addition the slow release of dipeptides of the type X-Gly or X-Ser is reported for some naturally occurring peptides. DPP IV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues, and is also found in body fluids. In the hematopoietic system, DPP IV was identified as the leukocyte antigen CD26. Prolyl oligopeptidase (PO, EC 3.4.21.26) was discovered in the human uterus as an oxytoein-degrading enzyme. The enzyme shows a high specificity for proline residues and hydrolyses the peptide bond at its carboxyl side, provided the proline is not at the peptide amino- terminus. This endopeptidase has like DPPIV, a serine type mechanism and it is characterised by its activity on oligopeptides. PO cleaves specifically the Pro-Xaa bond in biological active peptides (substance P, ocytoxin, vasopressin, gonadoliberin, bradykinin, neurotensin) and it is likely to participate in the in vivo regulation of their actions. A role for PO in memory and other neural processes has been proposed (Yoshimoto T. and Ito K. in Handbook of proteolytic enzymes, eds. Barrett et al.. Academic Press, 1998, p. 272-374). Fibroblast activation protein α (FAPα) was discovered as a cell surface antigen of cultured normal fibroblasts. Its expression in vivo revealed to be very restricted on normal cells. In contrast, activated tumor stromal fibroblasts found in certain carcinomas express high levels of FAPα. The biological role of FAPα expression remains to be elucidated but speculations on functions in tissue remodeling and repair have been made (Rettig, FAPα in Barrett supra, p. 385-389) .
3
Dipeptidyl peptidase II (DPPII, EC 3.4.14.2) releases N-terminal dipeptides from oligopeptides, provided their N-termini are unsubstituted. The preferred PI residues are Ala and Pro. An increase in serum DPPII has been observed in cancer patients and extremely high levels of DPPII are present in human carcinoma cells. DPPII can be inhibited by the classical (unspecific) inhibitors of serine type peptidases (J.K.McDonald in Barrett, supra. p. 408-411) . Elastases are defined by their ability to release soluble peptides from insoluble elastin fibers by a proteolytic process called elastinolysis. Elastase belongs to the chymotrypsin family of leucocyte serine- type proteases. Human leucocyte elastase (EC 3.4.21.37) preferentially cleaves peptides with a Val in PI but also peptide bonds with Ala, Ser and Cys in PI are hydrolyzed and it is believed to possess an extended substrate- binding site. The possible involvement of leucocyte elastase in inflammatory diseases, triggered the search for development of specific inhibitors. Moreover, a pathological role in lung emphysema, cystic fibrosis and adult respiratory distress syndrome has been suggested (J. Bieth in Barrett, supra. p. 54-60; D.Farley et al. in Pharmaceutical Enzymes, ed. A. Lauwers and S. Scharpe, Marcel Dekker, Inc., 1997, p. 306-326).
Lysosomal Pro-X carboxypeptidase (prolylcarboxypeptidase, angiotensinase C, EC 3.4.16.2) cleaves C-terminal amino acids from peptides with the general structure X-Pro-Y, where X is either a blocking group, another protected amino acid, or a peptide, and Y is an aromatic or aliphatic amino acid with a free carboxylie group. The enzyme is recovered from the lysosomal fraction of different tissues. Although the enzyme has an acidic pH optimum for small synthetic substrates (pH 5.0), it retains 50% of its maximal activity at physiological pH towards larger peptide substrates. (Des-Arg9) -bradykinin and angiotensin II are possible natural substrates for lysosomal Pro-X
4 carboxypeptidase (Tan, F. and Erdόs, E. in Barrett et al., supra. p. 405-407)
Because of their role in various physiological processes it is desirable to interfere in the activity of serine peptidases. Such interference can be either stimulation or inhibition. Various types of serine peptidase inhibitors have been described in for example EP-764 151 of the present inventors. The application inter alia describes compounds of the general formula Z- Xaa-Y' wherein Z may or may not be present and is a protecting group, Xaa represents a dipeptide or an amino acid and Y' may be a phosphonate, such as a diphenyl phosphonate. Further research of the present inventors has revealed that the toxicity thereof is not yet acceptable and the potency/efficacy are not sufficient. US-5,543,396 of Powers et al. relates to proline phosphonate derivatives. The phosphonate may be substituted with one or two phenyl groups which in turn may be mono-, di- or trisubstituted with a halogen, C1-C6 alkyl, C1-C6 perfluoralkyl, C.-C6 alkoxy, N02, CN, OH, C02H, amino, C1-C6 alkyla ino, C2-C12 dialkylamino, C1-C6 acyl, and C1-C6 alkoxy-CO-, C,-C6 alkyl-S-. The present inventors, in the research that led to this invention, developed independently the same compounds. However, they found that regarding toxicity, stability and efficacy these compounds did not perform optimally.
It is therefore the object of the present invention to provide inhibitors of serine peptidases/ proteases that have a more optimal combination of inhibitor capacity, stability in plasma, safety, bioavailability, duration of action and straightforward synthesis. In addition, the invention has for its object to provide compounds that have a stimulating activity on serine peptidases/ proteases. These two types of compounds of the invention will also be identified herein as "modulating compounds". More in particular, the invention provides compounds having such a more optimal combination for modulating the activity of DPP IV, PO,
5
DPP II, FAPα, lysosomal Pro-X carboxypeptidase and elastase.
Thus, in the research that led to the present invention, the influence of different functional groups on the inhibitory (or stimulatory) activity of phosphonates was investigated. Prolylpyrrolidine diphenyl phosphonates were synthesized, substituted on the phenyls with hydroxyl, methoxy, acylamino, sulfonylamino, ureyl, methoxycarbonyl and alkylaminocarbonyl groups. The phenylesters were also replaced by other groups with good leaving group capacities such as trichloroethyl and trifluoroethyl. The inhibitory activity in vitro and in vivo on DPP IV and other serine peptidases, the stability and specificity of these compounds was tested. It was then found that compounds as claimed in claim 1 are very potent modulators, in particular inhibitors, of serine peptidases/proteases in general and DPP IV, DPP II, PO, FAPα, lysosomal Pro-X carboxypeptidase and elastase in particular. The compounds as listed in claim 12 were found to be potent inhibitors of DPP IV and PO.
The compounds of the invention are based on peptides. These peptides are constituted by either naturally occurring amino acids or other amino acids. The C-terminal carboxyl function is replaced by a phosphonate group.
The compounds of the invention are represented by the general formula I:
χ-p; n^ « W l | Cλ A O A
wherein
- A is (R2) or H or C,-C6 alkyl or halogenoalkyl, except perfluoroalkyl,
6 the phenyl group is mono-, di- or trisubstituted with Rl or R2;
X is a peptide- or amino acid-derived moiety; A and the phenyl group substituted with Rl may optionally form a biphenyl diester; all Rl substituents and R2 substituents are each independently selected from the group consisting of: a) C1-C6 acylamino; b) aroylamino, optionally substituted at the o- and/or p- and/or m- position with alkyl, in particular C^
C6 alkyl, and/or a halogen; c) C1-C6 alkylsufonylamino ; d) arylsulfonylamino, optionally substituted at the o- and/or p- and/or m- position with alkyl, in particular C1-C6 alkyl, and/or a halogen; e) α aminoacylamino wherein the α aminoacyl represents a side chain blocked or unblocked α-amino acid residue with the L, D or DL configuration at the α-carbon atom selected from the group consisting of: alanine, methionine, methionine sulfoxide, arginine, homoarginine, phenylalanine, aspartic acid, proline, hydroxyproline, asparagine, serine, cysteine, threonine, histidine, glycine, tyrosine, glutamic acid, pyroglutamic acid, tryptophan, glutamine, valine, norvaline, isoleucine, lysine, leucine, norleucine, thioproline, homoproline, 1,2,3,4-tetrahydro- isoquinoline-3-carboxylic acid (Tic) , 2 , 3-dihydroindol-2-carboxylic acid, α-naphtylglycine, α-phenylglycine,
4-amidinophenylglycine, 4-phenylproline, 4-amidinophenylalanine, O-benzyl tyrosine, omega-acetyl lysine, α-aminobutyric acid, citrulline, homocitrulline, ornithine, o- methylserine, o-ethylserine, S-methylcysteine,
S-ethylcysteine, S-benzylcysteine, homoserine, 4-dehydroproline, penicillamine, β- (2- thienyl) alanine, NH2-CH(CH2CHEt2) -COOH, α-
a inoheptanoic acid, NH2-CH(CH2-l-naphthyl)- COOH, NH2-CH(CH2-2-naphthy1) -COOH, NH2-CH(C^- cyclohexyl) -COOH, NH2-CH[CH- (cyclohexyl) 2]-COOH, NH2-CH (CH2-cyclopenty1) -COOH, NH2-CH[CH- (cyclopentyl)2]-COOH, NH2-CH(CH2-cyclobutyl)-
COOH, NH2-CH[CH- (cyclobutyl) 2] -COOH, NH-.-CH(CH2- cyclopropy1) -COOH, NH2-CH[CH- (cyclopropy1)2]- COOH, 5,5,5-trifluoroleucine, hexafluoroleucine, (S) -azetidine-2-carboxylic acid, (S)-pipecolic acid, (S)-oxazolidine-4- carboxylic acid, (R)-thiazolidine-4- carboxylacid (L-thioproline) , sarcosine; f) residue selected from the group consisting of 3-aminobenzoic acid, e-aminocaproic acid, β- alanine; g) Y-NH-CO-NH-; h) Y '02CCH(NHCO-Y) -CH2-; i) Y'NHCO-; j) CH3-0-CO-Y'-NH-CO-; k) CH3-CH2-0-CO-Y » -NH-CO-; wherein Y is C1-C6 alkyl, aryl or H and Y1 is crc6 alkyl, and pharmaceutically acceptable salts thereof.
In a specific embodiment of the invention X is a moiety of the general formula (AA) -aa-, wherein: p indicates that there may be 0, 1, 2, 3, 4 or
5 residues AA, which can be the same or different within one molecule; AA and aa are selected from one of the following: a) α-amino carboxylic acids with in α position an optionally substituted C1-C6 alkyl or aryl or aralkylmoiety; b) alanine, methionine, methionine sulfoxide, arginine, homoarginine, phenylalanine, aspartic acid, proline, hydroxyproline, asparagine, serine, cysteine, threonine, histidine,
8 glycine, tyrosine, glutamic acid, pyroglutamic acid, tryptophan, glutamine, valine, norvaline, isoleucine, lysine, leucine, norleucine, thioproline, homoproline, 1,2,3,4-tetrahydro- isoquinoline-3-carboxylic acid (Tic) ,
2 , 3-dihydroindol-2-carboxylic acid, α-naphtylglycine, α-phenylglycine, 4-amidinophenylglycine, 4-phenylproline, 4-amidinophenylalanine, O-benzyl tyrosine, omega-acetyl lysine, α-aminobutyric acid, citrulline, homocitrulline, ornithine, o- methylserine, o-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzylcysteine, homoserine, 4-dehydroproline, penicillamine, β- (2- thienyl) alanine, NH2-CH(CH2CHEt2)-COOH, α- aminoheptanoic acid, NH2-CH(CH2-l-naphthyl)- COOH, NH2-CH(CH2-2-naphthy1) -COOH, NH2-CH(CH2~ cyclohexyl) -COOH, NH2-CH[CH- (cyclohexyl) 2] -COOH, NH2-CH(CH2-cyclopenty1) -COOH, NH2-CH[CH- (cyclopentyl) 2] -COOH, NH2-CH(CH2-cyclobutyl) -
COOH, NH2-CH[CH-(cyclobutyl)2]-COOH, NH2-CH(CH2- cyclopropyl) -COOH, NH2-CH[CH- (cyclopropyl) 2] - COOH, 5,5,5-trifluoroleucine, hexafluoroleucine, (S) -azetidine-2-carboxylic acid, (S)-pipecolic acid, (S)-oxazolidine-4- carboxylic acid, (R)-thiazolidine-4- carboxylacid (L-thioproline) , 3-aminobenzoic acid, sarcosine, e-aminocaproic acid, β- alanine, wherein the alpha amino residue may be side chain blocked or unblocked and has the L, D, or DL configuration at the alpha carbon atom; and pharmaceutically acceptable salts thereof.
In an alternative embodiment of the invention X is M-(AA)p-aa- wherein: p, AA and aa are as defined above; and
M is selected from:
a) the group consisting of optionally substituted -CONH2, -CSNH2, -S02NH2, phenyl-S02-, phenyl-CH2S02-, 2-furyl- acryloyl ; and b) the group of protecting groups consisting of: acetyl, adamantyloxycarbonyl, benzyl- oxycarbonyl, benzoyl, benzyl, t-butoxycarbonyl, t-butyl, 2,4-dinitrophenyl, formyl, fluorenylmethoxycarbonyl, 4-methoxybenzyl, tosyl, trifluoro- acetyl, trityl, phthaloyl, phenylalkylcarbonyl, 2-indanylacetyl, 2-(l,2,3,4-tetrahydronaphty1) acetyl,
4-(4-benzylphenoxy) alkyl ; In a specific embodiment X represents AA-aa-, wherein aa is proline and AA is as defined above. In an alternative embodiment X represents AA-aa-, wherein AA and aa are both proline. In case aa is alanine, Rl and R2 may further be selected from:
1) H, halogen, N02, CN, OH, COOH m) amino, C1-C6 alkylamino, C2-C12 dialkylamino, n) C1-C6 acyl o) C1-C6 alkoxy-CO- p) C.-C6 alkyl-S-. In such compounds aa is alanine and preferably at least the AA coupled to aa is proline or phenylalanine. Preferred examples of the compounds are Phe-Ala-diphenyl- phosphonate or Pro-Ala-diphenylphosphonate and pharmaceutically acceptable salts thereof.
The invention can be divided in three groups of compounds.
In preferred compounds of this invention the phosphonate group is a diphenyl-phosphonate group
(indicated with the symbol P(0Ph)2), which is preferably substituted. The first group thus consists of compounds of the general formula II:
10
x- x-P ΓII.
wherein the substituents Rl, R2 and X are as defined above (group 1) .
Alternatively, the compounds are 2,2' biphenyl diesters of α-aminoalkyl phosphonic acid having the general formula III:
(III)
wherein the substituents Rl, R2 and X are as defined above (group 2) .
The third group (group 3) consists of compounds having the general formula IV: Rl o
X-P (IV)
O O
A wherein X and Rl are as defined above, A is H or C1-C6 alkyl or halogenoalkyl, except perfluoroalkyl.
Specific members of these three groups will be listed below.
For inhibition of the serine protease cathepsin G, X is preferably selected from Cbz-Gly-Leu-Phe-, Z-Phe- Pro-Phe, and Suc-Val-Pro-Phe-. For prolyl oligopeptidase X may be selected from among the following: Cbz-Gly-Gly- Pro-, Cbz-Pro-Pro-, Boc-Val-Pro-Val-, MeO-Suc-Ala-Ala- Ala-Val-, MeO-Suc-Ala-Ala-Pro-Val-. For DPP IV, X is as follows: Ala-Pro-, Pro-Pro-, Ala-Pip-, Phe-Pro-, lie- Pro-, Arg-Pro-, pF-Phe-Pro-, cyclohexylala-Pro-, Pro- azetidine-, Phe-azetidine-, Lys-Pro-, Lys-azetidine-. X is selected from among Suc-Lys(Cbz) -Val-Pro-Val-, Z-Ala-
11
Ala-Ala and Boc-Val-Pro-Val- in case the enzyme to be inhibited is human leukocyte elastase. For Granzyme A, X may be selected from Cbz-(4-amidinophenylalanine)-, Z- Met-, 3-phenyl propanoyl-Pro-(4-aminophenylalanine)-, Cbz-Thr-(4-amidinophenylglycine)-, and Boc-D-Phe-Pro-(4- amidinophenylalanine)-. X may be Z-Phe-Pro-Phe-, Z-Phe-, Suc-Val-Pro-Phe-, MeO-Suc-Ala-Ala-Pro-Phe-, or MeO-Suc- Ala-Ala-Ala-Phe- when the enzyme to be inhibited is chymotrypsine. For trypsin-like serine-type proteases, X may be selected from among Cbz-Orn-, Cbz-Lys-Ala-, Cbz- Lys, Cbz-Ho oLys-, Cbz-(4-amidinophenylalanine)-, Cbz-(4- amidinophenylglycine) -, Ph-CH2-S02-Gly-Pro- (4-amidino- phenylglycine)-, 3-(2-furyl)acryloyl-(4-amidinophenyl- glycine) , Cbz-Lys-(4-amidinophenylglycine)-, Cbz-Lys-Ala- (4-amidinophenylglycine)-, Cbz-Thr-(4-amidinophenyl- glycine)-, 3-(2-furyl)acryloyl-(4-amidinophenylalanine)-, Cbz-Ala-(4-amidinophenylglycine)-, Cbz-Ala-Ala-Ala-(4- amidinophenylglycine) -, 2-phenoxybenzoyl-Pro- (4- amidinophenylglycine) -, 3-phenoxybenzoyl-Pro-(4- amidinophenylglycine)-, 3-phenyl propanoyl-Pro-(4- amidinophenylalanine)-, 3,3-diphenyl propanoyl-Pro-(4- amidinophenylglycine)-. For inhibition of V8 protease of S . aureus X can be either Acetyl.Glu- or Acetyl.Asp-. Rl and R2 are preferably selected from the group consisting of: 3-AcNH, 4-AcNH, 4-MeS02NH, 3-H2NCONH, 3-H2NCONH, 4-(N-Bz-Gly-NH) , 4-(H-Gly-NH) , 4 (H- (S) -Ala-NH) , 4-((S)-Pyr-NH) , 4-((2S)-Me02CCH(NHAc)CH2) , 4-Me02C, 4- (Et02CCH2NHCO) , 4-(Me02C(CH2)2NHCO) , 4-CH3(CH2) 2NHCO.
Particularly preferred compounds of group 1 (formula II) are the following:
Di(3-acetamidophenyl) l-(benzyloxycarbonyl-(S)- prolyl)pyrrolidine-2(R,S) -phosphonate (lOd) ; Di(4-acetamidophenyl) l-(benzyloxycarbonyl-(S)- prolyl)pyrrolidine-2(R,S) -phosphonate (lOe) ; - Di(4-methylsulfonylaminophenyl) 1- (benzyloxy- carbonyl-(S) -prolyl)pyrrolidine-2 (R,S) -phosphonate (lOf) ;
12
Di(3-ureylphenyl) 1- (benzyloxycarbonyl- (S)- prolyl)pyrrolidine-2 (R,S) -phosphonate (lOg) ; Di [4- (N-benzoylglycylamino)phenyl] -1- (benzyl- oxycarbonyl-(S) -prolyl)pyrrolidine-2 (R,S) -phospho- nate (lOh) ;
Di[4- (N-benzyloxycarbonylglycylamino)phenyl]-1- (benzyloxycarbonyl-(S) -prolyl) yrrolidine-2 (R,S) - phosphonate (lOi) ; Di [4- (N-benzyloxycarbonyl- (S) -alanylamino) phenyl]- 1- (benzyloxycarbonyl- (S) -prolyl) pyrrolidine-2 (R,S) - phosphonate (lOj) ;
Di[4-( (S) -pyroglutamylamino)phenyl]-l- (benzyloxycarbonyl- (S) -prolyl)pyrrolidine-2 (R,S) -phosphonate (10k) ; - Di{4-[-(S)-(2-methoxycarbonyl-2-acetamido)ethyl]- phenyl}1- (benzyloxycarbonyl- (S) -prolyl)pyrrolidine- 2 (R,S) -phosphonate (101);
Di (4-methoxycarbonylphenyl) 1- (tert-butyloxycarbonyl- (S) -prolyl)pyrrolidine-2(R,S) -phosphonate (10m) ; - Di{4-[(ethoxycarbony1)methylaminocarbony1]phenyl} 1- (benzyloxycarbonyl- (S) -prolyl) -pyrrolidine- 2 (R,S) -phosphonate (10n) ;
Di{ 4- [2- (methoxycarbonyl) ethylaminocarbonyl]phenyl} 1- (benzyloxycarbonyl- (S) -prolyl) -pyrrolidine- 2 (R,S) -phosphonate (lOo) ;
Di[4- (n-propylaminocarbonyl)phenyl] 1- (benzyloxycarbonyl- (S) -prolyl) -pyrrolidine-2 (R, S) -phosphonate (iop); Di (3-acetamidopheny1) 1- ( (S) -prolyl) pyrrolidine- 2 (R,S) -phosphonate hydrochloride (lid);
Di(4-acetamidopheny1) l-( (S) -prolyl)pyrrolidine- 2 (R,S) -phosphonate hydrochloride (lie); Di(4-methylsulfonylaminophenyl) l-( (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate hydrochloride (llf) ; - Di(3-ureylphenyl) l-( (S) -prolyl)pyrrolidine-2(R,S)- phosphonate hydrochloride (llg) ;
Di [4- (N-benzoylglycylamino) phenyl] -1- ( (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate hydrochloride (llh) ;
13
Di[4- (N-glycylamino) phenyl]-l-( (S) -prolyl) - pyrrolidine-2 (R,S) -phosphonate trihydrochloride
(Hi) ;
Di(4-(S) -alanylaminophenyl) -l-( (S) -prolyl)pyrroli- dine-2 (R,S) -phosphonate trihydrochloride (llj) ;
Di(4-(S)-pyroglutamylaminophenyl) -l-( (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate hydrochloride (Ilk); Di{4-[-(S)-(2-methoxycarbonyl-2-acetamido)ethyl]- phenyl} 1- ( (S) -prolyl)pyrrolidine-2-phosphonate hydrochloride (111) ;
Di{4-[ (ethoxycarbony1)methylaminocarbony1]phenyl} l-( (S) -prolyl)pyrrolidine-2 (R,S) -phosphonate (lln) ; Di{4-[2- (methoxycarbonyl) ethylaminocarbonyl]phenyl} 1- ( (S) -prolyl) -pyrrolidine-2 (R, S) -phosphonate hydrochloride (Ho) ;
Di[4- (n-propylaminocarbonyl) phenyl] l-( (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate hydrochloride (lip). A compound having an inhibitory activity for DPP IV, is for example 2 , 2 ' -Biphenyl l-( (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate hydrochloride (19) or a pharmaceutically acceptable salt.
Other specific compounds of group 2 (formula
III) are the following:
2 , 2 ' -Biphenyl 1- (benzyloxycarbonyl- (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate (17a);
2,2' -Biphenyl 1- (t-butyloxycarbonyl- (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate (17b) .
An example of a compound of group 3 (formula
IV) is: - 2-(2 ' -Hydroxyphenyl)phenyl methyl 1-(S) -prolyl) - pyrrolidine-2 (R,S) -phosphonate hydrochloride (18); The advantage of compounds of the invention over Powers et al. (supra) follows from the comparison of the properties of the leaving groups that are created from Powers' compounds and from the compounds of the invention when the inhibitors enter into a covalent binding with the serine in the active center of the
14 peptidases. The information comes from the Merck Index, 12th edition, Merck & Co, Inc. USA (1996).
Powers' leaving groups are among others 2- methylphenol (o-cresol) , 3-methylphenol (m-cresol) and 4- methylphenol (p-cresol) . The compounds belong to the group of cresols, which are desinfectants. These compounds are toxic to humans. Chronic poisoning from oral or percutaneous absorption may produce digestive disturbances, nervous disorders, vertigo, skin eruptions, jaundice, oliguria, uremia. Another leaving group in Powers' compounds is 4-hydroxybenzoic acid methylester (methyl paraben, Nipagin M) which is also a preservative in foods beverages and cosmetics and of which allergic reactions are frequently observed. 1,4-Benzenediol (hydroquinone) is a photographic developer and reducer and is used as an antioxidant. At very low concentrations there is no systemic toxicity. However, ingestion of more than 1 g results in nausea, vomiting, shortness of breath, cyanosis, convulsions and collapse. It is lethal in a dose above 5 g.
The leaving groups of the compounds of the invention however, are for example 4-hydroxyacetanilide (paracetamol, compound He) which is used commonly as a very safe analgesic/antipyretic drug. Another leaving group is 4-hydroxyhippuric acid ethyl ester (compound lln) of which no toxicity has been noticed, and hippuric acid is known to be a metabolite occurring in human metabolism and a normal constituent in human urine.
From the above it follows that in comparison to Powers' compounds, the compounds of the invention do not present safety problems which could obstruct their further pharmaceutical development.
The compounds of the invention can be used for the therapy of pathological states associated with excessive, impaired or unbalanced activity of said enzymes.
Starting from the available information on the correlation between particular serine protease activities
15 and various disease states the skilled person will be able to define therapeutical utilities for the modulatory compounds of the invention. Hereinbelow examples of such disease states will be listed and support for their utility given.
Thus, the invention relates to the compounds for use as a therapeutical agent. In particular, the invention relates to the compounds for use in the treatment or prophylaxis of inflammation, vascular diseases, organ specific or systemic auto-immune diseases (e.g. Graves' disease or multiple slerosis, inflammatory bowel disease) , joint diseases, muscle diseases, neurological diseases, obesity, diseases associated with benign and malign cell transformation, spreading of malignant cells, conditions of glucose-intolerance, abnormal growth or growth retardation, rejection of foreign cells or tissues after transplantation, abnormalities in blood cell development, abnormal blood clotting, pain, or diseases of the central nervous system.
Support for the pharmaceutical utility of the compounds of the invention in the above indications follows from the following publications, which demonstrate the correlation of specific serine peptidases with medical indications. Inhibition of these enzymes can thus be used as treatment or prophylaxis.
The involvement of plasma prekallikrein or kallikrein in shock is described by W. Colman in Barrett, A., et al., supra. page 147-153. The compounds of the invention can be used for prevention and treatment of thrombosis and conjunction therapy of acute myocardial infarction by specifically inhibiting Factor X (Vlasuk, G.P. in New Therapeutic Agents in Thrombosis and Thrombolysis, Sasahara, A., Loscalzo, J., eds (1997), pages 261-283), thrombin
(Shafer, J.A. in New Therapeutic Agents in Thrombosis and Thrombolysis, (supra) pages 143-157) and Factor VII (factor VII-Tissue Factor) (Shafer, J.A. in New
16
Therapeutic Agents in Thrombosis and Thrombolysis, (supra) pages 225-260) .
Various serine peptidases are known to be involved in inflammation. That this is the case is described for elastases (Bank U. et al., in Cellular
Peptidases in Immune Function and Diseases, Ansorge, S. & Langner, J., Plenum Press (1997), pages 231-242, D. Farley et al. in Lauwers, A. and Scharpe, S. eds., supra), kallikrein (Chao, J. in Barrett et al., supra. pages 97-101; Naidoo, Y. & Bhoola, K. in The kinin
System, Framer, S.G., Academic Press (1998), pages 187- 197) ; and Erdόs, E.G. & Skidgel, R.A. in The Kinin System, supra , pages 112-141), cathepsin G (Flad, H.D. et al., in Cellular Peptidases in Immune Function and Diseases, supra. pages 223-230), DPP IV (Tanaka, S. et al., Immunopharmacology 40 (1998), 21-26), and granzymes (Berthou, C. et al., Pathol. Biol. 46 (1998), 617-624). DPP IV (Cheng, H.C. et al. J. Biol. Chem. 273 (1998) 24207-24215), PO (Goossens et al., Eur. J. Clin. Chem. Clin. Biochem. 34 (1996), 17-22; and Ishino, T. et al., J. Biochem. 123 (1998), 540-545) and urokinase are involved in tu origenesis and metastasis.
Hoist, J.J. & Deacon, C. have described the potential of DPP IV inhibition in Type 2 diabetes or glucose intolerance (Diabetes 47 (1998) , 1663-1670) .
Elastase plays a role in autoim unity diseases such as rheumatoid arthritis (Mo ohara, S. et al., Clin. Rheumatol. 16 (1997), 133-140; and Shinguh, Y. et al., Eur. J. Pharmacol. 337 (1997), 63-71; Barrett, supra. Lauwers & Scharpe, supra) .
Korom, S. et al., (Transplantation 63 (1997), 1495-1500 have found an involvement of DPP IV in transplant rejection. Likewise, DPP IV has been found to be involved in growth abnormalities (Bai, P. & Chang, L.L., J. Pharm. Pharmacol. 47 (1995), 698-701; and Martin, R. et al., Biochim. Biophys. Acta 1164 (1993), 252-260) and hypertension and pre-eclampsia (Neudeck, H. et al., J. Reproductive Immunology 37 (1997), 449-458).
17
The latter two indications are also correlated with PO (Chappell, M.C. et al., Braz. J. Med. Biol. Res. 31 (1998), 1205-1212; and Umemura, K. et al., Br. J. Clin. Pharmacol. 43 (1997), 613-618). PO is furthermore involved in muscle dystrophy
(Kar, N. & Pearson, C. , Clin. Chim. Acta 111 (1981), 271- 273) and behavioral and neurochemical diseases (Toide, K. et al., Reviews in Neurosciences 9 (1998), 17-29).
DPP IV is a very versatile enzyme according to its localisation and different substrates and correlated with pain (Shane, R. et al., Brain Res. 815 (1999), 278- 286) and obesity (Pederson, R. et al., Diabetes 47 (1998) 1253; Flint, A. et al., J. Clin. Investigation 101 (1998), 515-520) and tissue repair (Drucker, D. et al., Am. J. Physiol. 276 (1999), G79-91) .
The present invention also includes derivatives which have been modified in the N-terminal amino acid side chain without abolishing the reactivity with the active site. Examples of such modifications are the incorporation of a radioactive label such as Iodine125 into tyrosine, extension of the side chain to attach biotin or a fluorophore. To improve the half-life in the circulation the peptide bond between the two amino acids may be replaced by a non-hydrolyzable bond. The incorporation of a radioactive label is useful in diagnostic methods using the modulating compounds.
The compounds are for example labeled for use in diagnostic and research methods such as fluorescence and radio-assays, imaging, in situ histochemical and cytochemical staining etc. as will be further explained hereinbelow.
According to a further aspect thereof, the invention relates to the use of the compounds for the preparation of a therapeutical composition for modulating (inhibiting or stimulating) the activity of serine proteases. Such therapeutical composition is then specifically intended for treatment and prophylaxis of the conditions listed above.
18
Furthermore, the invention provides a pharmaceutical preparation comprising one or more compounds of the invention and a suitable excipient, carrier or diluent. Such pharmaceutical preparations are intended for the treatment and prophylaxis of the above conditions.
Acceptable excipients, carriers and diluents are well known and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985) . Preservatives, stabilizers, dyes and flavoring agents may be provided in the pharmaceutical compositions. For example, sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives. In addition antioxidants and suspending agents may be used.
The compounds of this invention may be formulated and used as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for injectable administration, aerosols, galenic preparations for topical and bucal administration and aerosols for nasal administration. If desired, absorption enhancing preparations (e.g. liposomes) or other appropriate delivery systems may be used. The amount of the active substance (s) in a dosage unit may vary between 0.001 mg and 1 g.
The compounds or pharmaceutical compositions of this invention can be used alone or in combination with one another, or in combination with other therapeutic or diagnostic agents. Such other therapeutic or diagnostic agent(s) can have a different dosage form or can be present in the same dosage form as the compounds of the invention. The dosage for the compounds of the present invention can range broadly depending upon the desired effects and the therapeutic indication.
The invention also relates to a method for in vitro inhibition or stimulation (modulation) of protease activity by means of a suitable concentration of a
19 compound of the invention. Such method is in particular useful when a protease inactivates a peptide prior to measurement thereof in a peptide assay. The compounds of the invention can be used to inhibit the degradation of the peptide substrate by the enzyme in such assay.
The compounds of the invention are also useful in a method for the 'ex vivo' inhibition of protease activity, such as the treatment outside the body of cells and organs for transplantation in order to avoid rejection thereof by the recipient body.
Furthermore, the compounds of the invention can be used in a method for in vivo inhibiting or stimulating (modulating) protease activity by means of administering to a living organism a suitable amount of a compound of the invention.
Such modulation (inhibition or stimulation) can be used for pharmacotherapy of disease states related to one of the following conditions: inflammation, organ specific or systemic auto-immune diseases, non-malignant disorder of leukocytes and/or immunoglobulins, rejection of cells or tissues after transplantation, tissue destructive and bone degenerative diseases, neuroendocrine dysfunction, glucose-intolerance, obesitas, functional gastrointestinal disorder, abnormal growth or growth retardation, thrombosis and hemorrhage, vascular and cardiopulmonary diseases, neurodegenerative and affective disorders, pain, diseases associated with neoplasia.
As already indicated above, the invention also relates to the diagnostic use of the compounds. Labeled inhibitors or stimulators can be used essentially in the same type of applications as labeled monoclonal antibodies, e.g. fluorescence and radioassays, cytofluorimetry, fluorescence activated cell sorting etc. The principles of such techniques can be found in immunochemistry handbooks, for example: Coligan, J. et al., Current Protocols in Immunology, vol. 1, 2 & 3, Wiley, 1998.
20
The compounds of the present invention can also be used as affinity ligands for analytical and preparative purposes.
In cytochemistry and histoche istry labeled modulators can be used to directly visualize the cellular distribution of the target protease. The label can be fluorescent for fluorescence microscopy, radioactive for autoradiography, or electron dense for electron microscopy. The target structures can be whole cells, cells fixed onto slides or sections through solid tissue. A useful modification of these techniques is to use an indirect ("sandwich") assay employing the specific high affinity interaction between biotin and avidin (Coligan et al . , supra) . For imaging or therapeutic targeting of tumours expressing high amounts of the target protease, modulators labeled with a suitable isotope can be injected. Eventually, after clearing of the excess modulator from the circulation, the tumour can be visualized by radioscintigraphy. The principles of imaging are summarized by A. Bamias & A.A.Epenetos (1995) , Monoclonal antibodies, production, engineering and clinical application (M.A. Ritter and M.M. Ladyman, eds.) Cambridge University Press, Cambridge, pp. 222-246) .
The modulators of the invention are suitable for the diagnostic applications described above, such as imaging and histochemical staining of the respective proteases end peptidases, because they form covalent, long-lived adducts with the proteases and peptidases. Because of their small size they are expected to penetrate tissue more easily than, for example, antibodies. In the case of DPP IV it was found that the modulators only recognize DPP IV which is native and enzymatically active. Formulations of the compounds to be used in diagnostic applications are also part of this invention.
21
Localisation of DPP IV by means of monoclonal antibody and by enzymatic activity is diagnostically useful and applicable to clinical material in the case of thyroid follicular tumours and thyroid papillary carcinoma (Kotani, T. et al., Int. J. Exp. Path. 73, 215-222 (1992) ; Kotani, T. et al., J. Path. 168, 41-45 (1992) . In an analogous manner the compounds of the invention which form a stable adduct with DPP IV or other serine proteases may be used as a tool for diagnosing of certain disease states or monitoring the progression thereof or of treatments (Kurktschiev, D. et al., Clin. Exp. Immunol. (1999) 115, 144-146).
The invention is not limited to the compounds as claimed but also relates to pharmaceutically acceptable salts thereof.
The compounds of the invention may be pure diastereo-isomers or racemic mixtures.
Hereinbelow the invention will be described in more detail. The Examples disclose the synthesis of the modulating compounds of the invention, the inhibitory or stimulatory (modulatory) activity of the compounds of the invention on the catalytic activity of human DPP IV, PO, DPP II and elastase.
Serine protease activity can interfere with enzymatic assays for other substrates by cleaving the substrate used in the test and thereby giving either false positive (when a chromogenic substrate is cleaved) or false negative results (when a peptide substrate is degraded) . The inhibitors of this invention can be used to inactivate contaminating serine proteases or peptidases before carrying on with the analysis.
This application relates to compounds that can either inhibit or stimulate the activity of serine proteases and peptidases. Because the activity of individual compounds of the group of compounds may be opposed (i.e. either inhibiting or stimulating) the general terms "modulating" and "modulation" are intended when reference is made to a group of compounds.
22
Individual compounds will have either a inhibitory or a stimulatory activity on individual serine peptidases and proteases. A prerequisite of the invention is that the compounds that are claimed are active, i.e. have a modulatory (either inhibitory or stimulatory) activity on serine peptidases or serine proteases.
The terms "modulator", "inhibitor", "stimulator", "compound", "derivative" and "modulating compound" are used interchangeably. The present invention will be further elucidated with reference to the following examples which are only given for illustration purposes and are in no way intended to limit the invention. The examples show how the previously reported diphenyl l-(S)-prolyl- pyrrolidine-2-(R,S)- phosphonate (5) was used as a lead compound for the development of potent and irreversible inhibitors of dipeptidyl peptidase IV (DPP IV, EC 3.4.14.5). The synthesis of a series of diaryl l-(S)-prolylpyrrolidine- 2-(R,S) -phosphonates with different substituents on the aryl rings started from the corresponding phosphites. A good correlation was found between the electronic properties of the substituent and the inhibitory activity and stability. The most striking divergence of this correlation was the high potency combined with a high stability of the 4-acetylamino substituted derivative (He) . For this compound no cytotoxicity in human peripheral blood mononuclear cells could be observed and it also has favourable properties in vivo. Therefore di(4-acetamidophenyl) l-(S)-prolyl- pyrrolidine-2-(R,S)- phosphonate (He) is considered as a major improvement and will be a highly valuable DPP IV inhibitor for further studies on the biological function of the enzyme and the therapeutic value of its inhibition.
In the Examples reference is made to the following schemes and figures:
23
Scheme 1
"^
-R1
R1 R1
R = Z, Boc or Trr ^ ivorv
6a R = 2 7a R = Z 6b R = Boc 7b R = Boc a 0 xx χχ'
Reagents : i) PC13 ; ii) HC1 ; iii) HOAc, 90 °C, 2 h ; iv) HCl/EtOAc (1 M) ; v) H2, Pd/C
For 8-11 : Rl = a) H ; b) 4-OMe ; c) 4-OAc (4-OH for 11) ; d) 3-NHAc ; e) 4-NHAc ; f) 4-NHSθ2Me ; g) 3-NHCONH2 ; h) 4- (N-Bz-Gly-NH) ; i) 4- (N-Z-Gly-NH) [4-(H-Gly-NH) for 11] ; j) 4- (N-Z-(S) -Ala-NH) [ 4- (H-(S) -Ala-NH) for 11] ; k) 4-( (S) -Pyr-NH) ; 1) 4-[(2S)-Me02CCH(NHAc)CH2] ; m) 4-COOMe ; n) 4-(CONHCH2COOEt) ; o) 4-[CONH(CH2) 2COOMe] ; p) 4-(CONH(CH2)2CH3) .
Scheme 2
14 15
24
Ml N-
O
O j>"
17a: R = Z
16 17b: R = Boc
'from 17b ι from 17a
+ N- H' H
cr O ° .0 O- "O O „P cι- O*
19
18
Reagents : i) ; ii) AcOH, Et3N ; iii) 7, HOAc,
90"C, 2 h ; iv) H2, Pd/C ; v) HCl/EtOAc (1 M) .
Figure 1. Correlation between Hammett constant and log J ca.ic. A good correlation (log k = 4.6504σ + 2.5472, r2
= 0.82) was observed between the Hammett constant and log kcalc, the most striking divergence being the difference between the unsubstituted (5) and the 4-acetylamino
(lie). Figure 2. Correlation between Hammett constant and log half-life.
A good correlation (log t1/2 = -2.2138σ + 2.3043, r2 = 0.77) was observed between the Hammett constant and log t1/2. Figure 3. Correlation between log kcalc and log half-life.
Figure 4. Plasma DPP IV activity in rabbits treated with lln. "R7" and "R8" are rabbits no. 7 and 8. Figure 5. Residual plasma DPP IV activity in rats treated subcutaneously on days 0 to 5 with He. The indications "Rl", "R2", "R3" and "R4" identify the various rats.
25
A good correlation (log t1/2 = -0.4051 (log k) + 3.2899, r2 = 0.75) was observed between log half-life and log k. Compounds Hi, 11j , 18 and 19 were left out. Compounds Hi and llj have a considerable shorter half-life than could be expected, presumably because they suffer from another metabolism, extra to the phosphonate ester hydrolysis (see discussion) . Compounds 18 and 19 cannot be compared directly to the other diaryl phosphonate esters.
EXAMPLES
EXAMPLE 1
Synthesis of a series of protected and unprotected prolylpyrrolidine diaryl phosphonates The synthesis of a series of prolylpyrrolidine diaryl phosphonates started with the coupling of 4-aminobutyraldehyde diethyl acetal to N-protected proline, activated as mixed anhydride with isobutyl chloroformate, as published previously (Belyaev, A. et al. A New Synthetic Method for Proline Diphenyl
Phosphonates. Tetrahedron Lett. 1995, 36, 3755-3758). The acetal 6 was hydrolysed with HC1, and the crude aldehyde 7 was treated with the corresponding triaryl phosphite 9 in acetic acid to give diastereoisomeric mixtures of the protected prolylpyrrolidine diaryl phosphonate 10
(Belyaev et al., (1995), supra) (Scheme 1). Deprotection using standard methods afforded the final compounds 11.
For the preparation of substituted phenyl phosphonates, it was necessary to prepare some commercially unavailable phenols. The 4-methylsulfonyl- aminophenol 8f was prepared from the corresponding sulfonylchloride and 4-aminophenol. Likewise, the 4-acylaminophenols 8h-k were prepared by condensation of the corresponding carboxylic acid with 4-aminophenol using the mixed anhydride method. N-acetyl-L-tyrosine methyl ester (81) was prepared as described (Jackson, E. L. O-p-Toluenesulfonyl-L-tyrosine, its N-acetyl and N-benzoyl Derivatives. J. Am. Chem. Soc. 1952, 74,
26
837-838) . The glycine derivative 8n was obtained after condensation of glycine ethyl ester with 4-hydroxybenzoic acid using diphenylphosphoryl azide (DPPA) . The synthesis of the 4-hydroxybenzoic acid amides 8o and 8p was accomplished by coupling of 4-acetoxybenzoic acid with the corresponding amine using the mixed anhydride method followed by mild alkaline hydrolysis of the phenyl esters 12 and 13 (Bύchi, G. ; Weinreb, S. M. Total Syntheses of Aflatoxins Ml and Gl and an Improved Synthesis of Aflatoxin Bl. J. Am. Chem. Soc. 1971, 93, 746-752). The triaryl phosphites 9 were then synthesised from the corresponding substituted phenols 8 and phosphorous trichloride.
Cyclic N-protected 2 , 2 ' -biphenyl derivatives 17a and 17b were prepared by reacting 2,2 '-biphenylacetyl phosphite (16) with aldehyde 7a or 7b in acetic acid (Scheme 2) . Attempted removal of benzyloxycarbonyl (Z) protection from phosphonate 17a by hydrogenolysis with a Pd/C catalyst in methanol resulted in the opening of the dioxaphosphepan ring to give the mixed methyl aryl ester 18. Deprotection of the Boc-derivative 17b with HCl/EtOAc yielded free 2,2' -biphenyl phosphonate 19.
Generally, with this method we obtained a mixture of diastereoisomers of the phosphonates 10. To obtain the pure diastereoisomers of 5, it was necessary to introduce a trityl protection after removal of the Z-protection, which resulted in easily separable isomers (10a(S,R) and 10a(S,S)). We suppose that the most active iso er has the R configuration at the carbon atom next to phosphorus, and this was confirmed by comparison of the relative mobility on TLC, optical activity, 1H-NMR spectrum and biological activity with that of (S)-Ile-(R)-ProP(0Ph)2. The configuration of this reference compound was unambiguously determined with X-ray crystallography (Belyaev et al., (1995), supra) .
27
Experimental :
General. 4-methoxyphenol (8b), l-(3-hydroxy- phenyl)urea (8g) , methyl 4-hydroxybenzoate (8m), tri- phenyl phosphite (9a), 2 , 2 ' -biphenol (14), L-proline, L-tyrosine, 4-aminophenol, glycine, L-pyroglutamic acid, 4-hydroxybenzoic acid, glycine ethyl ester hydrochloride, β-alanine and all common chemicals were purchased from Acros Chimica N.V. , Belgium. 3-Acetamidophenol (8d) , 4-aminobutyraldehyde diethyl acetal, PC13, diphenyl- phosphoryl azide (DPPA) and 4-acetoxybenzoic acid were obtained from Sigma-Aldrich Chemie BV, Belgium. 4-Acetamidophenol (paracetamol) (8e) was obtained from Sterling Organics Ltd., England. Purity of all new synthesised compounds were checked by TLC, ^- MR, 13C-NMR or MS. The final products were checked by TLC, 1H-NMR, 13C-NMR, FAB-MS and(or) elemental analysis. Thin-layer chromatography was performed with POLYGRAM(r) SIL G/UV254 plates precoated with silica gel (Machinery-Nagel GmbH, Germany) using EtOAc-petroleum ether, EtOAc-MeOH or n-BuOH-AcOH-H20 (4:1:1) mixtures as eluent. Silica gel H, 5-40 μm (Fluka, Switzerland) was used for preparative vacuum column chromatography. The NMR spectra were recorded on a Varian EM360L or a Brucker Avance DRX 400 spectrometer. Mass-spectra were recorded on a VG 70-SEQ spectrometer. Optical rotation was measured on a Perkin-Elmer 241 polarimeter. Melting points were determined on a Digital Melting Points Apparatus (Electrothermal) and are uncorrected. Z- and Boc-protected amino acids were prepared according to standard procedures (Bodanszky, M. & Bodanszky, A. In The Practice of Peptide Synthesis, 2nd ed. ; Springer-Verlag: Berlin Heidelberg, 1994; pp 11-18 and 28-29) using Z-Cl and (Boc)20, respectively. β-Alanine methyl ester was synthesised by treatment of the amino acid in methanolic HC1 similarly to described procedure (Bodanszky & Bodanszky (1994), supra) . The preparation of 4- (Z-(S) -prolyl) aminobutyraldehyde diethyl acetal (6a) was described earlier (Belyaev et al., (1995), supra) .
28
2-Chloro-(dibenzo[d;f]-l, 3,2-dioxaphosphepan) (15) was prepared as described (Veriznikov, L.V. & Kirpichnikov, P. A. Synthesis of the o,o*-Biphenylphosphinic Acid Esters. Zh. Obshch. Khim. 1967, 37, 1355-1358).
4- (Boc- (S) -prolyl) aminobutyraldehyde diethyl acetal (6b) . To a solution of Boc- (S) -Proline (10 mmol, 2.14 g) in dry CHC13 (20 mL) , Et3N (10 mmol, 1.4 mL) was added with stirring at -10°C followed by isobutyl chloroformate (10 mmol, 1.31 mL) . After 20 min, 4-aminobutyraldehyde diethyl acetal (10 mmol, 1.73 mL) was added and the mixture was stirred overnight (-10"C to room temperature) . Chloroform was removed, the residue was distributed between EtOAc (100 mL) and water (100 mL) , the organic layer was dried (MgS0;) and purified by column chromatography. Yield 2.96 g (83%): oil; 1H-NMR (CDC13) δ (ppm) 1.0-2.4 (m, 23H, 3- and 4-CH2 (Pro), CH2CH2, C(CH3)3, CH3) , 2.9-3.9 (m, 9H, 5-CH2, NCH2, 0CH2 and (EtO)2CH), 4.25 (m, 1H, 2-CH) , 4.5 (t, 'H, NH) .
4-Methylsulfonylaminophenol (8f) .
To a suspension of 4-aminophenol (200 mmol,
21.8 g) in MeOH (250 mL) , CH3S02C1 (100 mmol, 7.75 L) was added at 10-15°C with stirring. The resulting solution was stirred for 1 h at room temperature and evaporated.
The residue was suspended in IN HC1 (250 L) , the solid was filtered, washed with water and dried in vacuum over
NaOH. Yield 13.6 g (81%): mp 165-166°C; 1H-NMR (DMSO) δ (ppm) 2.85 (s, 3H, CH3S) , 6.70 (d, 2Haro , 7.10 (d, 2Harom) ,
8.70 (s, 1H, OH), 8.85 (s, 1H, NH) .
Synthesis of 4-acylaminophenols 8h-k General procedure. To a solution of carboxylic acid (100 mmol) in
DMF (100 mL) , Et3N (100 mmol, 14 mL) was added at -10°C, followed by isobutyl chloroformate (100 mmol, 13 mL) . After 0.5 h at this temperature, 4-aminophenol (115 mmol.
29
12.5 g) was added and the mixture was stirred overnight (-10°C to room temperature). After dilution with IN HC1 (500 mL) , the precipitate was collected by filtration, and washed on the filter with water, NaHC03 solution, water and, finally, ether. The product was dried and, if necessary, recrystallized from an appropriate solvent.
N2-Benzoyl-N- (4-hvdroxyphenyl) glycinamide (8h) . Recrystallized from EtOH-acetone. Yield 35%: mp
244-245°C; 1H-NMR (DMSO) <S (ppm) 4.05 (d, 2H, CH2CO) , 6.5-8.0 (m, 9Harom) , 8.7 ( , 1H, NH) , 9.15 (s, 1H, OH), 9.75 (s, 1H, NH) .
N2-Benzyloxycarbonyl-N- (4-hydroxyphenyl) glycinamide (8i) . Yield 44%: mp 184-185 °C; 1H-NMR (DMSO) δ (ppm) 3.80 (d, 2H, CH2CO) , 6.5-7.5 (m, 10H, 9Harom and NH) , 8.85 (s, 'H, OH), 9.40 (S, 1H, NH) .
N2-Benzyloxycarbonyl-N- (4-hydroxyphenyl) - (S) -alaninamide <8j).
Yield 73%: mp 97-100"C; H-NMR (DMSO) δ (ppm) 1.36 (d, 3H, CH3) , 4.29 (m, 1H, CH of L-Ala) , 5.00 (s, 2H, CH2) , 6.00 (m, 1H, NH) , 6.35-7.38 (m, 9H, Haro 8.69 (br s, 1H, OH), 9.24 (br s, 1H, NHCO)
N- (4 -Hydroxyphenyl) - (S) -pyroglutamyl amide (8k) .
Yield 64%: mp 303-305 "C dec; 1H-NMR (DMSO) <S (ppm) 1.7-2.7 ( , 4H, CH2CH2) , 4.2 (m, 1H, CHCO) , 6.65 (d, 2Haro ' 7'40 (d' 2Har ' 7-8 <S' 1li' NH) ' 9'1 <br S' lH' OH), 9.7 (S, 1H, NH) .
N- (4-Hydroxybenzoyl) lycine ethyl ester (8n) .
To a solution of 4-hydroxybenzoic acid (100 mmol, 13.8 g) in DMF (70 mL) , H-Gly-OEt.HCl (100 mmol, 14 g) was added followed by DPPA (100 mmol, 21.6 mL) and Et3N (200 mmol, 28 mL) with stirring at 0°C. The mixture was stirred overnight (0°C to room temperature), Et3N.HCl was
30 removed by filtration and the filtrate was evaporated to half of the initial volume. The residue was mixed with 5% NaHC03 (200 mL) and extracted with EtOAc (500 mL) . The organic layer was washed with brine, dried (MgS04) and evaporated until crystallisation. The mixture was diluted with ether (100 mL) , and the crystals were collected. Yield 9 g (40%): mp 205-209βC; 1H-NMR (DMSO) δ (ppm) 1.25 (t, 3H, CH3) , 4.05 (m, 4H, C02CH2 and COCH2N) , 6.8 (d,
2Haro ' 7'75 <d' 2Harom)' 8'35 <tr' ^E > NH> ' 9*7 <S' 'H' OH) .
Synthesis of 4-hydroxybenzoic acid amides 8o and 8p General procedure.
To a solution of 4-acetoxybenzoic acid (100 mmol, 18 g) in THF (250 mL) , Et3N (100 mmol, 14 mL) was added followed by isobutyl chloroformate (100 mmol, 13 L) with stirring at -10°C. After 15 min the corresponding amine (free base or HC1 salt) was added followed by Et3N (100 mmol, 14 mL) in case of a hydrochloride. The mixture was stirred overnight (-10"C to room temperature) , the solid was removed by filtration, the filtrate was evaporated and the residue crystallised from an ether-hexane mixture. 4-Acetoxybenzoic acid amide 12, 13 thus obtained (70 mmol) was dissolved in MeOH (240 mL) ,
H20 (90 mL) was added followed by saturated NaHC03 solution (120 mL) . An excess of NaHC03 precipitated. The heterogeneous mixture was stirred for 4 h at room temperature, methanol was removed in vacuum, the residue was extracted with EtOAc (250 mL) , the organic layer was washed with IN HC1, brine, then dried (MgS04) and evaporated. The residue crystallised from ether or was purified on a silica gel column.
N-(4-Acetoxybenzoyl)-β-alanine methyl ester (12) .
Yield 69%: mp 84-88 °C; 1H-NMR (CDC13) <S (ppm) 2.35 (s, 3H, C0CH3) , 2.6 (t, 2H, C02CH2) , 3.7 (m, 5H, NCH2 and C02CH3), 7.15 (m, 3H, 2Harom and NH) , 7.75 (d, 2Har( .
31
N-n-Propyl-4-acetoxybenzoylamide (13) .
Yield 73%: mp 94-98 °C; 1H-NMR (CDC13) δ (ppm) 0.9 (t, 3H, CH3) , 1.6 (m, 2H, CH2) , 2.25 (s, 3H, COCH3) , 3.4 (m, 2H, NCH2) , 7.1 (m, 3H, 2Harom and NH) , 7.8 (d, 2H arom' .
N-(4-Hydroxybenzoyl)-β-alanine methyl ester (8o) .
Yield 65%: mp 124-126°C; 1H-NMR (DMSO) δ (ppm) 2.55 (t, 2H, C02CH2) , 3.7 (m, 5H, NCH2 and C02CH3) , 6.9 (m, 3H, 2Haro(_ and NH) , 7.55 (d, 2Haroπ|) , 8.7 (br s, 1H, OH).
N-n-Propyl-4-hydroxybenzoylamide (8p) .
Yield 78%: oil; 1H-NMR (DMSO) <S (ppm) 1.1 (t, 3H, CH3) , 1.55 (m, 2H, CH2) , 3.3 (m, 2H, NCH2) , 6.9 (m, 3H, 2Har«n and m) ' 7'65 <d' 2Har ' 8'5 <br S' 1lϊ' 0H) ' MS (FAB+) m/z 180 (M+H) + .
Synthesis of triaryl phosphites 9 General procedure.
To a stirred solution of the corresponding phenol (90 mmol) and Et3N (90 mmol, 12.6 mL) in dry DMF (30 mL) , a solution of PC13 (30 mmol, 2.62 mL) in dry CHC13 (10 L) was added dropwise at 0°C. The mixture was stirred overnight (0°C to room temperature), diluted with CHC13 (500 L) and the resulting solution was washed with water (2x500 mL) . The organic layer was dried (MgS04) , evaporated and the residue, eventually together with the product insoluble in both layers, was purified by column chromatography with an EtOAc - methanol or an EtOAc - petroleum ether mixture as eluent.
Tris (3-acetamidophenyl) phosphite (9d) .
Yield: 42%: solid foam; 1H-NMR (DMSO) δ (ppm) 2.1 (s, 9H, C0CH3) , 6.7-7.7 (m, 12Harom) , 9.7 (s, 3H, NH) .
32
Tris (4-acetamidophenyl) phosphite (9e) .
Yield 37%: solid foam; 1H-NMR (DMSO) δ (ppm) 2.1 (s, 9H, COCH3) , 6.9-7.7 (dd, 12Har< , 9.2 (s, 3H, NH) .
Tris (4-methylsulfonylaminophenyl) phosphite (9 ) .
Yield 60%: solid foam; 'H-NMR (DMSO) δ (ppm) 2.95 (S, 9H, S02CH3) , 7.2 (m, 12Haro , 9.15 (s, 3H, NH) .
Tris (3-ureylpheny1) phosphite (9g) . Yield 30%: solid foam; 1H-NMR (DMSO) -5 (ppm)
5.85 (m, 6H, CONH2) , 6.5-7.5 (m, 12Haro , 8.65 (s, 3H, NH) .
Tris r4- (N-benzoylglycylamino) phenyl1 phosphite (9h) . Yield 90%: mp 210βC (dec); H-NMR (DMSO) δ
(ppm) 4.1 (d, 6H, COCH2N) , 6.9-8.0 (m, 27Har0 , 8.5 (m, 3H, NH) , 9.9 (s, 3H, NH) .
Tris f4- (N-benzγloxycarbonylglvcylamino) phenyl1 phosphite (9i) .
Yield 76%: mp 173°C (dec); 1H-NMR (DMSO) δ (ppm) 3.85 (d, 6H, C0CH2N) , 5.05 (s, 6H, CH2Ph) , 6.5-8.0 (m, 30H, NH and Haro , 9.8 (br s, 3H, NH) .
Tris r 4- (N-benzyloxycarbonyl- (S) -alanylamino) henyl1 phosphite (9j) .
Yield: 85%: solid foam; 1H-NMR (DMSO) δ (ppm) 1.42 (d, 9H, CH3) , 4.29 (m, 3H, CH) , 5.01(s, 6H, CH2Ph) , 6.45-7.15 (d, 3H, NH) , 7.25 (m, 27H, Harom) , 9.76 (br s, 3H, NH) .
Trisr4-( (S) -pyroglutamylamino)phenyπ phosphite (9k) .
Yield 31%: solid foam; 1H-NMR (DMSO) δ (ppm) 1.8-2.8 (m, 12H, CH2CH2) , 4.25 (m, 3H, COCHN) , 7.1 (d, 6Haro ' 7'65 (d' 6Haro ' 8'25 <S< 3H' NH) < 10'3 <S' 3H' NH) .
33
Tris ( 4 - r - ( S ) - ( 2 -methoxycarbonyl - 2 -acetamido ) ethyl ] phenyl ) phosphite (91) .
Yield 73%: solid foam; 1H-NMR (DMSO) δ (ppm) 2.0 (s, 9H, C0CH3) , 3.1 (d, 6H, ArCH2) , 3.7 (s, 9H, C02CH3) , 4.8 (m, 3H, COCHN) , 6.6 (d, 3H, NH) , 7.1 (br s, 12Harc .
Tris(4-methoxycarbonylphenyl) phosphite (9m) .
Yield: 57%: oil; 1H-NMR (CDC13) δ (ppm) 3.95 (s, 9H, C02CH3) , 6.65-8.05 (m, 12Haro .
Tris ( 4- f (ethoxycarbonyl ) methylaminocarbonyl 1 phenyl ) phosphite (9n) . Yield 70%: solid foam; 1H-NMR (CDC13) δ
(ppm) 1.3 (t, 9H, CH3) , 3.9-4.3 (m, 12H, C0CH2N and 0CH2) , 6.7-8.0 ( s ,i 15H, i NH and H arom \' .
Tris ( 4- r 2 - (methoxycarbonyl ) ethylaminocarbonyl ] henyl ) phosphite (9o) .
Yield 71%: solid foam; 1H-NMR (CDC13) δ (ppm) 2.65 (t, 6H, C02CH2) , 3.7 (m, 15H, NCH2 and C02CH3) , 7.1
<d' 6Haro ' 7'9 (», 9H' Har«n and NH) *
Tris r 4- (n-propylaminocarbonyl) phenyl] phosphite (9p) .
Yield 54%: mp 207 °C; 1H-NMR (DMSO) δ (ppm) 1.1 (t, 9H, CH3) , 1.6 (m, 6H, CH2) , 3.25 (m, 6H, CH2N) , 7.15
<d' 6Haro ' S-1 (m> 9H' NH and Har< •
Synthesis of N-Boc- or N-Z-protected diaryl l-( (S) -prolyl) pyrrolidine-2 (R.S) -phosphonates 10 General procedure.
Diethyl acetal 6a or 6b (10 mmol) was dissolved in a mixture of THF (60 mL) and 0.5N HC1 (30 mL, lδmmol) with stirring at room temperature. After 2 h ether (90 mL) was added with stirring and the mixture was neutralised with an excess of solid NaHC03 (ca. 5 g) . The organic layer was separated, dried (MgS0) and evaporated. The residue (crude aldehyde 7a or 7b) was dissolved in acetic acid (30 mL) together with the corresponding
34 triaryl phosphite (9, 10 mmol) and the resulting solution was stirred at 85-90°C for 1.5-2 h. After cooling to room temperature, acetic acid was evaporated, the residue was dissolved in chloroform (250 L) , washed with water (200 mL) , saturated NaHC03 solution (100 mL) and water (100 mL) . The organic layer was dried (MgS04) , evaporated and the residue was purified by column chromatography with an ethyl acetate-petroleum ether or ethyl acetate-methanol mixture as eluent.
Di (3-acetamidophenyl) 1- (benzyloxycarbonyl- (S) -prolyl) - pyrrolidine-2 (R.S) -phosphonate (lOd) .
Yield 31%: solid foam: 1H-NMR (CDC13) δ (ppm) 1.0-2.7 (m, 8H, 3-CH2 and 4-CH2) , 2.1 (s, 6H, CH3C0) , 4.0-3.2 (m, 4H, 5-CH2) , 4.3-5.1 (m, 2H, 2-CH) , 5.1 (br s, 2H, CH2Ph) , 6.6-7.7 (m, 13Haro , 9.1 (s, 2H, NH) ; MS (FAB+) m/z 649 (M+H)+.
Di (4-acetamidophenyl) 1- (benzyloxycarbonyl- . S) -prolyl) - pyrrolidine-2 (R. S) -phosphonate (lOe) .
Yield 60%: solid foam; 1H-NMR (CDC13) δ (ppm) 1.6-2.7 (m, 8H, 3-CH2 and 4-CH2) , 2.1 (s, 6H, CH3C0) , 3.3-3.8 ( , 4H, 5-CH2) , 4.3-5.1 (m, 2H, 2-CH) , 5.1 (br s, 2H, CH2Ph) , 6.8-7.5 (m, 13Har< , 8.8 (s, 2H, NH) ; MS (FAB+) m/z 649 (M+H)+.
Di (4-methylsulfonylaminophenyl) 1- (benzyloxycarbonyl- (S) -prolyl) yrrolidine-2 (R.S) -phosphonate (lOf) .
Yield 66%: solid foam; 1H-NMR (CDC13) δ (ppm) 1.2-2.7 (m, 8H, 3-CH2 and 4-CH2) , 2.8 (s, 6H, CH3S02) ,
3.3-3.8 (m, 4H, 5-CH2) , 4.3-5.2 (m, 4H, 2-CH and CH2Ph) , 6.8-7.4 ( , 13Harom) , 8.0 (s, 2H, NH) ; MS (FAB+) m/z 721 (M+H) + .
Di ( 3 -ureylphenyl ) 1- (benzyloxycarbonyl- (S ) -prolyl ) - pyrrol idine-2 (R.S) -phosphonate (lOg) .
Yield 8%: solid foam; 1H-NMR (CDC13) <S (ppm) 1.3-2.4 (m, 8H, 3-CH2 and 4-CH2) , 2.8-3.8 (m, 4H, 5-CH2) ,
35
4.3-5.2 (m, 4H, 2-CH and CH2Ph) , 5.6 (m, 4H, NH2) , 6.8-7.5 (m, 13Haroπ)) , 8.65 (br s, 2H, NH) ; MS (FAB+) m/z 651 (M+H)+.
Di f4- (N-benzoγlglvcylamino) henyl1 -1- (benzyloxycarbonyl- ( S) -prolyl) pyrrolidine-2 (R.S) -phosphonate (lOh) .
Yield 47%: solid foam; 1H-NMR (CDC13) δ (ppm) 1.2-2.7 (m, 8H, 3-CH2 and 4-CH2) , 3.2-3.8 (m, 4H, 5-CH2) , 4.0 (m, 4H, NCH2CO) , 4.4-5.0 (m, 2H, 2-CH) , 5.1 (br s, 2H, CH2Ph) , 6.6-8.3 (m, 25H, 23Hapom and NH) , 9.5 (br s, 2H, NH) ; MS (FAB+) m/z 887 (M+H)+.
Dif4-(N-benzyloxycarbonylglycylamino)phenyl1-1-(benzyloxy carbonyl-(S) -prolyl)pyrrolidine-2 (R.S) -phosphonate (lOi) . Yield 19%: solid foam; 'H-NMR (CDC13) δ (ppm)
1.2-2.6 (m, 8H, 3-CH2 and 4-CH2) , 3.2-4.1 (m, 8H, 5-CH2 and COCH2N) , 4.3-5.2 (m, 8H, 2-CH and CH2Ph) , 6.1 (m, 2H, NH) , 6.7-7.6 (m, 23Harom) , 8.95 (br S, 2H, NH) ; MS (FAB+) m/Z 947 (M+H)+.
Di r4- (N-benzyloxycarbonyl- (S) -alanylamino)phenyl1 -1- (benz yloxycarbonyl-(S) -prolyl)pyrrolidine-2 (R.S) -phosphonate (10J).
Yield 40%. mp: 200-203 °C; 1H-NMR (CDC13) <S (ppm) 1.35 (d, 6H, CH3) , 1.65-2.35 (m, 8H, 3-CH2 and 4-CH2) ,
2.95-3.95 (m, 4H, 5-CH2) , 4.0-4.65 (m, 4H, 2-CH, CH) , 5.00 (s, 6H, CH2Ph) , 6.20 (br, 2H, NH) , 7.04 (s, 23H, Hapo , 9.25 (br, 2H, NH) ; MS (FAB+) m/z 975 (M+H)+.
Di T4- ( (S) -pyroglutamylamino) phenyll -1- (benzyloxycarbonyl- (S) -prolyl) pyrrolidine-2 (R.S) -phosphonate (10k) .
Yield 25%: mp 170°C (dec); 1H-NMR (CDC13) δ (ppm) 1.2-2.9 (m, 16H, 3-CH2 and 4-CH2) , 3.55 (m, 4H, 5-CH2) , 4.1 (m, 2H, 5-CH Pyr) , 4.3-5.2 (m, 4H, 2-CH and CH2Ph) , 6.7-8.1 (m, 15H, NH and 13Harofl)) , 9.55 (br s, 2H, NH) ; MS (FAB+) m/z 787 (M+H)+.
36
Di(4-r-fS)-(2-methoxycarbonyl-2-acetamido) ethyl]phenyl ) 1- (benzyloxycarbonyl- (S) -prolyl) pyrrolidine-2 (R.S) -phosph onate (101) .
Yield 57%: solid foam; 'H-NMR (CDC13) δ (ppm) 1.3-2.7 (m, 8H, 3-CH2 and 4-CH2) , 1.9 (s, 6H, C0CH3) , 3.1 (d, 4H, CH-jAr) , 3.7 (s, 6H, C00CH3) , 3.2-3.9 (m, 4H, 5-CH2) , 4.5-5.0 (m, 4H, 2-CH) , 5.1 (br S, 2H, CH2Ph) , 6.1 (d, 2H, NH), 7.0 (S, 8Harom), 7.3 (br s, 5H, C6H5) ; MS (FAB+) m/z 821 (M+H)+.
Di(4-f (ethoxycarbonyl)methylaminocarbonyl]phenyl ) 1- (benzyloxycarbonyl- (S) -prolyl) -pyrrolidine-2 (R.S)- phosphonate (lOn) .
Yield 32%: solid foam; 1H-NMR (CDC13) δ (ppm) 1.2-2.7 (m, 8H, 3-CH2 and 4-CH2) , 1.3 (t, 6H, CH3) , 3.2-3.9 (m, 4H, 5-CH2) , 4.0 (m, 4H, NCH2CO) , 4.2 (q, 4H, OCH2) , 4.3-5.1 (m, 2H, 2-CH) , 5.1 (br S, 2H, CH2Ph) , 6.9-7.8 (m, 15H, 13Harom and NH) ; MS (FAB+) m/z 793 (M+H)+.
Di( 4-f2- (methoxycarbonyl) ethylaminocarbonyl1phenyl )
1- (benzyloxycarbonyl- (S) -prolyl) -pyrrolidine-2 (R.S) - phosphonate (lOo) .
Yield 22%: solid foam; 1H-NMR (CDC13) δ (ppm)
1.2-2.8 (m, 8H, 3-CH2 and 4-CH2) , 2.65 (t, 4H, CH2C02) , 3.2-3.8 (m, 8H, 5-CH2 and CH2N) , 3.75 (s, 6H, C02CH3) ,
4.3-5.2 (m, 4H, 2-CH and CH2Ph) , 6.7-7.9 (m, 15H, 13Har(χn and NH) ; MS (FAB+) m/z 793 (M+H)+.
Di T4- (n-propylaminocarbonyl) henyl1 1- (benzyloxycarbonyl- (S) -prolyl) -pyrrolidine-2 (R. S) -phosphonate (lOp) .
Yield 4.3%: solid foam; 1H-NMR (CDC13) δ (ppm) 0.85 (t, 6H, CH3) , 1.3-2.8 (m, 12H, 3-CH2, 4-CH2 and CH2) , 3.1-3.9 (m, 8H, 5-CH2 and CH2N) , 4.5 (m, 1H, 2-CH Pro), 4.7-5.2 (m, 3H, CH2Ph and 2-CH ProP) , 6.9-8.1 (m, 15H, 13H and NH) ; MS (FAB+) m/z 705 (M+H)+.
37
Diaryl l-( (S) -prolyl) pyrrolidine-2-phosphonate hydrochlorides (11) . Procedure A.
The diaryl l-(t-butyloxycarbonyl-(S) -prolyl) - pyrrolidine-2-phosphonate (10) or diaryl l-(trityl-(S)- prolyl) pyrrolidine-2-phosphonate (10, 5 mmol) was dissolved in a IM HC1 solution in EtOAc (25 mL) and the solution was stirred for 2 h at room temperature. Dry ether (30 mL) was added and the mixture was left in the fridge overnight. If the product crystallised, the crystals were collected by filtration, otherwise the oil was triturated in dry ether. The material obtained was dried in vacuum over NaOH pellets.
Procedure B.
The diaryl 1- ( (S) -benzyloxycarbonylprolyl) - pyrrolidine-2-phosphonate (10, 2 mmol) was hydrogenated over Pd/C in methanol (50 mL) for 5-6 h. The catalyst was removed by filtration through celite, the filtrate was acidified with IM HCl/EtOAc (2.2 mL) , evaporated and the residue was precipitated with dry ether from methanol (5 mL) . The resulting product was dried in vacuum over NaOH pellets.
Diphenyl 1- ( (S) -prolyl) yrrolidine-2 (R) -phosphonate hydrochloride (lla(S,R)).
A. Yield 81%: mp 175-177 °C; 1H-NMR (CDCl3) δ (ppm) 1.6-2.8 (m, 8H, 3-CH2 and 4-CH2) , 3.3-3.9 (m, 4H, 5-CH2) , 4.8 (m, 1H, 2-CH) , 5.0 (m, 1H, 2-CH) , 7.2 (m, 5Haro ' 7'3 (m' 5Haro ' 8 ' <br S' 1H' N+H) ' 10'2 <br S'
1H, N+H) ; 13C-NMR (CDC13) δ (ppm) 24.1(4-CH2), 24.6 (4-CH2) ,
26.1 (3-CH2), 28.8 (3-CH2) , 46.2 (5-CH2) , 47.1 (5-CH2) ,
54.5 (d, 2-CH-P, U (C-P) = 162 Hz), 59.1 (2-CH) , 120.3,
125. 2 , 129 . 7 , 150 . 3 (Carom) , 168 . 2 (CO) ; [ α ] D20 = -100. 4 ° (C. , CHC13) ; Anal . (C21H25N204P 1. 25 HC1 ) C , H , N .
38
Diphenyl l-( (S) -prolyl) pyrrolidine-2 (S)- phosphonate hydrochloride (Ha(S,S)).
A. Yield 88%: solid foam; 1H-NMR (CDC13) δ (ppm) 1.7-2.6 (m, 8H, 3-CH2 and 4-CH2) , 3.2-3.9 (m, 4H, 5-CH2) , 4.75 (m, 1H, 2-CH) , 4.95 (m, 0.7H, 2-CH) , 5.4 (m, 0.3H, 2-CH) , 6.9-7.4 (m, 10Harom) , 8.6 (br S, 1H, N+H) , 10.3 (br s, 0.3H, N+H), 10.6 (br S, 0.7H, N+H) ; 13C-NMR (CDC13) δ (ppm) 22.1, 24.0 (4-CH2) , 23.5, 23.9 (4-CH2) , 26.4, 27.7 (3-CH2), 28.5, 29.1 (3-CH2) , 45.6, 46.2 (5-CH2) , 46.6, 47.1 (5-CH2) , 54.4, 55.3 (d, 2-CH-P, U (C-P) = 160 Hz) , 58.3, 58.7 (2-CH), 120.1, 125.0, 129.4, 149.5 (Carom) , 167.3, 168.4 (CO) ; [α]D20 = 25.9° (C1# CHC13) ; MS (FAB+) m/z 401 (M+H) + .
Di(3-acetamidophenyl) l-( (S) -prolyl) pyrrol idine- 2 (R. S) -phosphonate hydrochloride (l d) .
B. Yield 83%: solid foam; 1H-NMR (DMSO) δ (ppm) 1.6-2.6 (m, 8H, 3-CH2 and 4-CH2) , 2.1 (s, 6H, COCH3) , 3.3-3.8 (m, 4H, 5-CH2) , 4.7 (m, 1H, 2-CH) , 4.9 (m, 1H, 2-CH) , 6.7-7.6 (m, 8Har( , 8.5 (m, 1H, N+H), 9.7 (m, , N+H), 9.9 (m, 2H, CONHPh) ; Anal. (C25H31N406P 1.5 HC1 0.5 H20) C, H, N.
Di( 4 -acetamidopheny 1) l-( (S) -prolyl) pyrrol idine- 2 (R . S ) -phosphonate hydrochloride (He) .
B. Yield 90%: solid foam; H-NMR (DMSO) δ (ppm) 1.6-2.6 ( , 8H, 3-CH2 and 4-CH2) , 2.1 (s, 6H, COCH3) , 3.3-3.8 (m, 4H, 5-CH2) , 4.6 (m, 1H, 2-CH) , 4.9 (m, 1H, 2-CH), 7.1 (m, 4Har , 7.6 (m, 4Harom) , 8.7 (m, 1H, N+H), 10.0 (m, 2H, CONHPh), 10.2 (m, 1H, N+H) ; 31P-NMR (DMSO) δ (ppm) 17.48, 17.62; Anal. (C25H31N406P HC1 2 H20) C, H, N.
Di (4-methylsulfonylaminophenyl) 1- ( (S) -prolyl) - pyrrol idine-2 (R.S) -phosphonate hydrochloride (llf) . B. Yield 80%: solid foam; 1H-NMR (DMSO) <5 (ppm)
1.55-2.5 (m, 8H, 3-CH2 and 4-CH2) , 2.95 (s, 6H, S02CH3) , 3.3-3.8 (m, 4H, 5-CH2) , 4.55 (m, 1H, 2-CH) , 4.85 (m, 1H, 2-CH) , 7.15 (m, 8Harom) , 8.6 (br s, 1H, N+H), 9.79 (s, 2H,
39
S02NHPh) , 10.3 (br s, 1H, N+H) ; Anal. (C23H31N408PS2 HCl) C, H, N.
Di (3-ureylphenyl) 1- ( (S) -prolyl) yrrol idine-2 (R.S) - phosphonate hydrochloride (llg) .
B. Yield 90%: solid foam; 1H-NMR (CD30D) -5 (ppm) 1.4-2.5 (m, 8H, 3-CH2 and 4-CH2) , 3.3-3.8 (m, 4H, 5-CH2) , 4.5 (m, 1H, 2-CH) , 4.8 (m, 'H, 2-CH) , 6.4-7.2 (m, 6Haron)) , 7.4 (m, 2Harom) ; MS (FAB+) m/z 517 (M+H) + ; Anal (C23H29N606P HCl 2.3 H20) C, H, N.
Di r 4- (N-benzoylglycylamino) phenyl ] -1- ( (S) -prolyl) pyrrol id ine-2 (R.S) -phosphonate hydrochloride (lib) .
B. Yield 87%; solid foam; 1H-NMR (DMSO) δ (ppm) 1.6-2.6 (m, 8H, 3-CH2 and 4-CH2) , 3.2-3.6 (m, 4H, 5-CH2) , 4.2 (d, 4H, NCH2CO) , 4.5-4.9 (m, 2H, 2-CH) , 6.9-7.9 (m, 20H, 18Harom and NH) , 8.5 (m, 1H, N+H), 10.0 (s, 2H, NH) , 10.2 (m, 1H,N+H); MS (FAB+) m/z 753 (M+H) + ; Anal. (C39H41N608P HCl 2 H20) C, H, N.
Dir4-(N-glycylamino) phenyl] -l-( (S) -prolyl)pyrrolidine-2 (R.S) -phosphonate trihydrochloride (Hi) .
B. Yield 81%: solid foam; 1H-NMR (DMSO) δ (ppm) 1.55-2.5 ( . 8H, 3-CH2 and 4-CH2) , 3.3-3.8 ( , 4H, 5-CH2) , 3.8 (s, 4H, C0CH2N) , 4.55 (m, 1H, 2-CH) , 4.85 (m, 1H,
2-CH), 7.15 (m, 4Harom) , 7.65 (m, 4Harom) , 8.35 (br s, 6H, N+H) , 8.5 (br s, 1H, N+H), 10.35 (br s, 1H, N+H), 11.0 (s, 2H, NH) ; Anal. (C25H33N606P 3 HCl 2.5 H20) C, H, N.
Di (4- (S) -alanylaminophenyl) -1- ( (S) -prolyl) pyrrolidine-
2 (R. S) -phosphonate trihydrochloride (llj).
B. Yield 70%; solid foam; 1H-NMR (D20) δ (ppm)
1.49 (d, 6H, CH3) , 1.65-2.60 (m, 8H, 3-CH2 and 4-CH2) ,
3.23-3.75 ( , 4H, 5-CH2) , 4.12 (m, 2H, CH of Ala), 7.05 (m, 4H, Harom), 7.35 (m, 4H, Harαη) ; Anal. (C27H3/N606P 3 HCl
0.5 H20) C, H; N: calcd, 12.16; found, 11.73.
40
Di (4- (S) -pyroglutamylaminophenyl) -1- ( (S) -prolyl) yrrolidi ne-2 (R.S) -phosphonate hydrochloride (Ilk) .
B. Yield 95%: solid foam; 1H-NMR (DMSO) <S (ppm) 1.5-2.4 (m, 16H, 3-CH2 and 4-CH2) , 3.1-4.2 (m, 6H, 5-CH2 and 5-CH) , 4.5 (m, 1H, 2-CH Pro), 4.85 (m, 1H, 2-CH ProP) , 7.1 (m, 4Harom), 7.65 (m, 4Hapom), 7.9 (s, 2H, NH) , 8.6 (m, 1H, N+H), 10.1 (m, 1H, N+H), 10.3 (s, 2H, NH) ; Anal. (C31H37N608P 1.5 HCl 3 H.,0) C, H, N.
Di( 4-f- (S) - (2-methoxycarbonyl-2-acetamido) ethyl]phenyl ) 1- ( (S) -prolyl) pyrrolidine-2-phosphonate hydrochloride (111).
B. Yield 85%: solid foam; 1H-NMR (DMSO) <S (ppm) 1.6-2.6 (m, 8H, 3-CH2 and 4-CH2) , 1.9 (s, 6H, C0CH3) , 3.0 (d, 4H, CH^r) , 3.2-3.8 (m, 4H, 5-CH2) , 3.7 (s, 6H,
COOCH3) , 4.4-4.9 ( , 4H, 2-CH) , 7.1 (m, 8Haron)) , 8.2 (d, 2H, AcNH) , 8.7 (m, 1H, N+H), 10.4 (m, Η, N+H); MS (FAB+) m/z 687 (M+H) + ; Anal. (C33H43N401QP 1.5 HCl 2 H20) C, N; H: calcd, 6.29; found, 5.81.
Di ( 4 - r . ethoxycarbonyl ) methy laminocarbonyl ] phenyl l-( (S) -prolyl) pyrrolidine-2 (R.S) -phosphonate (lln) .
B. Yield 86%: solid foam; 1H-NMR (DMSO) δ (ppm) 1.3 (t, 6H, CH3) , 1.4-2.6 (m, 8H, 3-CH2 and 4-CH2) , 3.2-3.8 (m, 4H, 5-CH2) , 4.0 (m, 4H, NCH2C0) , 4.2 (q, 4H, 0CH2) , 4.6 (m, 1H, 2-CH), 4.9 (m, 1H, 2-CH) , 7.3 (m, 4Haroπ|) , 7.9 (m, 4Harom) , 8.7 (m, 4H, N+H and NH) ; MS (FAB+) m/z 659 (M+H) + ; Anal. (C31H39N4O10P HCl 1.5 H20) C, H, N.
Di ( 4- f 2- (methoxycarbonyl ) ethylaminocarbonyl ] henyl ) l-( (S) -prolyl) -pyrrol idine-2 (R.S) -phosphonate hydrochloride (Ho) .
B. Yield 79%: solid foam; 1H-NMR (DMSO) δ (ppm)
1.2-2.8 (m, 8H, 3-CH2 and 4-CH2) , 2.65 (t, 4H, CH2C00) , 3.2-3.9 (m, 8H, 5-CH2 and CH2N) , 3.8 (s, 6H, COOCH3) , 4.7
(m, 1H, 2-CH), 4.9 (m, 1H, 2-CH), 7.55 (m, 4Harom) , 8.15 (m,
4H ) , 8.55 (m, 4H, N+H and NH) .
41
Dir 4- (n-propylaminocarbonyl) phenyl] l-( (S) -prolyl) - pyrrol idine-2 (R.S) -phosphonate hydrochloride (lip) .
B. Yield 80%: solid foam; 1H-NMR (CD30D) δ (ppm) 0.95 (t, 6H, CH3) , 1.6 (m, 4H, CH2) , 1.7-2.6 (m, 8H, 3-CH2 and 4-CH2) , 3.2-3.9 (m, 8H, 5-CH2 and CH2N) , 4.65 (m, 1H, 2-CH Pro), 5.1 (m, 1H, 2-CH ProP) , 7.3 (m, 4Haronι) , 7.85 (m, 4Harom) ; 13C-NMR (CD30D) δ (ppm) 11.7 (CH3) , 23.5 (CH2) , 25.0 (4-CH2) , 25.8 (4-CH2) , 27.3 (3-CH2) , 29.7 (3-CH2) , 42.8 (NCH2) , 47.4 (5-CH2) , 48.3 (5-CH2) , 55.9 (d, 2-CH-P, U (C-P) = 161 HZ), 60.6 (2-CH) , 121.4, 130.4, 133.1, 153.7 (Caro , 168.8 (CO), 169.2 (CO).
2.2' -Biphenylacetyl phosphite (16) .
A solution of chloroanhydride 15 (0.152 mol, 38 g) in dry THF (50 L) was added dropwise to a solution of AcOH (0.152 mol, 9.1 mL) and Et3N (0.152 mol, 21.3 mL) in dry THF (100 mL) with stirring at 0°C. The cooling was removed and the mixture was stirred at room temperature for 3 h. The solid was filtered off and the filtrate was evaporated. The crude product was used in the next step without further purification. Yield 40 g (96%) : viscous oil; 1H-NMR (CDC13) δ (ppm) 2.1 (s, 3H, CH3CO) , 6.9-7.5 (m, 8H, H rnm) .
2.2' -Biphenyl 1- (benzyloxycarbonyl- (S) -prolyl) - pyrrolidine-2 (R.S) -phosphonate (17a) .
Prepared according to the general procedure for diaryl phosphonates with acetal 6a and phosphite 16. Yield 27%: solid foam; 1H-NMR (CDC13) δ (ppm) 1.2-2.9 (m, 8H, 3-CH2 and 4-CH2) , 3.1-4.0 (m, 4H, 5-CH2) , 4.55 (m, 1H, 2-CH Pro), 4.85 (m, H, 2-CH ProP) , 5.2 (br S, 2H, CH2Ph) , 7.1-7.85 (m, 15Haro ; MS (El) m/z (relative intensity) 532 (M, 40), 397 (20), 300 (26), 232 (29), 215 (41), 204 (45), 168 (42), 160 (74), 91 (100), 70 (48).
42
2.2' -Biphenyl 1- (t-butyloxycarbonyl- (S) -prolyl) - pyrrolidine-2 (R. S) -phosphonate (17b) .
Prepared according to the general procedure for diaryl phosphonates with acetal 6b and phosphite 16. Yield 24%: solid foam; 1H-NMR (CDC13) δ (ppm)
1.3-2.55 (m, 8H, 3-CH2 and 4-CH2) , 1.5 (s, 9H, CH3) , 3.35-3.9 (m, 4H, 5-CH2) , 4.55 (m, 1H, 2-CH) , 4.9 (m, 1H, 2-CH) , 6.95-7.75 (m, 8H, Harom) ; MS (FAB+) m/z 499 (M+H) +.
2-(2'-Hydroxyphenyl)phenyl methyl 1- (S) -prolyl) - pyrrolidine-2 (R.S) -phosphonate hydrochloride (18) .
Prepared from the Z-protected derivative 17a using procedure "B" for diaryl phosphonates.
Yield 92%: solid foam; 1H-NMR (CDC13) δ (ppm) 1.5-2.6 (m, 8H, 3-CH2 and 4-CH2) , 3.1-3.9 (m, 7H, 5-CH2 and OCH3) , 4.4-4.8 (m, 2H, 2-CH Pro and 2-CH ProP), 6.85 (br s, 1H, PhOH) , 7.1-7.6 (m, 8Harom) , 8.4 (m, 1H, N+H), 9.6 (m, 1H, N+H); 13C-NMR (CDC13) δ (ppm) 25.7 (4-CH2) , 26.1 (4-CH2) , 28.2 (3-CH2), 30.5 (3-CH2) , 48.1 (5-CH2) , 48.6 (5-CH2) , 55.6 (0CH3) , 55.6 (2-CH-P, U (C-P) = 142 Hz) , 60.8 (2-CH) , 117.8, 121.0, 126.3, 130.1, 132.5, 133.8 149.7, 156.2 (Caro , 168.9 (CO); MS (FAB+) m/z 431 (M+H) +; Anal. (C22H27N205P HCl H20) C, H; N: calcd, 5.78; found, 6.26.
2.2 ' -Biphenyl l-( (S) -prolyl)pyrrolidine-2 (R.S) - phosphonate hydrochloride (19) .
Prepared from the Boc-protected derivative 17b using procedure "A" for diaryl phosphonates. Yield 81%: solid foam; 1H-NMR (CDC13) δ (ppm)
1.3-2.55 (m, 8H, 3-CH2 and 4-CH2) , 3.35-3.75 (m, 4H, 5-CH2) , 4.75 (m, 2H, 2-CH) , 7.0-7.5 (m, 8H, Haro , 10.9 (m, 2H, N+H); 13C-NMR (CDC13) δ (ppm) 24.4 (4-CH2) , 24.9 (4-CH2) , 26.7 (3-CH2), 28.7 (3-CH2) , 46.6 (5-CH2) , 51.9 (5-CH2), 53.4 (2-CH-P, U (C-P) = 151 Hz) , 59.2 (2-CH) , 116.9, 120.9, 121.7, 121.9, 125.8, 126.6, 128.4, 129.0, 130.3, 131.5, 147.9 (Caro , 167.8 (CO) ; MS (FAB+) m/z 399
43
(M+H) + ; Anal . (C21H23N204P 1. 4 HCl 1. 1 H20) C , H ; N : calcd, 5. 97 ; found , 5. 43 .
EXAMPLE 2
Synthesis of a series of diaryl phosphonates with an alanine as residue aa
Diphenyl alanine phosphonates were synthesized following the principle described by Oleksyszyn et al., Synthesis 1979, 985-986. The method was used with acetaldehyde for the preparation of the alanine analogue, diphenyl 1-benzyloxycarbonylaminoethane phosphonate.
After deprotection, the mixed anhydride method was used to couple diphenyl 1-aminoethane phosphonate to various amino acids : glycine, L-alanine, L-valine, L-isoleucine,
L-phenylalanine and L-proline.
Experimental :
Preparation of the diphenyl alanine phosphonates Diphenyl l-(N-benzyloxycarbonyl) aminoethane phosphonate
(X)
A mixture of triphenyl phosphate (100 mmol, 31.03 g) , acetaldehyde (150 mmol, 6.61 g - freshly distilled), benzylcarbamate (100 mmol, 15.10 g) and glacial acetic acid (15 ml) was stirred for about 30 minutes until the exothermic reaction subsides.
The mixture was heated at 80-85°C for one hour and the volatile products were removed on a rotary evaporator under reduced pressure with heating on a boiling water bath. The oily residue was dissolved in methanol (180 ml) and left overnight for crystallization at -10°C. The crystalline ester was collected by filtration, redissolved in a small amount of hot chloroform (30-40 ml) and recrystallization occurred by adding a 4-fold volume of methanol.
Yield: 46%; m.p.: 117-118°C IR (KBr) : 3260 (NH) ; 3050, 3020 (CHar) ; 2960, 2920 (CHalif) ; 1720 (C=0) ; 1240 (P=0) ; 1200 (P-0) ; 740, 690 (C6H5) ; 1H-NMR (CDC13, 60
44
MHZ ) : 1. 55 ( 3H, dd , JpH= 17 . 5 Hz , JHH= 7 Hz , CH3) ; 4 . 53 ( 1H, m, CH) ; 5. 10 (2H, S , OCH , ) ; 5. 37 ( 1H , br , NH) ; 6.93- 7.23 ( 10H, m, Har) ; 7.23-7.37 (5H, , Har)
Diphenyl 1-aminoethane phosphonate hydrobromide (Y)
Compound X (10 mmol, 4.11 g) was dissolved in a 45% solution of hydrogen bromide in acetic acid (5 ml) . After-one hour at room temperature the solvent and volatile products were removed under reduced pressure on a boiling water bath. The oily residue was triturated with dry ether. The crystals were filtered and dried over sodium hydroxide in a vacuum oven to give the pure hydrobromides.
Yield: 95%; m.p. : 148.5°C; IR (KBr) : 3100-2700 (NH3 +) ; 1230 (P=0) ; 1200 (P-0) ; 760, 680 (C6H5) ; 1H-NMR (CDC13 + d6-DMSO, 60 MHz): 1.77 (3H, dd, JpH = 17.0 Hz, JHH = 7 Hz, CH3) ; 4.05 (1H, m, CH) ; 6.97-7.30 (10H, m, Har)
Diphenyl 1 (R.S) -rN-benzyloxycarbonyl-L-phenylalanyl]- aminoethane phosphonate. Diphenyl l(R.S)-fN-benzyl- oxycarbonyl-L-prolγl1 aminoethane phosphonate (T, Q) General procedure for the mixed anhydride coupling with isobutyl chloroformate.
The Z-protected amino acid (5 mmol) was dissolved in dry tetrahydrofuran (25 ml) and cooled to -150°C in an ice-sodium chloride bath. N-Methyl- morpholine (5 mmol, 0.51 g) and isobutyl chloroformate (5 mmol, 0.68 g) were added to this solution and stirring was continued for 10 minutes. A solution of Y (5 mmol, 1.79 g) and triethylamine (5 mmol, 0.51 g) in dimethyl- formamide (10 ml) , was introduced dropwise to the stirring mixture, keeping the temperature below -100 °C.
After one hour in a cold water bath, the reaction mixture was allowed to warm to room temperature. The hydrochlorides of N-methylmorpholine and triethylamine were removed by filtration and washed with tetrahydrofuran. The combined filtrate and washings were concentrated on a rotary evaporator. The residue was
45 dissolved in ethyl acetate (75 ml) and water (25 ml) and the organic phase was washed with 5% sodium bicarbonate (25 ml) , 0.5N hydrogen chloride solution (25 ml) and saturated sodium chloride solution (25 ml) , dried over sodium sulphate and evaporated to dryness under reduced pressure.
T: Yield: 84%; oil; IR(KBr) :3280(NH) ; 3060(CHar); 2960, 2930, 2880 (CHalif) ; 1720-1660 (C=0) ; 1250(P=O); 1180 (P-O) ;760,685(C6H5) 1H-NMR(CDC13, 60MHz) : 1.33 (3H,dd,JpH=17.5Hz,
JHH=7.0Hz,CH3) ; 2.80-3.10 (2H,m,,9H) ; 4.27-4.73 (2H,m,αH,CH) ; 5.05(2H,m,CH2) ; 5.53(2H,br,NH) ; 6.87-7.30 (20H,m,Har)
Q: Yield: 79%; oil; IR(KBr) :3280(NH) ; 3060(CHar); 2960,2930,2880(CHalif) ; 1720-1660 (C=0) ; 1260 (P=0) ; 1180 (P-
0) ;760,685(C6H5)
1H-NMR(CDC13, 60MHz) : 1.43 (3H,dd,JpH=18.0Hz ,
JHH=7.0Hz,CH3) ;1.75-2.10(4H,m,j8H,yH) ;3.35-3.70 (2H,m, δH) 7
4.25-4.50(lH,m,αH) ;4.85 (lH,m,CH) ; 5.13(2H,s,CH2) ;7.10-7.4- 0(15H,m,Har)
Diphenyl 1 (R. s) -L-phenylalanyl aminoethane phosphonate. diphenyl KR.S) -L-prolyl aminoethane phosphonate (K, L) General procedure for removal of the Z-group by hydrogenolysis
The Z-protected dipeptide phosphonates T and Q (1.5 mmol) were dissolved in dry methanol (20 ml) and acetic acid (0.7 ml). After the addition of palladium on charcoal (10%, 0.25 g) , the air above the solution was displaced with nitrogen and hydrogen was led over the solution for 3 hours. Before removing the solvent under reduced pressure, the flask was flushed with nitrogen for 10 minutes. The residue was dissolved in dry chloroform (15 ml) and 0.5N hydrogen chloride in ethyl acetate was added slowly to the stirring solution. Removal of the solvent under reduced pressure and co-evaporation with 0.5N hydrogen chloride in ethyl acetate (10 ml) afforded a white foam, which was triturated with dry ether. After
46
2 days at -10°C, the crystals were filtered off and the hygroscopic product was kept in a desiccator.
K: Yield: 80%; oil; IR: 3240(NH) ;3100-2800 (NH3 +) ; 1690 (C=0) ;1250(P=O) ;1180(P-O) ;750, 680 (C6H5)
1H-NMR(CDC13, 250MHz) : 1.15-1.50 (3H,dd,JpH=17Hz, JHH=6.7HZ,CH3) ; 3.16,3.43(2H,m,/9H) ; 44.46-4.58; 4.46- 4.70(3H,m,αH,CH,NH) ; 6.98-7.34 (15H,m,Har) ;8.30-8.52 (2H, - br,NH2)
L: Yield 75%; oil; IR: 3240 (NH) : 3100-2800 (NH3 +) ; 1690 (C=0) ;1250(P=O) ; 1180 (P-0) ;760, 680 (C6H5)
1H-NMR(CDCl3,d6-DMSO, 250MHz) : 1.37-1.65 (3H,m,CH3); 1.77-2.03 (4H,m,,3H,yH) ; 3.38-3.51(2H,m, 6H) ; 4.31(lH,m,NH) ; 4.55 (lH,m,αH) ; 4.77-4.88(lH,m,CH) ;7.13- 7.31(10H,m,Har)
EXAMPLE 3 DPP IV inhibition and stability of the inhibitors
In a previous study (Lambeir, A. M. et al. Dipeptide-derived Diphenyl Phosphonate Esters: Mechanism-based Inhibitors of Dipeptidyl Peptidase IV. Biochim. Biophys. Acta 1996, 1290, 76-82) on the role of the P-2 amino acid in dipeptide diphenyl phosphonates, the present inventors showed that proline in this position gives one of the most potent inhibitors. A major advantage of 5 (the mixture of diastereoisomers of Ha) was its greater stability in human citrated plasma compared to the other dipeptide derivatives. The stability of 5 in plasma equals the stability in buffer, whereas for the other compounds the stability in plasma was reduced compared to buffer. This reflects the relative stability of a Pro-Pro amino acid sequence to proteolytic breakdown, and indicates that the decrease in activity of 5 is mainly caused by hydrolysis of the phosphonate ester.
47
To increase the inhibitory activity while retaining the stability several substituents were introduced on the phenyl rings that act as leaving groups. The influence of electron-donating or
-withdrawing substituents on enzyme inhibition and stability was investigated as shown in Table 1. All compounds were irreversible inhibitors of DPP IV, probably due to the formation of a phosphonylated serine at the active site of the enzyme. The inactivation rate constants were calculated from experimental IC50 values and were in reasonable agreement with the measured inactivation rate constants, where available.
A good correlation was observed between the electron-withdrawing properties of the substituent and its activity (Figure 1) . Introduction of an electron-donating substituent (4-OH, He) decreases potency, whereas an electron-withdrawing substituent (4-methoxycarbonyl, 11m) increases potency. Quite unexpectedly, a striking divergence was observed in the correlation between the Hammett constant and the inhibitory activity for compounds He (4-acetylaminophenyl) and llf (4-methylsulfonyl- aminophenyl) . Both the compounds (He) and (llf) strongly inhibited DPP IV. These compounds have similar Hammett constants compared to the diastereoisomeric mixture of 5, but are nevertheless about 100 times more potent.
Introduction of other acylamino substituents was investigated. The 4-glycylamino (Hi) and the
4-alanylamino (llj) have a comparable activity, but are considerably less stable in plasma than the 4-acetylamino (He) substituted diphenyl phosphonate.
The half-life of the inhibitors seems to also correlate with the Hammett constant (Figure 2) . Compounds with similar electronic properties (e.g. 5 and He) have a similar stability in plasma.
48
The O-methyl derivative (18) is almost as potent and stable as 5.
The correlation between electronic properties and inhibitory activity and between electronic properties and stability results in an inverse correlation between inhibitory activity and stability (Figure 3) . This means that a more active compound is also more unstable. Therefore, the higher potency (IC50 = 0.4 μM) and equal stability (t1/2 = 320 min) of the paracetamol substituted phenyl phosphonate (He) is a major improvement to the unsubstituted 5.
Experimental:
DPP IV was purified from human seminal plasma as described previously (De Meester et al., J. Immunol. Meth. 189, 99-105 (1996)). Enzymatic activity was measured at 37 βC in a Spectramax 340 (Molecular Devices) microtiterplate reader using Gly-Pro-p-nitroanilide (Sigma) as a chromogenic substrate. The reaction was monitored at 405 nm and the initial rate was determined between 0 and 0.25 absorbance units. The reaction mixture contained 2 mM substrate, approximately 1 mU of DPP IV, 40 mM TRIS-HC1 buffer, pH 8.3, and a suitable amount of inhibitor (ranging between 0 an 10 mM) in a total volume of 0.2 ml. Activity measurements were routinely performed in duplicate.
The IC50 value is defined as the concentration of inhibitor required to reduce the DPP IV activity to 50% after a 15 min pre-incubation with the enzyme at 37 °C before addition of the substrate. Inhibitor stock solutions (100 mM) were prepared in DMSO or phosphate buffer, pH 7.4, depending on the solubility of the compound, and stored at -20°C. Stock solutions were diluted with 50 mM TRIS-HC1 buffer, pH 8.3, as required, immediately before the experiment. Since the compounds described in this paper completely inactivate DPP IV following pseudo-first order kinetics, the IC50 value is inversely correlated with the second order rate constant
49 of inactivation (Lambeir et al., (1996), supra) . For a simple pseudo-first order inactivation process, the activity after incubation with inhibitor (vi) varies with the inhibitor concentration (i) as described in the 5 following equation: vi - vo * e-k.i.t, where vo is the activity in absence of inhibitor, k is the second order rate constant of inactivation and t is the time. Since at i = IC50 by definition vi = 1/2 vo, it follows from the equation that k = ln2/(ti*IC50) where ti = 15 min. These 0 calculated k values are listed in Table 1.
Table 1. Potency and stability of DPP IV inhibitors
*ι Configuration IC50 -alc t1/2 (min) at Prop C(2) (yM) In plasma
5 H R,S 32 (n-1) 2.4*10' 250 ± 10
11a H R 15 ± 3 (n-3) 5.1*10' 300 ± 30
11a H S >ιo*
lid 3-AcNH R,S 0.8 ± 0.1 (n-2) θ.ό O2 220 ± 30
He 4-AcNH R,S 0.4 ± 0.2 (n-5) l-9'l 3 320 ± 140 llf 4-MeS02NH R,S 0.40 ± 0.02 (n-2) 1.9 05 150 ± 30
Ug 3-H2NCONH R,S 2.3 ± 0.3 (n-2) 3.3 02 210 ± 80
Uh 4-(N-B.-Gly-NH) R,S 0.7 ± 0.3 (n-2) l.l'lO3 93 ± 3 in 4-(H-Gly-NH) R,S 0.5 ± 0.1 (n-2) LS'IO5 28 ± 3
Hj 4-(H-(S)-*Ala-NH) R,S 0.6 ± 0.2 (n-2) O'lO3 8 ± 1
Ilk 4-((S)-Pyr-NH) R,S 5.0 ± 0.8 (n-2) LS^IO2 170 ± 30 in 4-[(2S)-M.-02CCH(NHAc)CH2] R,S 1.4 ± 0.5 (n-4) 5.5 02 190 ± 150 l lm 4-Me02C R,S 0.016 ± 0.004 (n-2) 4.8'lϋ4 19 ± 1 lln 4-(EtO2CCH2NHC0) R,S 0.023 ± 0.007 (n-2) 3.3 04 35 ± 2
Ho 4-[MeO2C(CH2)2NH00] R,S 0.036 ± 0.006 (n-4) uno4 26 ± 1 lip 4-[CH3(CH2)2NHCO] R,S 0.03 ± 0.01 (n-2) 2.6 04 12 ± 1
18 PfOMeXOCβH^Z-OH-Q- )) R.S 47 ± 18 (n-2) 1.6*10' 140 ± 80
19 P-2,2'-biphenyl R,S 31 ± 6 (n-2) 2.5*10' 6 ± 1
IC50 values were determined after 15 min pre-incubation with DPP IV at 37 *C. The listed values are the average of n independent measurements ± the standard deviation. Functional stability in plasma was estimated by fitting the inverse of the apparent IC50 values versus time with a single exponential decay. The half-life is listed ± the standard error of fit.
50
For some inhibitors (5, Ha, lib, lid, He, llh, lln) the inactivation rate constant was determined from the time course of inhibition as described before (Lambeir et al., (1996), supra) . The functional stability of the inhibitors was estimated by measuring the inhibitory potency (apparent IC50) of a 1 mM dilution of the compounds in citrated human plasma at 3 or 4 time points between 0 and 300 min at 37 °C. Fitting the inverse of the apparent IC50 values versus time with a single exponential decay gives the half-lives reported in table 1.
EXAMPLE 4
Inhibition of prolyl oligopeptidase (PO) by protected prolylpyrrolidine diaryl phosphonates
The inhibitory capacity of various compounds of the invention was evaluated. The results are shown in table 2.
Table 2
Potency of the compounds 10 as PO inhibitors. IC50 values are expressed in μM
compound Rl or R2 ιc50 lOd 3-AcNH 10 lOe 4-AcNH 21 lOf 4-MeS02NH 10 lOh 4- (N-Bz-Gly-NH) 12 lOi 4- (N-Z-Gly-NH) 15
10J 4- (N-Z-Ala-NH) >500
101 4- [ ( 2S ) -Me02CCH- 20 (NHAC) CH2]
10k 4- ( (S) -Pyr-NH 9
51
10n 4- (Et02CCH2NHCO) 5
10O 4- [Me02C- 2 . 8 (CH2) 2NHCO] lOp 4- [ CH3 (CH2) 2NHCO] 3 . 2
Experimental :
Prolyl oligopeptidase was purified from human platelets and the enzyme activity was measured using Z-Gly-Pro-AMC (4.4 mM) as the substrate in a K-phosphate buffer 100 mM, pH 7.5 containing 1 mM EDTA, 1 mM dithiothreitol and 1 mM NaN3. The incubation was carried out during 20 min at 37°C. The reaction was stopped by the addition of 5 volumes 1.5 M acetic acid. Fluorescence was measured at 370 and 440 nm as excitation and emission wavelengths respectively. The inhibitors were added at concentrations varying between 1 μM and 1 mM.
EXAMPLE 5
Inhibition of Dipeptidyl peptidase II by dipeptide-derived diaryl phosponate esters with an ala in position aa
The compounds Pro-AlaP(OPh) 2 and Phe-AlaP(OPh) 2 inhibited DPP II in vitro and the IC50 values calculated were 1.5 mM for Pro-AlaP(0Ph)2 and 0.8 mM for Phe-AlaP(0Ph)2.
Experimental :
Dipeptidyl peptidase II was semi-purified from rabbit kidney and its activity was determined by the hydrolysis of Lys-Ala-4-Me0-2-NA 1.4 mM (Sigma, L-2270) in 100 mM acetate buffer, pH 5.5 containing 2 mM EDTA. After incubation during 20 minutes at 37 °C, the reaction was stopped by the addition of 10 fold excess sodium-acetate pH 3.6. The fluorescence of the formed 4-MeO-2-NA was measured at 340 and 425 nm as excitation and emission wavelengths respectively. For the determination of the IC50 values the compounds were tested
52 at a series of concentrations ranging from 1 μM to 5 mM during incubation.
EXAMPLE 6 In vitro cytotoxicity and efficacy of prolylpyrrolidine diaryl phosphonates in human peripheral blood mononuclear cells (PBMC)
Based on inhibition potency, stability in plasma and synthesis efficiency, compounds He and lln were selected for further in vitro and in vivo studies. Both compounds were evaluated in human peripheral blood mononuclear cells (PBMC) and did not show cytotoxicity in freshly isolated mononuclear cells or phytohemagglutinin stimulated blasts when concentrations up to 100 μM were used. Under these circumstances, more than 90 % of the DPP IV activity in cell lysates as well as in supernatants was inhibited. This is in contrast with the results obtained for the active diastereoisomer of the unsubstituted diphenyl phosphonate (Ha) , where no satisfactory inhibition of DPP IV activity could be reached without cytotoxic effects on PBMC cultures. The compounds He and lln are therefore promising tools for further studies on cellular level. The irreversible mechanism of inhibition overcomes the rather limited stability of the compounds in biological media.
Experimental :
Peripheral blood mononuclear cells were isolated from buffy coats (obtained from the blood transfusion center of Antwerp). After dilution (1/4) in phosphate buffer saline (PBS) , cells were layered onto Ficoll-Hypaque density gradient (Pharmacia, Uppsala, Sweden) and centrifuged at room temperature at 550 x g during 20 min. The interfaces were collected and washed 3 times in RPMI-1640. Finally the cells were resuspended at lxlO6 cells/mL in RPMI-1640 containing 10 % heat-inactivated foetal calf serum, and antibiotics (penicillin/streptomycin) (Gibco) . These freshly isolated
53 cells were used immediately for inhibitor studies or first stimulated with phytohaemagglutinin (Murex diagnostics) at lμg/mL during 3 days at 37 °C in a 5 % C02 humidified incubator. Inhibitor (stock solution at -80°C in phosphate buffer, diluted ex tempore in RPMI-1640) or vehicle alone was added to the cells (5xl06/test) at different concentrations. After overnight incubation at 37 "C, an aliquot was taken for cytotoxicity evaluation by 0.4 % trypan blue exclusion. The remaining cells were washed 3 times in PBS and the final cell pellet was solubilised in 200 μL PBS containing 1 % v/v Triton X-100 and 100 KIU/mL aprotinin (Bayer) and centrifuged during 10 min at 20000 x g. Supernatants were used immediately for enzyme assay and protein determination by the Bradford micro-assay. Specific activities (U/g protein) are compared and the % inhibition is given toward control samples without inhibitor.
EXAMPLE 7 DPP IV inhibition in vivo
It was reported previously (De Meester et al., Biochem. Pharmacol. 54, 173-179 (1997)) that a single intravenous injection of 5 (0.3-5 mg/kg) in rabbits caused a decrease in plasma DPP IV activity with more than 80 % and it took more than 20 days for complete recovery.
In rats, a comparable dose per weight intravenously did not result in a sufficient inhibition of circulating DPP IV, because adequate inhibition could not be reached without severe systemic toxicity. However, a combination of subcutaneous and intraperitoneal injections of Ha allowed us to bring plasma DPP IV to less than 15 % of pre-treatment values. The observation that monotherapy with the diastereoisomeric mixture of Ha (5) not only significantly prolonged graft acceptance upon alloantigen challenge, but occasionally also caused systemic toxicity and more often local ulcerations,
54 stimulated the in vivo testing of He and lln in rabbits, rats and mice.
In rabbits, the higher in vivo potency of lln compared to He was also observed. The IC50 values for inhibition of plasma DPP IV in rabbits upon single intravenous injection was below 20 μg/kg for lln and was around 0.2 mg/kg for He. In this species single intravenous injection of 0.2 mg/kg of lln inhibited plasma DPP IV activity for more than 90 % during at least 24 h, without side effects (see figure 4) .
In rats. He as well as lln could keep plasma DPP IV activity below 10 % of pre-treatment values by daily subcutaneous injection of 50 mg/kg (initial dose 100 mg/kg) , without any sign of acute systemic or local toxicity. Figure 5 depicts residual plasma DPP IV activity in rats treated subcutaneously on days 0 to 5 with He.
Different administration routes in rats were examined for compound lln: oral as well as subcutaneous as intraperitoneal and intrarectal routes of administration allowed an in vivo inhibition of DPP IV. The intraperitoneal route being the least efficient i.e. no 50% inhibition after 24h while for the other routes DPP IV activity was still very low (<35% of initial value) 1 day after a single dose (all routes 50 mg/kg) . In mice, a pharmacologically useful inhibition was only obtained with lln and not with Ha and He. The molecular basis for the large interspecies differences in efficiency remains to be elucidated.
Experimental :
Male New Zealand white rabbits (2.5-3.5 kg), istar rats (250-350 g) and Swiss mice (23-36 g) were allowed to adjust to their environment for at least 7 days. They received standard diet and water ad lib. Test compounds were dissolved in 50 mM phosphate buffer pH 7.4 at concentrations ranging from 10-100 mg/mL and stored in aliquots at -80"C and were thawed ex tempore. Rabbits
55 received a single slow intravenous bolus injection of test compound or vehicle alone in the marginal ear vein. Blood was sampled from the central ear artery. Rats and mice were injected subcutaneously or intraperitoneally. Rat blood samples were obtained under anesthesia (Forene) from the vena femoralis by puncture after incision of the skin. The mice were bled by orbita puncture after induction of anesthesia with pentobarbital. After clotting, blood samples were centrifuged (3000 x g, 10 min) and the resulting sera were stored at -80βC until assayed for DPP IV activity.
The above Examples show that all compounds tested were irreversible inhibitors. A good correlation was observed between the electron-withdrawing properties of the substituents and the inhibition of DPP IV. The methoxycarbonyl and alkylaminocarbonyl substituted derivatives were the most potent inhibitors with IC50 values around 20 nM and inactivation rate constants around 3000 M"1 s"1. The same correlation was also observed between the electron-donating properties of the substituents and the stability in plasma. The most potent inhibitors are also the most unstable compounds. A notable exception is the good stability of the
4-acetylaminophenyl phosphonate ester (He, t1/2 = 320 min) , together with a higher potency than could be expected (IC50 = 0.4 μM, k = 1900 M"1 s"1) . Therefore, this compound together with the very potent lln were further investigated in vitro and in vivo. These inhibitors showed no cytotoxicity in human peripheral blood mononuclear cells in concentrations up to 100 μM. The IC50 values of lie and lln for inhibition of plasma DPP IV in rabbits upon single intravenous injection were around 0.2 mg/kg and below 20 μg/kg respectively. The compounds also showed no acute systemic or local toxicity, as was observed with the unsubstituted compound 5.
56
Due to the higher stability of He compared to lln, it is believed that di(4-acetamidopheny1) l-(S)-prolylpyrrolidine-2-(R,S) -phosphonate (He) is a major improvement. The advantage of this compound compared to the pyrrolidine-2-nitrile reversible inhibitors is its long-lasting irreversible inhibition. Moreover, it is more stable than the frequently used boronic acid inhibitors.
Claims
1. Compounds having a modulating activity on serine proteases and having the general formula
n (I) x-pn
wherein - A is R2 or H or C1-C6 alkyl or halogenoalkyl , except perfluoroalkyl, the phenyl group is mono-, di- or trisubstituted with Rl or R2 ;
X is a peptide- or amino acid-derived moiety; - A and the phenyl group substituted with Rl may optionally form a biphenyl diester; all Rl substituents and R2 substituents are each independently selected from the group consisting of: a) C1-C6 acylamino; b) aroylamino, optionally substituted at the o- and/or p- and/or m- position with alkyl, in particular C,- C6 alkyl, and/or a halogen; c) C1-C6 alkylsulfonylamino ; d) arylsulfonylamino, optionally substituted at the o- and/or p- and/or m- position with alkyl, in particular C,-C6 alkyl, and/or a halogen; e) ╬▒-aminoacylamino wherein the ╬▒-aminoacyl represents a side chain blocked or unblocked ╬▒-amino acid residue with the L, D or DL configuration at the ╬▒-carbon atom selected from the group consisting of: alanine, methionine, methionine sulfoxide, arginine, homoarginine, phenylalanine, aspartic acid, proline, hydroxyproline, asparagine, serine, cysteine, threonine, histidine, glycine, tyrosine, glutamic acid, pyroglutamic acid, tryptophan, glutamine, valine, norvaline. 58 isoleucine, lysine, leucine, norleucine, thioproline, homoproline, 1,2,3,4-tetrahydro- isoquinoline-3-carboxylic acid (Tic) , 2 , 3-dihydroindol-2-carboxylic acid, ╬▒-naphtylglycine, ╬▒-phenylglycine,
4-amidinophenylglycine, 4-phenylproline, 4-amidinophenylalanine, O-benzyl tyrosine, omega-acetyl lysine, ╬▒-aminobutyric acid, citrulline, homocitrulline, ornithine, 0- methylserine, O-ethylserine, S-methylcysteine,
S-ethylcysteine, S-benzylcysteine, homoserine, 4-dehydroproline, penicilla ine ,9-(2- thienyl) alanine, NH2-CH(CH2CHEt2)-COOH, ╬▒- a inoheptanoic acid, NH2-CH (CH2-l-naphthyl) - COOH, NH2-CH(CH2-2-naphthyl)-COOH, NH-,-CH(CH2- cyclohexyl) -COOH, NH2-CH[CH- (cyclohexyl) 2] -COOH, NH2-CH(CH2-cyclopenty1) -COOH, NH2-CH[CH- (cyclopentyl) 2] -COOH, NH2-CH (CH2-cyclobutyl) - COOH, NH2-CH[CH- (cyclobuty1) 2] -COOH, NH2-CH (CH2- cyclopropyl)-COOH, NH2-CH[CH-(cyclopropyl)2]-
COOH, 5,5,5-trifluoroleucine, hexafluoroleucine, (S) -azetidine-2-carboxylic acid, (S)-pipecolic acid, (S)-oxazolidine-4- carboxylic acid, (R)-thiazolidine-4- carboxylacid (L-thioproline) , sarcosine; f) residue selected from the group consisting of 3-aminobenzoic acid; e-aminocaproic acid, ╬▓- alanine; g) Y-NH-C0-NH-; h) Y'02CCH(NHCO-Y)-CH2-; i) Y'NHCO-; j ) CH3-0-C0-Y ΓÇó -NH-CO- ; k) CH3-CH2-0-CO-Y ΓÇó -NH-CO- ; wherein Y is C1-C6 alkyl, aryl or H and Y' is C C6 alkyl, and pharmaceutically acceptable salts thereof.
2. Compounds according to claim 1, wherein X is a moiety of the general formula (AA) -aa-. 59 wherein : p indicates that there may be 0, 1, 2, 3, 4 or 5 residues AA, which can be the same or different within one molecule; AA and aa are ╬▒-amino carboxylic acids with in ╬▒ position an optionally substituted C--C6 alkyl or aryl or aralkylmoiety; and pharmaceutically acceptable salts thereof.
3. Compounds according to claim 1, wherein X is a moiety of the general formula (AA) -aa-, wherein: p indicates that there may be 0, 1, 2, 3, 4 or 5 residues AA, which can be the same or different within one molecule; AA and aa are selected from the group consisting of: alanine, methionine, methionine sulfoxide, arginine, homoarginine, phenylalanine, aspartic acid, proline, hydroxyproline, asparagine, serine, cysteine, threonine, histidine, glycine, tyrosine, glutamic acid, pyroglutamic acid, trytophan, glutamine, valine, norvaline, isoleucine, lysine, leucine, norleucine, thioproline, homoproline, 1,2,3,4-tetrahydro- isoquinoline-3-carboxylic acid (Tic) ,
2 , 3-dihydroindol-2-carboxylic acid, ╬▒-naphtylglycine, ╬▒-phenylglycine, 4-amidinophenylglycine, 4-phenylproline, 4-amidinophenylalanine, O-benzyl tyrosine, omega-acetyl lysine, ╬▒-aminobutyric acid, citrulline, homocitrulline, ornithine, 0- methylserine, O-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzylcysteine, homoserine, 4-dehydroproline, penicillamine ╬▓- (2- thienyl) alanine, NH2-CH(CH2CHEt2)-COOH, ╬▒- aminoheptanoic acid, NH2-CH(CH2-l-naphthyl)- COOH, NH2-CH(CH2-2-naphthyl)-COOH, NH2~CH(CH2- cyclohexyl) -COOH, NH2-CH[CH- (cyclohexyl) 2]-COOH, 60
NH2-CH(CH2-cyclopentyl) -COOH, NH2-CH[CH- (cyclopentyl) 2] -COOH, NH2-CH (CH2-cyclobutyl) - COOH, NH2-CH[CH-(cyclobutyl)2]-COOH, NHg-CHfC^- cyclopropyl) -COOH, NH2-CH[CH-(cyclopropyl)2]- COOH, 5,5,5-trifluoroleucine, hexafluoroleucine, (S) -azetidine-2-carboxylic acid, (S)-pipecolic acid, (S)-oxazolidine-4- carboxylic acid, (R)-thiazolidine-4- carboxylacid (L-thioproline) , 3-aminobenzoic acid, sarcosine, e-aminocaproic acid, ╬▓- alanine, wherein the alpha amino residue may be side chain blocked or unblocked and has the L, D, or DL configuration at the alpha carbon atom; and pharmaceutically acceptable salts thereof.
4. Compounds as claimed in claims 2-3, wherein AA is lysine or ornithine, and the amino side chain thereof is involved in an intramolecular covalent bond.
5. Compounds as claimed in claim 1, wherein X is M-(AA)p-aa- wherein: p, AA and aa are as defined in claims 2-4; and
M is selected from: a) the group consisting of optionally substituted -CONH2, -CSNH2, -SO-^, phenyl-S02-, phenyl-CH2S02-, 2-furyl- acryloyl ; and b) the group of protecting groups consisting of: acetyl, adamantyloxycarbonyl , benzyloxycarbonyl , benzoyl , benzyl , t-butoxycarbonyl , t-butyl , 2 , 4-dinitropheny1 , formy1 , fluorenylmethoxycarbonyl , 4-methoxybenzyl, tosyl, trifluoro- acetyl, trityl, phthaloyl, phenyl- alkylcarbonyl , 2-indanylacetyl, 2- 61
(1,2,3,4-tetrahydronaphty1) acetyl, 4- (4-benzylphenoxy) alkyl ; and pharmaceutically acceptable salts thereof.
6. Compounds as claimed in claim 1-5, wherein X represents (M-)AA-aa-, wherein (M-) means that M may or may not be present, aa is proline and AA is as defined in claims 2-4.
7. Compounds as claimed in claims 1-5, wherein X represents (M-)AA-aa-, wherein (M-) means that M may or may not be present, and wherein AA and aa are both proline.
8. Compounds as claimed in claims 2-5, wherein aa is alanine, Rl and R2 may, in addition to the definitions in claim 1, further be selected from: 1) H, halogen, N02, CN, OH, COOH m) amino, C1-C6 alkylamino, C2-C12 dialkyla ino, n) C1-C6 acyl o) C1-C6 alkoxy-CO- p) C C6 alkyl-S-, and pharmaceutically acceptable salts thereof.
9. Compounds as claimed in claim 2-8 wherein at least the AA coupled to aa is proline or phenylalanine and pharmaceutically acceptable salts thereof.
10. Compound as claimed in claim 9, which compound is Phe-Ala-diphenylphosphonate or
Pro-Ala-diphenylphosphonate and pharmaceutically acceptable salts thereof.
11. Compounds according to claim 1, wherein the compounds (also indicated as group 1 compounds) have the general formula:
II :┬░┬░J-^R' (ii)
wherein the Rl, R2 and X are as defined in claims 1-9, and pharmaceutically acceptable salts thereof. 62
12. Compound as claimed in claim 11 selected from the group consisting of :
Di(3-acetamidopheny1) 1- (benzyloxycarbonyl- (S) - prolyl) pyrrolidine-2(R,S) -phosphonate (lOd) ; - Di(4-acetamidopheny1) 1- (benzyloxycarbonyl- (S)- prolyl) pyrrolidine-2 (R, S) -phosphonate (10e) ; Di(4-methylsulfonylaminophenyl) 1- (benzyloxycarbonyl- (S) -prolyl)pyrrolidine-2 (R,S) -phosphonate (lOf); - Di(3-ureylphenyl) 1-(benzyloxycarbonyl- (S)- prolyl) pyrrolidine-2 (R,S) -phosphonate (lOg) ; Di [4- (N-benzoylglycylamino) phenyl] -1- (benzyloxycarbonyl- (S) -prolyl)pyrrolidine-2 (R,S) -phosphonate (lOh) ; - Di[4- (N-glycylamino)phenyl]-l- (benzyloxycarbonyl- (S) -prolyl)pyrrolidine-2(R,S)- phosphonate (lOi) ; Di[4- (N-benzyloxycarbonyl-(S) -alanylamino) phenyl] - 1- (benzyloxycarbonyl-(S) -prolyl)pyrrolidine-2 (R,S) - phosphonate (lOj); - Di[4- ( (S) -pyroglutamylamino)phenyl]-l- (benzyloxycarbonyl- (S) -prolyl)pyrrolidine-2 (R,S) -phosphonate (10k);
Di{4-[-(S)-(2-methoxycarbonyl-2-acetamido) ethyl] - phenyl} 1- (benzyloxycarbonyl- (S) -prolyl)pyrrolidine- 2 (R,S) -phosphonate (101);
Di (4-methoxycarbonylphenyl) 1- (tert-butyloxycarbonyl- (S) -prolyl) pyrrolidine-2 (R,S) -phosphonate (10m) ; Di{4-[ (ethoxycarbonyl)methylaminocarbonyl]phenyl} 1- (benzyloxycarbonyl- (S) -prolyl) -pyrrolidine- 2 (R,S) -phosphonate (lOn) ;
Di{4-[2- (methoxycarbonyl) ethylaminocarbonyl]phenyl}
1- (benzyloxycarbonyl- (S) -prolyl) -pyrrolidine-
2 (R, S) -phosphonate (lOo) ;
Di[4- (n-propylaminocarbonyl) phenyl] l-(benzyloxy- carbonyl-(S) -prolyl) -pyrrolidine-2 (R,S) -phosphonate (10p) ;
Di(3-acetamidopheny1) l-( (S) -prolyl) pyrrolidine- 2 (R,S) -phosphonate hydrochloride (lid); 63
Di(4-acetamidopheny1) l-( (S) -prolyl)pyrrolidine- 2 (R,S) -phosphonate hydrochloride (He); Di(4-methylsulfonylaminophenyl) l-( (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate hydrochloride (llf); - Di(3-ureylphenyl) l-( (S) -prolyl) pyrrolidine-2 (R,S)- phosphonate hydrochloride (llg) ;
Di[4- (N-benzoylglycylamino) phenyl]-l-( (S)-prolyl)- pyrrolidine-2(R,S) -phosphonate hydrochloride (lib) ; Di[4- (N-glycylamino)phenyl]-l-( (S) -prolyl) - pyrrolidine-2 (R,S) -phosphonate trihydrochloride
(Hi);
Di(4-(S)-alanylaminophenyl)-l-( (S) -prolyl) yrroli- dine-2 (R,S) -phosphonate trihydrochloride (11j ) ;
Di (4- (S) -pyroglutamylaminophenyl) -1- ( (S) -prolyl) - pyrrolidine-2(R,S) -phosphonate hydrochloride (Ilk);
Di{4-[-(S)-(2-methoxycarbony1-2-acetamido) ethyl]- phenyl) 1- ( (S) -prolyl)pyrrolidine-2-phosphonate hydrochloride (111) ;
Di{4-[ (ethoxycarbonyl) ethylaminocarbonyl]phenyl} l-( (S) -prolyl)pyrrolidine-2(R,S) -phosphonate (lln);
Di{4-[2- (methoxycarbonyl) ethylaminocarbonyl]phenyl } l- ( (S) -prolyl) -pyrrolidine-2 (R, S) -phosphonate hydrochloride (Ho) ;
Di[4- (n-propylaminocarbonyl)phenyl] l-( (S) -prolyl) - pyrrolidine-2 (R,S) -phosphonate hydrochloride (lip); and pharmaceutically acceptable salts thereof.
13. Compounds according to claim 1, wherein the compounds are 2,2* biphenyl diesters of ╬▒-aminoalkyl phosphonic acid (group 2 compounds) having the general formula:
(III)
R. wherein the Rl, R2 and X are as defined in claims 1-11, and pharmaceutically acceptable salts thereof. 64
14. Compounds as claimed in claim 13 , selected from the group consisting of:
2 , 2 ' -Biphenyl 1- (benzyloxycarbonyl-(S) -prolyl)- pyrrolidine-2 (R,S) -phosphonate (17a) ; - 2 , 2 ' -Biphenyl l-(t-butyloxycarbonyl-(S) -prolyl) - pyrrolidine-2(R,S) -phosphonate (17b) ; 2 , 2 ' -Biphenyl l-( (S) -prolyl)pyrrolidine-2 (R,S)- phosphonate hydrochloride (19) .
15. Compound as claimed in claim 14 which compound is 2 , 2 ΓÇó -Biphenyl l-( (S) -prolyl)pyrrolidine-
2 (R,S) -phosphonate hydrochloride or a pharmaceutically acceptable salt thereof having an inhibitory activity for DPP IV.
16. Compounds according to claim 1 (group 3 compounds) , having the general formula:
(IV) x-p:o Ri n
II ┬░- o wherein the Rl is as defined in claim 1, X is as defined in claims 2-5 and A is H or C1-C6 alkyl or halogenoalkyl, except perfluoroalkyl, or pharmaceutically acceptable salts thereof.
17. Compound as claimed in claim 16, which compound is
2- (2 * -Hydroxypheny1) phenyl methyl 1- (S) -proly1- pyrrolidine-2 (R,S) -phosphonate hydrochloride (18).
18. Compounds as claimed in claims 1-17, wherein the compounds have a modulating activity for DPP IV, for DPP II, for PO, for lysosomal Pro-X carboxypeptidase or for elastase or for related peptidases with at least 45% amino acid sequence homology with one of these peptidases.
19. Compounds as claimed in claims 1-18 for use as a therapeutical agent.
20. Compounds as claimed in claims 1-18, which compounds may be optionally labeled, for use in the 65 treatment or prophylaxis of one of the following conditions: inflammation, organ specific or systemic auto-immune diseases, non-malignant disorder of leukocytes and/or immunoglobulins, rejection of cells or tissues after transplantation, tissue destructive and bone degenerative diseases, neuroendocrine dysfunction, glucose-intolerance, obesitas, functional gastrointestinal disorder, abnormal growth or growth retardation, thrombosis and hemorrhage, vascular and cardiopulmonary diseases, neurodegenerative and affective disorders, pain, diseases associated with neoplasia.
21. Compounds as claimed in claims 1-18, which compounds are optionally labeled, for use in diagnostic and research methods such as fluorescence, purification and radio-assays, imaging, in situ histochemical and cytochemical staining.
22. Compounds as claimed in claims 1-18, wherein X is as defined in claims 1-5, wherein Rl and/or R2 is selected from the group consisting of 3-AcNH, 4- AcNH, 4-MeS02NH, 4-(N-Bz-Gly-NH) , 4- (H- (S) -Ala-NH, 4-
[ (2S) -Me02CCH(NHAc) CH2] , 4- (S) -Pyr-NH, 4- (Et02CCH2NHCO) , 4- [Me02C (CH2) 2NHC0] , 4- [CH3 (CH2) 2NHC0] .
23. Compounds as claimed in claims 1-18, wherein X is as defined in claim 5, wherein Rl and/or R2 is selected from the group consisting of 3-AcNH, 4-AcNH, 4-MeS02NH, 4-(N-Bz-Gly-NH) , 4- (H- (S) -Ala-NH, 4-[(2S)- Me02CCH (NHAc) CH2] , 4- (S) -Pyr-NH, 4- (Et02CCH2NHCO) , 4- [Me02C (CH2) 2NHC0] , 4-[CH3 (CH2) 2NHC0] and which compounds have an modulating, in particular an inhibitory activity on PO.
24. Use of the compounds as claimed in claims 1-18 for the preparation of a therapeutical composition for inhibiting the activity of serine proteases.
25. Use of the compounds as claimed in claims 1-18 for the preparation of a therapeutical composition for the treatment or prophylaxis of one of the following conditions: inflammation, organ specific or systemic auto-immune diseases, non-malignant disorder of 66 leukocytes and/or immunoglobulins, rejection of cells or tissues after transplantation, tissue destructive and bone degenerative diseases, neuroendocrine dysfunction, glucose-intolerance, obesitas, functional gastrointestinal disorder, abnormal growth or growth retardation, thrombosis and hemorrhage, vascular and cardiopulmonary diseases, neurodegenerative and affective disorders, pain, diseases associated with neoplasia.
26. A pharmaceutical preparation comprising one or more compounds as claimed in claims 1-18 and a suitable excipient, carrier or diluent.
27. A pharmaceutical preparation as claimed in claim 26, further comprising one or more additional therapeutic ingredients.
28. Pharmaceutical preparation as claimed in claim 27 for use in the treatment or prophylaxis of one of the following conditions: inflammation, organ specific or systemic auto-immune diseases, non-malignant disorder of leukocytes and/or immunoglobulins, rejection of cells or tissues after transplantation, tissue destructive and bone degenerative diseases, neuroendocrine dysfunction, glucose-intolerance, obesitas, functional gastrointestinal disorder, abnormal growth or growth retardation, thrombosis and hemorrhage, vascular and cardiopulmonary diseases, neurodegenerative and affective disorders, pain, diseases associated with neoplasia.
29. A method for in vitro modulating protease activity by means of a suitable concentration of a compound as claimed in claims 1-18.
30. Method as claimed in claim 29, wherein the protease activity results in the unwanted degradation of a peptide substrate prior to measurement of the peptide substrate in a peptide assay.
31. A method for ex vivo inhibiting protease activity by means of a suitable concentration of a compound as claimed in claims 1-18. 67
32. Method as claimed in claim 31, wherein the suitable concentration of the compound is applied to cells or organs for transplantation.
33. A method for in vivo inhibiting protease activity by means of administering to a living organism a suitable amount of a compound as claimed in claims 1-18.
34. A method for treatment or prophylaxis of one of the following conditions: inflammation, organ specific or systemic auto-immune diseases, non-malignant disorder of leukocytes and/or immunoglobulins, rejection of cells or tissues after transplantation, tissue destructive and bone degenerative diseases, neuroendocrine dysfunction, glucose-intolerance, obesitas, functional gastrointestinal disorder, abnormal growth or growth retardation, thrombosis and hemorrhage, vascular and cardiopulmonary diseases, neurodegenerative and affective disorders, pain, diseases associated with neoplasia, comprising administering to a living organism an effective amount of a compound according to claims 1-18.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99911781A EP1062222A1 (en) | 1998-03-09 | 1999-03-09 | Serine peptidase modulators |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98200733 | 1998-03-09 | ||
EP98200733 | 1998-03-09 | ||
EP99911781A EP1062222A1 (en) | 1998-03-09 | 1999-03-09 | Serine peptidase modulators |
PCT/EP1999/001617 WO1999046272A1 (en) | 1998-03-09 | 1999-03-09 | Serine peptidase modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1062222A1 true EP1062222A1 (en) | 2000-12-27 |
Family
ID=8233450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99911781A Withdrawn EP1062222A1 (en) | 1998-03-09 | 1999-03-09 | Serine peptidase modulators |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1062222A1 (en) |
JP (1) | JP2002506075A (en) |
AU (1) | AU3034299A (en) |
WO (1) | WO1999046272A1 (en) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19828113A1 (en) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs of Dipeptidyl Peptidase IV Inhibitors |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
DE19940130A1 (en) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | New effectors of Dipeptidyl Peptidase IV for topical use |
AU2001233622A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Inhibition of beta cell degeneration |
HU229042B1 (en) | 2000-03-31 | 2013-07-29 | Prosidion Ltd | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
DE10025464A1 (en) * | 2000-05-23 | 2001-12-06 | Inst Medizintechnologie Magdeb | Combined use of enzyme inhibitors for the therapy of autoimmune diseases, in transplants and tumor diseases, as well as combinations of pharmaceutical preparations comprising enzyme inhibitors |
GB0020083D0 (en) * | 2000-08-15 | 2000-10-04 | Ribo Targets Ltd | Assay 14 |
US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
IL155116A0 (en) * | 2000-10-27 | 2003-10-31 | Probiodrug Ag | Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes |
EP1891948A1 (en) | 2000-10-27 | 2008-02-27 | Probiodrug AG | Treatment of neurological and neuropsychological disorders |
WO2002053170A2 (en) | 2001-01-02 | 2002-07-11 | Institut Für Medizintechnologie Magdeburg Gmbh (Imtm) | Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo |
GB0101760D0 (en) * | 2001-01-23 | 2001-03-07 | Glaxo Group Ltd | Novel protein |
US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
DE60209343T2 (en) | 2001-04-11 | 2006-10-26 | Bristol-Myers Squibb Co. | AMINO ACID COMPLEXES OF C-ARYL GLYCOSIDES FOR THE TREATMENT OF DIABETES AND METHODS |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
DE10150203A1 (en) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitor in treatment of cancer |
US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
MXPA04003553A (en) | 2001-10-18 | 2004-07-22 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions. |
US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
EP1443919A4 (en) | 2001-11-16 | 2006-03-22 | Bristol Myers Squibb Co | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
HUP0600057A2 (en) | 2002-02-28 | 2006-05-29 | Prosidion Ltd | Glutaminyl based dpiv inhibitors, pharmaceutical compositions comprising thereof and their use |
US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
ES2344057T3 (en) | 2002-10-23 | 2010-08-17 | Bristol-Myers Squibb Company | INHIBITORS OF DIPEPTIDIL PEPTIDASA IV BASED ON GLICINE NITRILS. |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
TW200504021A (en) | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
ATE462432T1 (en) | 2003-05-05 | 2010-04-15 | Probiodrug Ag | GLUTAMINYL CYCLASE INHIBITORS |
ATE464889T1 (en) | 2003-05-05 | 2010-05-15 | Probiodrug Ag | MEDICAL USE OF GLUTAMINYL AND GLUTAMATIC CYCLASE INHIBITORS |
US7381537B2 (en) | 2003-05-05 | 2008-06-03 | Probiodrug Ag | Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease |
EP1631680A2 (en) * | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
EP1631679A2 (en) * | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7) |
US7459474B2 (en) | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US7371759B2 (en) | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
KR20120007079A (en) | 2003-10-15 | 2012-01-19 | 프로비오드룩 아게 | Use of effectors of glutaminyl and glutamate cyclases |
AU2004290499C1 (en) | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
KR20180050427A (en) | 2003-11-17 | 2018-05-14 | 노파르티스 아게 | Use of dipeptidyl peptidase iv inhibitors |
US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
HRP20211766T1 (en) | 2004-01-20 | 2022-02-18 | Novartis Ag | Direct compression formulation and process |
BRPI0507485A (en) | 2004-02-05 | 2007-07-10 | Probiodrug Ag | new glutaminyl cyclase inhibitors |
US7145040B2 (en) | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
AR051446A1 (en) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2) |
US7635699B2 (en) | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7589088B2 (en) | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US7888381B2 (en) | 2005-06-14 | 2011-02-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof |
EP1942898B2 (en) | 2005-09-14 | 2014-05-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
CN102675221A (en) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | Intermediate in method for preparing pyrimidinedione derivative |
EP1943215A2 (en) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
KR20090004950A (en) | 2006-04-12 | 2009-01-12 | 프로비오드룩 아게 | Enzyme inhibitors |
US20100022457A1 (en) | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
EP2030022A1 (en) * | 2006-06-07 | 2009-03-04 | Bayer HealthCare AG | Use of lysosomal carboxypeptidase c (prcp) as a therapeutic or diagnostic target |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
US7795291B2 (en) | 2006-07-07 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method |
US8198311B2 (en) | 2006-11-01 | 2012-06-12 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
JP5523107B2 (en) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | Novel inhibitors of glutaminyl cyclase |
JP2010514777A (en) | 2006-12-26 | 2010-05-06 | ファーマサイクリックス,インク. | Methods for monitoring biomarkers using histone deacetylase inhibitors in combination therapy |
ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
PE20090185A1 (en) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR |
ES2533484T3 (en) | 2007-04-18 | 2015-04-10 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
PE20090696A1 (en) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
MX354786B (en) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS. |
EP2173717B9 (en) | 2007-07-27 | 2013-06-26 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
WO2009058944A2 (en) | 2007-11-01 | 2009-05-07 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof |
ES2627848T3 (en) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8106046B2 (en) | 2008-06-24 | 2012-01-31 | Bristol-Myers Squibb Company | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
ES2624828T3 (en) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others |
DK2475428T3 (en) | 2009-09-11 | 2015-09-28 | Probiodrug Ag | Heterocyclic derivatives as glutaminylcyklaseinhibitorer |
JP5798123B2 (en) | 2009-11-13 | 2015-10-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Low-form metformin formulation |
MX2012005365A (en) | 2009-11-13 | 2012-05-29 | Bristol Myers Squibb Co | Immediate release tablet formulations. |
RU2583920C2 (en) | 2009-11-13 | 2016-05-10 | Астразенека Аб | Bi-layer tablet composition |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
CN102791704B (en) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | The heterocycle inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5) |
US8592396B2 (en) | 2010-04-14 | 2013-11-26 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
JP5945532B2 (en) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
EP2611442B1 (en) | 2010-09-03 | 2018-07-04 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
TWI631963B (en) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
CA2826391C (en) | 2011-02-01 | 2017-01-24 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
CN103764672A (en) | 2011-03-01 | 2014-04-30 | 辛纳吉制药公司 | Process of preparing guanylate cyclase C agonists |
ES2570167T3 (en) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Benzimidazole derivatives as glutaminyl cyclase inhibitors |
KR102165224B1 (en) | 2012-11-20 | 2020-10-13 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Inhibitors of sodium glucose cotransporter 1 |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
KR102272746B1 (en) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
US9593113B2 (en) | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
MA53175A (en) | 2018-07-19 | 2021-05-26 | Astrazeneca Ab | METHODS OF TREATMENT OF HFPEF WITH DAPAGLIFLOZIN AND COMPOSITIONS INCLUDING IT |
MX2021003545A (en) | 2018-09-26 | 2021-05-27 | Lexicon Pharmaceuticals Inc | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5 -trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis. |
US20220023252A1 (en) | 2020-07-27 | 2022-01-27 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
EP0764151A2 (en) * | 1994-06-10 | 1997-03-26 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
-
1999
- 1999-03-09 WO PCT/EP1999/001617 patent/WO1999046272A1/en not_active Application Discontinuation
- 1999-03-09 AU AU30342/99A patent/AU3034299A/en not_active Abandoned
- 1999-03-09 EP EP99911781A patent/EP1062222A1/en not_active Withdrawn
- 1999-03-09 JP JP2000535649A patent/JP2002506075A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9946272A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999046272A1 (en) | 1999-09-16 |
JP2002506075A (en) | 2002-02-26 |
AU3034299A (en) | 1999-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1062222A1 (en) | Serine peptidase modulators | |
US20020061839A1 (en) | Serine peptidase modulators | |
Belyaev et al. | Structure− activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors | |
EP0063896B1 (en) | Amino and substituted amino phosphinyl-alkanoyl compositions | |
AU636521B2 (en) | Inhibitors and substrates of thrombin | |
US4316896A (en) | Aminoacid derivatives as antihypertensives | |
HU189207B (en) | Process for the preparation of phosphor containing compounds | |
EP0097534B1 (en) | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives | |
US4379146A (en) | Substituted phosphonamides as antihypertensives | |
CA1316630C (en) | Phosphinylcycloalkylcarbonyl and phosphinylcycloalkenylcarbonyl dipeptides | |
CA1248959A (en) | Amino and substituted amino phosphinylalkanoyl compounds | |
EP0871454A1 (en) | Phosphorous-containing cysteine and serine protease inhibitors | |
WO1995009859A1 (en) | Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring | |
US6127340A (en) | Serine protease inhibitors | |
JPS5838294A (en) | Phosphonamidate compound | |
US6630501B1 (en) | Phosphinic pseudo-peptides that may be used as matrix zinc metalloprotease inhibitors | |
US6207655B1 (en) | Bis-phosphonate confugates with alkylating moieties having antitumor activity | |
US5648338A (en) | Inhibitors and substrates of thrombin | |
EP0527761A1 (en) | Phosphonopeptides with collagenase inhibiting activity | |
US6482797B1 (en) | N-terminal site selective inhibitors of human angiotensin conversion enzyme (ACE) | |
US5639732A (en) | Phosphorous-containing cysteine and serine protease inhibitors | |
EP0253179B1 (en) | A-acylamino aminoalkyl phophonate angiotensin converting enzyme inhibitors | |
US4567167A (en) | Certain 3-phosphinyl-2-oxo-piperidine-1-acetic acid derivatives having anti-hypertensive activity | |
US4598071A (en) | Certain 3-phosphinyl-amino-2-oxo-1H-azocine or azonine-1-acetic acid derivatives having anti-hypertensive properties | |
EP0473936A1 (en) | Renin Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000919 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 20000919;LV PAYMENT 20000919;SI PAYMENT 20000919 |
|
17Q | First examination report despatched |
Effective date: 20010704 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030520 |